WO2018044783A1 - Heterocyclic compounds as immunomodulators - Google Patents
Heterocyclic compounds as immunomodulators Download PDFInfo
- Publication number
- WO2018044783A1 WO2018044783A1 PCT/US2017/048880 US2017048880W WO2018044783A1 WO 2018044783 A1 WO2018044783 A1 WO 2018044783A1 US 2017048880 W US2017048880 W US 2017048880W WO 2018044783 A1 WO2018044783 A1 WO 2018044783A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- membered heterocycloalkyl
- membered heteroaryl
- independently selected
- cycloalkyl
- Prior art date
Links
- 0 Cc(c(NC(C1=SC(CNCCI)=C*1)=O)ccc1)c1-c1ccccc1 Chemical compound Cc(c(NC(C1=SC(CNCCI)=C*1)=O)ccc1)c1-c1ccccc1 0.000 description 2
- GCCLNCITIFPCIO-UHFFFAOYSA-N C=C(c1nc(Cl)c(C2OCCO2)[s]1)O Chemical compound C=C(c1nc(Cl)c(C2OCCO2)[s]1)O GCCLNCITIFPCIO-UHFFFAOYSA-N 0.000 description 1
- MCIIVKGYMHKTCB-UHFFFAOYSA-N COC(c1ncc(C=C)[s]1)=N Chemical compound COC(c1ncc(C=C)[s]1)=N MCIIVKGYMHKTCB-UHFFFAOYSA-N 0.000 description 1
- JYNQAYGUTGPULV-UHFFFAOYSA-N C[n]1c(C(Nc2cccc(-c(cc3)cc4c3OCCO4)c2C#N)=O)ncc1CNCCO Chemical compound C[n]1c(C(Nc2cccc(-c(cc3)cc4c3OCCO4)c2C#N)=O)ncc1CNCCO JYNQAYGUTGPULV-UHFFFAOYSA-N 0.000 description 1
- JLNIZAXGCAAHOF-UHFFFAOYSA-N C[n]1c(C(O)=O)ncc1Br Chemical compound C[n]1c(C(O)=O)ncc1Br JLNIZAXGCAAHOF-UHFFFAOYSA-N 0.000 description 1
- YSBKOFYZLVOFAT-UHFFFAOYSA-N Cc(c(-c1ccccc1)ccc1)c1NC(c([s]1)ncc1Br)=O Chemical compound Cc(c(-c1ccccc1)ccc1)c1NC(c([s]1)ncc1Br)=O YSBKOFYZLVOFAT-UHFFFAOYSA-N 0.000 description 1
- NMRCIXCIRVZQNY-UHFFFAOYSA-N Cc(c(-c1ccccc1)ccc1)c1NC(c1ncc(CNCCO)[n]1C)=O Chemical compound Cc(c(-c1ccccc1)ccc1)c1NC(c1ncc(CNCCO)[n]1C)=O NMRCIXCIRVZQNY-UHFFFAOYSA-N 0.000 description 1
- NHOABGOOPZCIEM-UHFFFAOYSA-N Cc(c(-c1ccccc1)ccc1)c1NC(c1ncc(CO)[o]1)=O Chemical compound Cc(c(-c1ccccc1)ccc1)c1NC(c1ncc(CO)[o]1)=O NHOABGOOPZCIEM-UHFFFAOYSA-N 0.000 description 1
- OFPFOLWZWMSUMD-UHFFFAOYSA-N Cc(c(Br)ccc1)c1NC(c1ncc(C=C)[s]1)=O Chemical compound Cc(c(Br)ccc1)c1NC(c1ncc(C=C)[s]1)=O OFPFOLWZWMSUMD-UHFFFAOYSA-N 0.000 description 1
- NTJSODMKMSYIQP-VWLOTQADSA-N Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(CCCC3)[C@@H]3C(O)=O)cc2Cl)cccc1Br Chemical compound Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(CCCC3)[C@@H]3C(O)=O)cc2Cl)cccc1Br NTJSODMKMSYIQP-VWLOTQADSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present application is concerned with pharmaceutically active compounds.
- the disclosure provides compounds as well as their compositions and methods of use.
- the compounds modulate PD-1/PD-L1 protein/protein interaction and are useful in the treatment of various diseases including infectious diseases and cancer.
- the immune system plays an important role in controlling and eradicating diseases such as cancer.
- cancer cells often develop strategies to evade or to suppress the immune system in order to favor their growth.
- One such mechanism is altering the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al, J. Clinical Oncology 2015, 1-9). Blocking the signaling of an inhibitory immune checkpoint, such as PD-1, has proven to be a promising and effective treatment modality.
- PD-1 Programmed cell death- 1
- CD279 is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al, Annu. Rev. Immunol 2005, 23:515-548; Okazaki and Honjo, Trends Immunol 2006, (4): 195-201). It functions as an intrinsic negative feedback system to prevent the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance.
- PD- 1 is also known to play a critical role in the suppression of antigen-specific T cell response in diseases like cancer and viral infection (Sharpe et al, Nat Immunol 2007 8, 239-245; Postow et al, J. Clinical Oncol 2015, 1-9).
- the structure of PD-1 consists of an extracellular immunoglobulin variable-like domain followed by a transmembrane region and an intracellular domain (Parry et al, Mol Cell Biol 2005, 9543-9553).
- the intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor- mediated signals.
- PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al, Mol Cell Biol 2005, 9543-9553; Latchman et al, Nat Immunol 2001, 2, 261-268), and they differ in their expression patterns.
- PD-L1 protein is upregulated on macrophages and dendritic cells in response to lipopolysaccharide and GM-CSF treatment, and on T cells and B cells upon T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN- ⁇ treatment (Iwai et al, PNAS2002, 99(19): 12293-7; Blank et al, Cancer Res 2004, 64(3): 1140-5).
- tumor PD- Ll expression status has been shown to be prognostic in multiple tumor types (Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015; Sabatier et al, Oncotarget 2015, 6(7): 5449-5464).
- PD-L2 expression in contrast, is more restricted and is expressed mainly by dendritic cells (Nakae et al, J Immunol 2006, 177:566-73).
- Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers a signal that inhibits IL-2 and IFN- ⁇ production, as well as cell proliferation induced upon T cell receptor activation (Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000, 192(7): 1027-34).
- the mechanism involves recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol 2007, 8, 239-245).
- Activation of the PD-1 signaling axis also attenuates PKC- ⁇ activation loop phosphorylation, which is necessary for the activation of NF- ⁇ and API pathways, and for cytokine production such as IL-2, IFN- ⁇ and TNF (Sharpe et al, Nat Immunol 2007, 8, 239-245; Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000,
- PD-1 -deficient mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al, Immunity 1999, 1 1 : 141-151; Nishimura et al, Science 2001, 291 :319-322).
- LCMV model of chronic infection it has been shown that PD-1/PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus-specific CD8 T cells (Barber et al, Nature 2006, 439, 682-7).
- the present disclosure further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof, and at least one pharmaceutically acceptable carrier or excipient.
- the present disclosure further provides methods of modulating or inhibiting PD- 1/PD-Ll protein/protein interaction, which comprises administering to an individual a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
- the present disclosure further provides methods of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
- X 1 is N or CR 1 ;
- X 2 is N or CR 2 ;
- X 3 is N or CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is C 6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10cycloalkyl, C3- 10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C 6 -10 aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR 10 , C1-4 haloalkyl, C1-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 , OC(0)R 10 , OC(O)NR 10 R 10 , NR 10 C(O)R 10 , NR 10 C
- each R 10 is independently selected from H, C1-4 alky 1, C 2- 4 alkenyl, C1-4 alkynyl, C1-4alkoxy, C3-6 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4alkoxy, C
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N0 2 , OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a ,
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from B, P, N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents; R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkyl, C
- R 8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11
- R 9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl
- each R 11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents; each R b substituent is independently selected from halo, C1-6 alkyl
- each R c is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from C1-6 alkyl, C1-6 haloalkyl,
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R f are each optionally substituted with 1, 2 or 3 R n substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR 0 , OR 0 , SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°,
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -10aryl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH 2 , NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)OR e ,
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 R p substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl
- heterocycloalkyl, C6-10aryl, 5-6 membered heteroaryl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl- C14 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of R h are each optionally substituted by 1, 2, or 3 R j substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C1-4 alkenyl, C1-4 alkynyl, halo, C1-4haloalkyl, C1-4 haloalkoxy, CN, NHOR k , OR k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R
- R c substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R e substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R g substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 1 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents;
- R k substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents;
- R° substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R r substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 10 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 11 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- each R 1 , R k , R° or R r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
- each R q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently C1-6 alkyl; and
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- X 1 is N or CR 1 ;
- X 2 is N or CR 2 ;
- X 3 is N or CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4
- X 5 is O, S, N, NR. 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C1-4 alkenyl, C1-4 alkynyl, halo, CN, OR 10 , C1-4 haloalkyl, C1-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 ,
- each R 10 is independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, C1-4 alkynyl, C1-4alkoxy, C3-6 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4alkoxy,
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N0 2 , OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a , NR
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR 11 , SR 11 , NH2, -NHR 11 , -NR 11 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , NR 11 C(0)OR 11 , NR' ⁇ CON
- R 8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11
- R 9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
- each R 11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents; each R b substituent is independently selected from halo, C1-6 alkyl
- each R c is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R f are each optionally substituted with 1, 2 or 3 R n substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR 0 , OR 0 , SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°,
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -10aryl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)OR e , NR
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 R p substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C 2- 6 alkenyl, C 2- 6 alkyny
- heterocycloalkyl C 6 -10 aryl, 5-6 membered heteroaryl, C 6 -10 aiyl-C1-4 alkyl-, C3-10 cycloalkyl- C14 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of R h are each optionally substituted by 1, 2, or 3 R> substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C 6 -10 aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4haloalkyl, C1-4 haloalkoxy, CN, NHOR k , OR k , SR k , C(0)R k , CiCONR 1 ⁇ , C(0)OR k , OC(0)R k , OC(0)NR k
- 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C1-4 haloalkyl, and C1- 4 haloalkoxy of R" are each optionally substituted with 1, 2 or 3 independently selected R q substituents;
- R c substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R e substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R g substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents; or any two R 1 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R q substituents;
- R k substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R q substituents;
- R° substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R r substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 10 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 11 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- each R 1 , R k , R° or R r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
- each R q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently C1-6 alkyl; and
- ring A is a single bond or a double bond to maintain ring A being aromatic.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
- X 1 is N or CR 1 ;
- X 2 is N or CR 2 ;
- X 3 is N or CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C 2 ⁇ alkenyl, C 2 ⁇ alkynyl, halo, CN, OR 10 , C1 ⁇ haloalkyl, C1-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 ,
- each R 10 is independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, C 2- 4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-6alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, wherein the C1-4 alkyl, C1-6alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a , NR a C(0)R
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR 11 , SR 11 , NH2, -NHR 11 , -NR 11 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , NR 11 C(0)OR 11 , NR' 1 C ONR 11
- R 8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11
- R 9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
- each R 11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents; each R b substituent is independently selected from halo, C1-6 alkyl
- each R c is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -10aryl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)OR e , NR
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 R p substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R p is optionally substituted with 1, 2 or 3 R q substituents;
- R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R i substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents; or any two R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- each R i , R k , R° or R r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
- each Ri is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently C1-6 alkyl; and
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
- X 1 is N or CR 1 ;
- X 2 is N or CR 2 ;
- X 3 is N or CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C1-4 alkenyl, C1-4 alkynyl, halo, CN, OR 10 , C1-4 haloalkyl, C1-4 haloalkoxy, NH 2 , -NHR 10 , -
- each R 10 is independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, C 2- 4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N0 2 , OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a ,
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR 11 , SR 11 , NH2, -NHR 11 , -NR 11 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , NR 11 C(0)OR 11 , NR' 1 C ONR 11
- R 8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11
- R 9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl
- each R 11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents; each R b substituent is independently selected from halo, C1-6 alkyl
- each R bl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 - 10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R b are each further optionally substituted with 1-3 independently selected R d substituents; each R bl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocyclo
- each R c is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl
- NR°S(0) 2 NR°R°, and S(0) 2 NR°R° wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R n is optionally substituted with 1, 2 or 3 Ri substituents;
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -10aiyl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocy cloalkyl)-C 1-4 alkyl-, CN, NH 2 , NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
- each Rs is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 RP substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl,
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R p is optionally substituted with 1, 2 or 3 R q substituents;
- R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- each R 1 , R k , R° or R r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1,
- each R q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently C1-6 alkyl; and
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
- X 1 is N or CR 1 ;
- X 2 is N or CR 2 ;
- X 3 is N or CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-C 1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C2 ⁇ alkenyl, C2 ⁇ alkynyl, halo, CN, OR 10 , C1-4 haloalkyl, C1-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 ,
- each R 10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C 1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C 1-4 alkyl-, C6-10aryl,
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, NO2, OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a , NR a
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR 11 , SR 11 , NH 2 , -NHR 11 , -NR 11 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , NR 11 C(0)OR 11 , NR 1 1 C(
- R 8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C 2- 6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11
- R 9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl
- each R 11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents; each R b substituent is independently selected from halo, C1-6 alky
- each R c is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from C1-6 alkyl, C 1-6 haloal
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -10aryl-C1-4alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)OR e , NR
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 R p substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl
- heterocycloalkyl C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R p is optionally substituted with 1, 2 or 3 R q substituents;
- R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R q substituents;
- R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R q substituents;
- R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
- each R 1 , R k , R° or R r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
- each R q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently C1-6 alkyl; and
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- any two R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R q substituents;
- R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R q .
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, phenyl substituted with 1-3 independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11 , NH2, -NHR 9 , -NR 9 R 11 , NHOR 11 , C(0)R 11 ,
- R 9 is C 1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1-
- the compound provided herein is a compound having Formula
- X 1 is N, X 2 is CR 2 and X 3 is CR 3 ;
- X 1 is CR 1 , X 2 is N and X 3 is CR 3 ;
- X 1 is CR 1 , X 2 is CR 2 and X 3 is N;
- X 1 is N, X 2 is CR 2 and X 3 is N;
- X 1 is N, X 2 is N and X 3 is CR 3 ; or
- X 1 is CR 1 , X 2 is N and X 3 is N.
- X 1 is N, X 2 is CR 2 and X 3 is CR 3 . In some embodiments, X 1 is CR 1 , X 2 is N and X 3 is CR 3 . In some embodiments, X 1 is CR 1 , X 2 is CR 2 and X 3 is N. In some embodiments, X 1 is N, X 2 is CR 2 and X 3 is N. In some embodiments, X 1 is N, X 2 is N and X 3 is CR 3 . In some embodiments, X 1 is CR 1 , X 2 is N and X 3 is N.
- the compound provided herein is a compound having Formula
- L is a bond, -C(0)NR 13 -, -NR 13 C(0)-, O, -(CR 14 R 15 ) q -, -(CR 14 R 15 ) q -0-, -
- each R 13 is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CN, halo,
- R 14 and R 15 are each independently selected from H, halo, CN, OH, -COOH, C1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl) 2 , C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R 14 or R 15 are each optionally substituted with 1, 2, or 3 independently selected R q substituents;
- ring B is C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2 or 3 independently selected R d substituents;
- n is an integer of 1, 2, 3 or 4.
- the compound provided herein is a compound having Formula
- R 2 , R 3 , R 7 , X 4 , X 5 , and R 8 are as described herein.
- the compound provided herein is a compound having Formula
- the compound provided herein is a compound having Formula (IIIa-2):
- R d is C1-6 alkyl, phenyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, OR e , C(0)R e , halo or CN, wherein the C1-6 alkyl, phenyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R d are each optionally substituted with 1, 2 or 3 independently selected R f substituents.
- R d is (3-carboxypyrrolidin-l-yl)methyl, (R)-(3- carboxypyrrolidin-l-yl)methyl, (S)-(3-carboxypyrrolidin-l-yl)methyl, (3-hydroxypyrrolidin- l-yl)methyl, (R)-(3-hydroxypyrrolidin-l-yl)methyl, (S)-(3-hydroxypyrrolidin-l-yl)methyl, (2-hydroxyethylamino)methyl, (2-hydroxy-2-methylpropylamino)methyl, 2- (dimethylamino)ethanoyl, 2-(3-carboxyazetidin-l-yl)ethanoyl, (R)-2-(3-carboxyazetidin-l- yl)ethanoyl, (S)-2-(3-carboxyazetidin-l-yl)ethanoyl, 2-(2-carboxypiperid
- the moiety is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- X 4 is S and X 5 is CR 5 ;
- X 4 is O and X 5 is CR 5 ;
- X 4 is NR 4 and X 5 is CR 5 ; or
- X 4 is CR 4 and X 5 is NR 5 .
- X 4 is S and X 5 is CR 5 .
- X 4 is O and X 5 is CR 5 .
- X 4 is NR 4 and X 5 is CR 5 .
- X 4 is CR 4 and X 5 is NR 5 .
- Cy is phenyl, 5- or 6-membered heteroaryl, C3-6 cycloalkyl or
- 5- or 6-membered heterocycloalkyl each of which is optionally substituted with 1 to 5 independently selected R 6 substituents; or two adjacent R 6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or
- 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents.
- Cy is phenyl, 2-thiophenyl, 3-thiophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3,6-dihydro-2H-pyran-4-yl, cyclohexyl, cyclohexenyl, 2,3-dihydro-l,4- benzodioxin-6-yl, l,3-benzodioxin-5-yl, 2-methylindazol-6-yl or l-methylindazol-4-yl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents.
- Cy is phenyl, 2,3-dihydro-l,4-benzodioxin-6-yl, 2- fluorophenyl, 2-fluoro-3-methoxyphenyl, or l-methyl-lH-indazol-4-yl.
- Cy is unsubstituted phenyl.
- Cy is phenyl optionally substituted with 1 to 5 independently selected R 6 substituents.
- Cy is phenyl is substituted with 1 to 5 substituents selected from halo or OR a .
- Cy is phenyl is substituted with 1 to 2 substituents selected from halo or 0-C1-6 alkyl.
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, C 2 -4 alkenyl, C 2- 4 alkynyl, halo, CN, OR 10 , C1-4haloalkyl, C1-4haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 , OC(0)R 10 , OC(O)NR 10 R 10 , NR 10 C(O)R 10 , NR 10 C(O)R
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, C 2- 4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, NH 2 , -NH-C 1-4 alkyl, and -N(C1-4alkyl) 2 .
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, C 2- 4 alkynyl, halo, CN, and OH.
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, and C 2- 4 alkynyl.
- R 1 , R 2 and R 3 are H.
- R 4 is H, halo, C1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C1-6 haloalkyl or C1-6 haloalkoxy. In some embodiments, R 4 is H.
- R 5 is H, halo, C1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C1-6 haloalkyl or C1-6 haloalkoxy. In some embodiments, R 5 is H.
- R 6 is H, halo, C1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, CN, OR a , C(0)NR a R a , or NR a C(0)R a , wherein the C1-6 alkyl, C 2- 6 alkenyl, and C2-6 alkynyl of R 6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R b substituents; or two adjacent R 6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms
- R 6 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CN, or OR a , wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R 6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R b substituents; or two adjacent R 6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6- membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7- membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NH2, NH(C1-6 alkyl), N(C1-6 alky 1)2, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl or phenyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and phenyl are each optionally substituted with 1, 2 or 3 independently selected R q substituents.
- R 8 is C1-6 alkyl substituted with 1-3 independently selected R b2 substituents or (4-10 membered heterocycloalkyl)-C1-4 alkyl- optionally substituted with 1, 2 or 3 independently selected R b substituents. In some embodiments, R 8 is C1-6 alkyl substituted with 1-3 independently selected R b2 substituents.
- R 8 is C1-6 alkyl or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl and (4-10 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted with 1, 2 or 3 independently selected R b substituents.
- R 8 is C1-6 alkyl substituted with R b .
- R 8 is -CH2NHR C or -CH2NR C R C .
- R 8 is (2-hydroxyethylamino)methyl, 2-carboxy-l- piperidinylmethyl, (S)-2-carboxy-l-piperidinylmethyl, (R)-2-carboxy-l-piperidinylmethyl, or 3 -hy droxy py rrol i din- 1 -y 1 methy 1.
- R 8 is (2-hydroxyethylamino)methyl, 2-carboxy-l- piperidinylmethyl, (S)-2-carboxy-l-piperidinylmethyl, or (R)-2-carboxy-l-piperidinylmethyl.
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, N NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is phenyl, C3-6 cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused 5-, 6- or 7-membered heterocycloalkyl ring, or a fused 5- or 6-membered heteroaryl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C 2 ⁇ alkynyl, halo, CN, OH, COOH, C1-4 alkoxy, C1 ⁇ haloalkyl, C1 ⁇ haloalkoxy, cyclopropyl, cyclopropylmethyl, phenyl, phenyl-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-C1- 4 alkyl-, NH 2 , -NHC1-4 alkyl, -N(C1-4 alkyl) 2 , -C(0)R 10 , -0(CO)R 10 , -C(0)OR 10 , - 0(CO)NHR 10 , -NHC(0)OR 10 , -NHC(0)NHR 10 ,
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C1-6 alkoxy,
- R 7 is halo, C1-6 alkyl, CN, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C1-4 alkyl-, (4-6 membered heterocycloalkyl)-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl, wherein C1-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C1-4 alkyl-, (4-6 membered heterocycloalkyl)-C1-4 alkyl- and (5-6 membered heteroaryl)-C1-4 alkyl of R 7 are each optionally substituted with 1 or 2 susbtituents independently selected from halo, C1-6 alkyl, C1-4 haloalkyl, C1-6haloalkoxy,CN, OH, NH 2 , -NH(C1-6 al
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
- R bl substituents independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, OR 11 , NH 2 , -NHR 9 , -NR 9 R 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , NR 11 C(0)OR 11 , NR 1 1 C(OJNR 111 R 1 , NR 11 S(0)R 11 , NR ⁇ iOfcR 11 , NR 11 S(0) 2 NR
- R 9 is C 1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C1-6 haloalkyl, C 2- 6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- or (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C
- each R 11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered
- heterocycloalkyl phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)- C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R 11 are each optionally substituted with 1 or 2 R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-;
- each R b is independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NHR C , N(R C ) 2 , OR c , C(0)NR c R c , C(0)OR c , COOH, NR c C(0)R c , OC(0)NR c R c , NR c C(0)OR c , NR c C(0)NR c R c
- each R c is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, pheny 1-C 1-4 alky 1-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl- C14 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered
- R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected R h substituents;
- each R f is independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, 4-6 membered
- heterocycloalkyl 5-6 membered heteroaryl, CN, OH, COOH, OR g , C(0)OR g , NH 2 , -NHR g , - N(R g ) 2 , -C(0)NR g R g , -NR g C(0)R g , OC(0)NR g R g , NR g C(0)OR g , NR g C(0)NR g R g ,
- each R g is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl;
- each R h is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH 2 , NHR i , N(R') 2 , OR', C(0)NR i R i , NR'CiO)R i and C(0)OR', wherein R 1 is H or C1-6 alkyl.
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C6- 10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4 haloalkyl, C 1-4 haloalkoxy, NH2, -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 , OC(0)R 10 , OC(O)NR 10 R 10 , NR 10 C(O)R 10 , and NR 10 C(O)OR 10 , wherein each R 10 is independently selected from H, C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-10 membered hetero
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a , NR a C(0)R a , and
- NR a C(0)OR a wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- 14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 4 , R 5 and R 6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R b substituents;
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR 11 , SR 11 , NH2, -NHR 11 , -NR 11 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , and NR 11 C(0)OR 11 , wherein the C1-6 alkyl, C 2 ⁇ alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, phenyl substituted with 1-3
- R bl substituents independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl, NO2, OR 1 SR 11 , NH2, -NHR 9 , -NR'R 1 ⁇ NHOR 1 ⁇ C(0)R l ⁇ C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , or NR 11 C(0)OR 11 , wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 8 are each optionally substituted with 1, 2 or 3 independently
- each R 11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents;
- each R b substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , and OC(0)NR c R c ; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C 6 -10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b are each further optionally substituted with 1-3 independently selected R d substituents;
- each R bl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH 2 , NO2, NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , NR c C(0)OR c , and NR c C(0)NR c R c ; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4
- each R b2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , and NR c C(0)OR c ; wherein the C1-6 haloalkyl, Cw haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b2 are each further optionally substituted with 1-3 independently selected R d
- NR S C(0)NR S R S and NR S C(0)OR S ; wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R f are each optionally substituted with 1, 2 or 3 R n substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR 0 , OR 0 , SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°,
- NR°C(0)NR°R° NR°C(0)OR°
- the C1-4 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R n is optionally substituted with 1, 2 or 3 R q substituents;
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, CN, NH2, NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e ,
- NR e C(0)R e NR e C(0)NR e R e
- NR e C(0)OR e wherein the C1 -6 alkyl, C1-6 haloalkyl, C 6 -10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, and 4-10 membered heterocycloalkyl of R d are each optionally substituted with 1-3 independently selected R f substituents;
- each R e is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- each R° is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl,
- each R q is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 and each R 12 is
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, NR 4 or CR 4 ;
- X 5 is NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C 2 ⁇ alkynyl, halo, CN, OH, C1-6alkoxy, C1-4 haloalkyl, C1 ⁇ haloalkoxy, NH2, -NH-C1-4 alkyl, - N(C1-4 alky 1) 2 , wherein the C1-4 alkyl and C1-4 alkoxy of R 1 , R 2 and R 3 are each optionally substituted with 1 or 2 independently selected R d substituents;
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C 2 ⁇ alkynyl, C1 -6 haloalkyl, C1-6haloalkoxy, CN, NO2, OR a , SR a , NHOR a , C(0)R a ,
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN,
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, and phenyl substituted with 1-3 independently selected R bl substituents, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C 1-6 haloalkoxy of R 8 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R 11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents;
- each R b substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, CN, OH, NH 2 , NHOR c , OR c , C(0)R c , C(0)NR c R c , and C(0)OR c ; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of R b are each further optionally substituted with 1-3 independently selected R d substituents;
- each R bl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , NHR C , NR C R C , NR c C(0)R c , NR c C(0)OR c , and NR c C(0)NR c R c ; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of R bl are each further optionally substituted with 1-3 independently selected R d substituents;
- each R b2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , and NR c C(0)OR c ; wherein the C1-6 haloalkyl, C1-4 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b2 are each further optionally substituted with 1-3 independently selected R
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2 -6 alkenyl, and C 2 -6 alkynyl;
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2- 6 alkenyl, and
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, NR 4 or CR 4 ;
- X 5 is NR 5 or CR 5 ;
- Cy is C 6 -10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C 2- 4 alkenyl, C 2 ⁇ alkynyl, halo, CN, OH, NH 2 , -NH-C1-4 alkyl, and -N(C1-4 alky 1)2;
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and OR a , wherein the C1-6 alkyl, C 2- 6 alkenyl, and C2-6 alkynyl of R 4 , R 5 and R 6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R b substituents; or two adjacent R 6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or CN, wherein the C1-6 alkyl, C2-6 alkenyl, and C 2- 6 alkynyl of R 7 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, and C2-6 alkenyl, wherein the C2-6 alkenyl of R 8 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; each R b substituent is independently selected from halo and C1-6 alkyl;
- each R b2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, NHR C , NR C R C , and NR c C(0)R c ; wherein the C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b2 are each further optionally substituted with 1-3 independently selected R d substituents;
- each R c is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, OR S , C(0)R S , C(0)NR g R S NHR g , and NRSRS;
- each R d is independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, CN, NH2, OR e , C(0)R e , C(0)NR e R e , C(0)OR e , NHR e , NR e R e , and NR e C(0)R e ;
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, N, NR 4 or CR 4 ;
- X 5 is O, S, N, NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C6-
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a , SR a , NHOR a , C(0)R a ,
- NR a C(0)OR a wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -10 aryl, C3-10 cycloalkyl, 5- 14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 4 , R 5 and R 6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R b substituents;
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR 11 , SR 11 , NH2, -NHR 11 , -NR 11 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 , OC(0)NR 11 R 11 , NR 11 C(0)R 11 , and NR 11 C(0)OR 11 , wherein the C1-6 alkyl, C 2 ⁇ alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membere
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
- R bl substituents independently selected R bl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected R b substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR 11 , SR 11 , NH2, -NHR 9 , -NR 9 R 11 , NHOR 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , OC(0)R 11 ,
- OC(0)NR 11 R 11 NR 11 C(0)R 11 , or NR 11 C(0)OR 11 , wherein the C 2 ⁇ alkenyl, C 2 ⁇ alkynyl, Cw haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 8 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alky 1 substituted with 1-3 independently selected R b2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 9 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R 11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents;
- each R b substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1-
- each R bl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH 2 , NO2, NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , NR c C(0)OR c , and NR c C(0)NR c R c ; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4
- each R b2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH 2 , N0 2 , NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , and NR c C(0)OR c ; wherein the C1-4 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b2 are each further optionally substituted with
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2 -6 alkenyl, and C 2 -6 alkynyl;
- each R g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl and (5-10 membered heteroaryl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 R p substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, halo, CN, OR r , C(0)R r , €(0) ⁇ . ⁇ , C(0)OR r , OC(0)R r , OCCCONRT ⁇ , NHR r , NRH', and NR r C(0)R r ;
- each R° is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl;
- each R q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 and each R 12 is independently C1-6 alkyl; and
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, NR 4 or CR 4 ;
- X 5 is NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2 ⁇ alkynyl, halo, CN, OH, C1 ⁇ alkoxy, C1-4 haloalkyl, C1 ⁇ haloalkoxy, NH2, -NH-C1-4 alkyl, - N(C1-4 alky 1)2, wherein the C1-4 alkyl and C1-4 alkoxy of R 1 , R 2 and R 3 are each optionally substituted with 1 or 2 independently selected R d substituents;
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C 2 ⁇ alkynyl, C1 -6 haloalkyl, C1-6 haloalkoxy, CN, NO2, OR a , SR a , NHOR a , C(0)R a ,
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NO2, OR 11 , SR 11 , NH2, -NHR 11 , -NR 11 R 11 , C(0)R 11 , C(0)NR 11 R 11 , C(0)OR 11 , NR 11 C(0)R 11 , and NR 11 C(0)OR 11 , wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 haloalkoxy of R 7 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
- R bl substituents independently selected R bl substituents, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R 8 are each optionally substituted with 1, 2 or 3
- each R 11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and
- C2-6 alkynyl wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R 11 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and 5-10 membered heteroaryl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, 5-10 membered heteroaryl of R a are each optionally substituted with 1, 2 or 3 independently selected R d substituents;
- each R b substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, CN, OH, NH 2 , NHOR c , OR c , C(0)R c , C(0)NR c R c , and C(0)OR c ; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of R b are each further optionally substituted with 1-3 independently selected R d substituents;
- each R bl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , NHR C , NR C R C , NR c C(0)R c , NR c C(0)OR c , and NR c C(0)NR c R c ; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of R bl are each further optionally substituted with 1-3 independently selected R d substituents;
- each R b2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , and NR c C(0)OR c ; wherein the C1 -6 haloalkyl, C1-4 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b2 are each further optionally substituted with 1-3 independently selected
- each R d is independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHOR e , OR e , C(0)R e , C(0)NR e R e , C(0)OR e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , and NR e C(0)OR e , wherein the C1-4 alkyl and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R d are each optionally substituted with 1-3 independently selected R f substituents;
- each R e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- each R g is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl- of R g are each optionally substituted with 1-3 R p substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C 2 ⁇ alkynyl, halo, CN, OR r , C(0)R r , C(0)NRTl r , and C(0)OR r ;
- each R° is independently selected from H and C1-6 alkyl
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- X 1 is CR 1 ;
- X 2 is CR 2 ;
- X 3 is CR 3 ;
- X 4 is O, S, NR 4 or CR 4 ;
- X 5 is NR 5 or CR 5 ;
- Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 6 substituents;
- R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, CIA alkynyl, halo, CN, OH, NH 2 , -NH-C1-6 alkyl, and -N(C1-4 alkyl) 2 ;
- R 4 , R 5 and R 6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, OR a , C(0)NR a R a , and NR 1 RCOiR 3 , wherein the C1-6 alkyl, C 2- 6 alkenyl, and C 2- 6 alkynyl of R 4 , R 5 and R 6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R b substituents;
- R 6 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or CN, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R 7 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- R 8 is halo, C1-6 alkyl substituted with 1-3 independently selected R b2 substituents, C2-6 alkenyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C 2- 6 alkenyl and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R 8 are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
- each R a is independently selected from H, C1-6 alkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, and 5-
- each R b substituent is independently selected from halo, C1-6 alkyl, and OR c ;
- each R b2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, NHR C , NR C R C , and NR c C(0)R c ; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R b2 are each further optionally substituted with 1-3 independently selected R d substituents; each R c is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10aryl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10 aryl of R c are each optionally substituted with 1, 2 or 3 R f substituent
- each R d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH 2 , OR e , C(0)R e , C(0)NR e R e , C(0)OR e , NHR e , NR e R e , and NR e C(0)R e ; wherein the C1-6 alkyl and (4-10 membered
- heterocycloalkyl)-C 1-4 alkyl- of R d are each optionally substituted with 1-3 independently selected R f substituents;
- ⁇ is a single bond or a double bond to maintain ring A being aromatic.
- embodiments of the compounds of Formula (I) can be combined in any suitable combination.
- C1-6 alkyl is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C 4 alkyl, Cs alkyl and C6 alkyl.
- n-membered typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
- piperidinyl is an example of a 6-membered heterocycloalkyl ring
- pyrazolyl is an example of a 5-membered heteroaryl ring
- pyridyl is an example of a 6-membered heteroaryl ring
- 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
- each linking substituent include both the forward and backward forms of the linking substituent.
- -NR(CR i R") n - includes both -NR(CR i R")n- and -(CR i R")nNR- and is intended to disclose each of the forms individually.
- the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or "aryl” then it is understood that the "alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
- substituted means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group.
- substituted refers to any level of substitution, e.g., mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted.
- the substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
- optionally substituted means unsubstituted or substituted.
- substituted means that a hydrogen atom is removed and replaced by a substituent.
- a single divalent substituent e.g., oxo, can replace two hydrogen atoms.
- Cn-m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C1-4, C1-6 and the like.
- alkyl employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched.
- Cn-m alkyl refers to an alkyl group having n to m carbon atoms.
- An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
- the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
- alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, ⁇ -propyl, isopropyl, w-butyl, ter/-butyl, isobutyl, sec-butyl; higher homologs such as 2- methyl-1 -butyl, w-pentyl, 3-pentyl, w-hexyl, 1,2,2-trimethylpropyl and the like.
- alkenyl employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more double carbon-carbon bonds.
- An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound.
- Cn-m alkenyl refers to an alkenyl group having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- Example alkenyl groups include, but are not limited to, ethenyl, w-propenyl, isopropenyl, n- butenyl, seobutenyl and the like.
- alkynyl employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more triple carbon-carbon bonds.
- An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
- Cn-m alkynyl refers to an alkynyl group having n to m carbons.
- Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- alkylene employed alone or in combination with other terms, refers to a divalent alkyl linking group.
- An alkylene group formally corresponds to an alkane with two C-H bond replaced by points of attachment of the alkylene group to the remainder of the compound.
- Cn-m alkylene refers to an alkylene group having n to m carbon atoms.
- alkylene groups include, but are not limited to, ethan-l,2-diyl, propan-l,3-diyl, propan-l,2-diyl, butan-l,4-diyl, butan-l,3-diyl, butan-l,2-diyl, 2-methyl-propan-l,3-diyl and the like.
- alkoxy employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group is as defined above.
- Cn-m alkoxy refers to an alkoxy group, the alkyl group of which has n to m carbons.
- Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., w-propoxy and isopropoxy), /-butoxy and the like.
- the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- amino refers to a group of formula -NH 2 .
- cyano or “nitrile” refers to a group of formula -C ⁇ N, which also may be written as -CN.
- halo refers to fluoro, chloro, bromo and iodo.
- halo refers to a halogen atom selected from F, CI, or Br.
- halo groups are F.
- haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom.
- Cn-m haloalkyl refers to a Cn-m alkyl group having n to m carbon atoms and from at least one up to ⁇ 2(n to m)+l ⁇ halogen atoms, which may either be the same or different.
- the halogen atoms are fluoro atoms.
- the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms.
- Example haloalkyl groups include CF3, C2F5, CHF2, CCb, CHCh, C2CI5 and the like.
- the haloalkyl group is a fluoroalkyl group.
- haloalkoxy refers to a group of formula -O-haloalkyl, wherein the haloalkyl group is as defined above.
- Cn-m haloalkoxy refers to a haloalkoxy group, the haloalkyl group of which has n to m carbons.
- Example haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- oxo refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N-oxide group.
- aromatic refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i.e., having (4n + 2) delocalized ⁇ (pi) electrons where n is an integer).
- aryl employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or poly cyclic (e.g., having 2 fused rings).
- Cn-m aryl refers to an aryl group having from n to m ring carbon atoms.
- Aryl groups include, e.g., phenyl, naphthyl, indanyl, indenyl and the like. In some embodiments, aryl groups have from 6 to about 10 ring carbon atoms. In some embodiments aryl groups have 6 carbon atoms. In some embodiments aryl groups have 10 ring carbon atoms. In some embodiments, the aryl group is phenyl. In some embodiments, the aryl group is naphthyl.
- '3 ⁇ 4eteroatom used herein is meant to include boron, phosphorus, sulfur, oxygen and nitrogen.
- heteroaryl or “heteroaromatic,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from boron, phosphorus, sulfur, oxygen and nitrogen.
- the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- any ring- forming N in a heteroaryl moiety can be an N-oxide.
- the heteroaryl has 5-14 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- the heteroaryl has 5-10 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight- membered, nine-membered or ten-membered fused bicyclic heteroaryl ring.
- Example heteroaryl groups include, but are not limited to, pyridintl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl, naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3- and 2,6-naphthyridine), indolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[l,2-6]thiazolyl, purinyl, and the like.
- pyridintl pyridyl
- pyrimidinyl pyrazinyl
- pyridazinyl pyr
- a five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
- Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
- a six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
- Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
- cycloalkyl employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), including cyclized alkyl and alkenyl groups.
- Cn-m cycloalkyl refers to a cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles.
- Cycloalkyl groups can have 3, 4, 5, 6 or 7 ring-forming carbons (C3-7). In some embodiments, the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring- forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes.
- cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like.
- a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
- cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, bicyclo[l . l . l]pentanyl, bicyclo[2.1.1]hexanyl, and the like.
- the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- heterocycloalkyl refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, boron, sulfur, oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) ring systems.
- the heterocycloalkyl group is a monocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring- forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(0)2, N-oxide etc.) or a nitrogen atom can be quaternized.
- the heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some
- the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
- a heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
- heterocycloalkyl groups include azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, morpholino, 3-oxa-9- azaspiro[5.5]undecanyl, l-oxa-8-azaspiro[4.5]decanyl, piperidinyl, piperazinyl,
- oxopiperazdnyl pyranyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropanyl, and thiomorpholino.
- the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.
- the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
- One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid.
- Suitable resolving agents for fractional recrystallization methods are, e.g., optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as ⁇ - camphorsulfonic acid.
- resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane and the like.
- Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
- an optically active resolving agent e.g., dinitrobenzoylphenylglycine
- Suitable elution solvent composition can be determined by one skilled in the art.
- the compounds of the invention have the (/ ⁇ -configuration. In other embodiments, the compounds have the (/ ⁇ -configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g., 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, 1H- and 2H- isoindole and 1H- and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium.
- One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance.
- the compound includes at least one deuterium atom.
- one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium.
- the compound includes two or more deuterium atoms.
- the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art.
- compound as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted.
- the term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
- All compounds, and pharmaceutically acceptable salts thereof can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated.
- solvents e.g., hydrates and solvates
- the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates.
- the compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
- the compounds of the invention, or salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, e.g., a composition enriched in the compounds of the invention.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- ambient temperature and “room temperature,” as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, e.g., a temperature from about 20 °C to about 30 °C.
- the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g., from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
- suitable salts are found in Remington's Pharmaceutical Sciences, 17 th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge e/ a/., J. Pharm. Sci., 1977, 66( ⁇ ), 1-19 and in Stahl et al.,
- the reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., l H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV -visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
- spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., l H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV -visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
- HPLC high performance liquid chromatography
- TLC thin layer chromatography
- Acids of formula 1-2 can react with aromatic amines of formula 1-1 under amide coupling conditions [e.g., in the presence of l-[bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate (HATU) and a suitable base such as N,N- diisopropylethylamine (DIPEA)] to give amide derivatives of formula 1-3.
- amide coupling conditions e.g., in the presence of l-[bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate (HATU) and a suitable base such as N,N- diisopropylethylamine (DIPEA)] to give amide derivatives of formula 1-3.
- DIPEA N,N- diisopropylethyl
- M is a boronic acid, boronic ester or an appropriately substituted metal
- Suzuki coupling conditions e.g., in the presence of a palladium catalyst and a suitable base
- Stille coupling conditions e.g., in the presence of a palladium catalyst
- Negishi coupling conditions e
- compound 1-4 can be a cyclic amine (where M is H and attached to an amine nitrogen in ring Cy) and the coupling of aryl halide 1-3 with the cyclic amine 1-4 can be performed under Buchwald amination conditions (e.g., in the presence of a palladium catalyst and a base such as sodium tert-butoxide).
- Buchwald amination conditions e.g., in the presence of a palladium catalyst and a base such as sodium tert-butoxide.
- compounds of formula 2-5 can also be prepared using reaction sequence as outlined in Scheme 2. Coupling of aromatic halides of formula 2-1 with compounds of formula 2-2 can be achieved using similar conditions as described in Scheme 1 to give compounds of formula 2-3. Acids of formula 2-4 can react with aromatic amines of formula 2-3 under amide coupling conditions to give compounds of formula 2-5.
- Compounds of the present disclosure can inhibit the activity of PD-1/PD-L1 protein/protein interaction and, thus, are useful in treating diseases and disorders associated with activity of PD-1 and the diseases and disorders associated with PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80).
- the compounds of the present disclosure demonstrate better efficacy and favorable safety and toxicity profiles in animal studies.
- the compounds of the present disclosure, or pharmaceutically acceptable salts or stereoisomers thereof are useful for therapeutic administration to enhance, stimulate and/or increase immunity in cancer, sepsis, or chronic infection, including enhancement of response to vaccination.
- the present disclosure provides a method for inhibiting or blocking the PD- 1/PD-Ll protein/protein interaction.
- the method includes administering to an individual or a patient a compound of Formula (I) or any of the formulas as described herein or of a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt or a stereoisomer thereof.
- the compounds of the present disclosure can be used alone, in combination with other agents or therapies or as an adjuvant or neoadjuvant for the treatment of diseases or disorders, including cancer or infection diseases.
- any of the compounds of the disclosure including any of the embodiments thereof, may be used.
- the compounds of the present disclosure inhibit the PD-1/PD-L1 protein/protein interaction, resulting in a PD-1 pathway blockade.
- the blockade of PD-1 can enhance the immune response to cancerous cells and infectious diseases in mammals, including humans.
- the present disclosure provides treatment of an individual or a patient in vivo using a compound of Formula (I) or a salt or stereoisomer thereof such that growth of cancerous tumors is inhibited.
- a compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof, can be used to inhibit the growth of cancerous tumors.
- a compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof can be used in conjunction with other agents or standard cancer treatments, as described below.
- the present disclosure provides a method for inhibiting growth of tumor cells in vitro. The method includes contacting the tumor cells in vitro with a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or of a salt or stereoisomer thereof.
- the present disclosure provides a method for inhibiting growth of tumor cells in an individual or a patient.
- the method includes administering to the individual or patient in need thereof a therapeutically effective amount of a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or a salt or a stereoisomer thereof.
- a method for treating cancer includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
- cancers include those whose growth may be inhibited using compounds of the disclosure and cancers typically responsive to immunotherapy.
- the present disclosure provides a method of enhancing, stimulating and/or increasing the immune response in a patient.
- the method includes administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
- cancers that are treatable using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leuk
- cancers treatable with compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, triple-negative breast cancer, colon cancer, lung cancer (e.g. non-small cell lung cancer and small cell lung cancer), squamous cell head and neck cancer, urothelial cancer (e.g. bladder ) and cancers with high microsatellite instability (MSHiigh). Additionally, the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure.
- melanoma e.g., metastatic malignant melanoma
- renal cancer e.g. clear cell carcinoma
- prostate cancer e.g. hormone refractory prostate adenocarcinoma
- breast cancer triple-negative breast cancer
- colon cancer e.g. non-small cell lung cancer and small cell lung cancer
- cancers that are treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma or multiple myeloma) and combinations
- diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
- Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL) and multiple myeloma (MM).
- ALL acute lymphoblastic leukemia
- AML acute myelog
- Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma.
- Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma.
- NSCLC non-small cell lung cancer
- small cell lung cancer bronchogenic carcinoma
- squamous cell undifferentiated small cell, undifferentiated large cell
- adenocarcinoma adenocarcinoma
- alveolar (bronchiolar) carcinoma bronchial adenoma
- chondromatous hamartoma chondromatous hamartoma
- mesothelioma mesothelioma
- Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.
- esophagus squamous cell carcinoma, adenocarcinoma, leiomy
- Exemplary genitourinary tract cancers include cancers of the kidney
- bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
- liver cancers include hepatoma (hepatocellular carcinoma),
- cholangiocarcinoma hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma
- Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma,
- osteogenic sarcoma osteosarcoma
- fibrosarcoma malignant fibrous histiocytoma
- chondrosarcoma chondrosarcoma
- Ewing's sarcoma malignant lymphoma
- multiple myeloma malignant giant cell tumor chordoma
- osteochronfroma osteocartilaginous exostoses
- benign chondroma chondroma
- Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Duclos disease.
- skull osteoma, hemangioma, granuloma, xanthoma, osteitis de
- Exemplary gynecological cancers include cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma,
- vagina clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes
- Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
- diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple-negative breast cancer (TNBC), myelodysplasia syndromes, testicular cancer, bile duct cancer, esophageal cancer, and urothelial carcinoma.
- PD-1 pathway blockade with compounds of the present disclosure can also be used for treating infections such as viral, bacteria, fungus and parasite infections.
- the present disclosure provides a method for treating infections such as viral infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, a salt thereof.
- viruses causing infections treatable by methods of the present disclosure include, but are not limit to, human immunodeficiency virus, human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, and measles virus.
- viruses causing infections treatable by methods of the present disclosure include, but are not limit to, hepatitis (A, B, or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
- herpes virus e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus
- adenovirus e.g., adenovirus
- influenza virus flaviviruses
- the present disclosure provides a method for treating bacterial infections.
- the method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
- Non-limiting examples of pathogenic bacteria causing infections treatable by methods of the disclosure include chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
- the present disclosure provides a method for treating fungus infections.
- the method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
- pathogenic fungi causing infections treatable by methods of the disclosure include Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus
- Genus Mucorales micor, absidia, rhizophus
- Sporothrix schenkii Blastomyces dermatitidis
- Paracoccidioides brasiliensis Coccidioides immitis
- Histoplasma capsulatum Histoplasma capsulatum.
- the present disclosure provides a method for treating parasite infections.
- the method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
- Non-limiting examples of pathogenic parasites causing infections treatable by methods of the disclosure include Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
- mice preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- treating refers to one or more of (1) inhibiting the disease; e.g., inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; e.g., ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
- the compounds of the invention are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g., preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
- Cancer cell growth and survival can be impacted by multiple signaling pathways.
- Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
- the compounds of the present disclosure can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of diseases, such as cancer or infections.
- diseases such as cancer or infections.
- cancers include solid tumors and liquid tumors, such as blood cancers.
- infections include viral infections, bacterial infections, fungus infections or parasite infections.
- the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF- ⁇ , PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR,
- PDGFPR PI3K (alpha, beta, gamma, delta), CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt- 1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf.
- PI3K alpha, beta, gamma, delta
- the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infections.
- inhibitors that can be combined with the compounds of the present disclosure for treatment of cancer and infections include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib or INCB391 10), an IDO inhibitor (e.g., epacadostat, NLG919, and BMS-986205), an LSD1 inhibitor (e.g., INCB59872 and INCB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50797 and INCB50465), a PI3K-gamma inhibitor such as a PI3K-gamma selective inhibitor, a Pir
- immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1 BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, ⁇ 3, VISTA, PD-1, PD-L1 and PD-L2.
- immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1 BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, L
- the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD 137.
- the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, ⁇ 3, and VISTA.
- the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
- the inhibitor of an immune checkpoint molecule is anti-PDl antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody.
- the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody.
- the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224.
- the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab.
- the anti-PDl antibody is pembrolizumab.
- the anti PD-1 antibody is SHR-1210.
- the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody.
- the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
- the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
- the anti-PD-Ll monoclonal antibody is
- the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
- the anti-CTLA-4 antibody is ipilimumab or tremelimumab.
- the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody.
- the anti-LAG3 antibody is BMS-986016, INCAGN2385 or LAG525.
- the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody.
- the anti-GITR antibody is
- the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody.
- the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
- the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein.
- OX40 e.g., an anti-OX40 antibody or OX40L fusion protein.
- the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS- 986178.
- the OX40L fusion protein is MEDI6383.
- the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
- an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine.
- the proteasome inhibitor is carfilzomib.
- the corticosteroid is dexamethasone (DEX).
- the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
- the compounds of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor- targeted therapy, adjuvant therapy, immunotherapy or surgery.
- immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207
- chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine,
- bevacizumab bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fent
- meclorethamine megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine,
- nofetumomab nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorin
- anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4 (e.g., ipilimumab), 4- 1BB (e.g. urelumab, utomilumab), antibodies to PD-1 and PD-L1, or antibodies to cytokines (IL-10, TGF- ⁇ , etc.).
- CTLA-4 e.g., ipilimumab
- 4- 1BB e.g. urelumab, utomilumab
- PD-1 and PD-L1 antibodies to cytokines (IL-10, TGF- ⁇ , etc.
- cytokines IL-10, TGF- ⁇ , etc.
- Examples of antibodies to PD-1 and/or PD-L1 that can be combined with compounds of the present disclosure for the treatment of cancer or infections such as viral, bacteria, fungus and parasite infections include, but are not limited to, nivoluma
- the compounds of the present disclosure can further be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants or therapeutic antibodies.
- the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines.
- tumor vaccines include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
- tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
- HPV Human Papilloma Viruses
- HBV and HCV Hepatitis Viruses
- KHSV Kaposi's Herpes Sarcoma Virus
- the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself.
- the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
- the compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells.
- the compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
- the compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
- the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self antigens.
- pathogens for which this therapeutic approach may be particularly useful include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to, HIV, Hepatitis (A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa
- Viruses causing infections treatable by methods of the present disclosure include, but are not limit to human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
- human papillomavirus influenza, hepatitis A,
- Pathogenic bacteria causing infections treatable by methods of the disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
- Pathogenic fungi causing infections treatable by methods of the disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.
- Candida albicans, krusei, glabrata, tropicalis, etc.
- Cryptococcus neoformans Aspergillus (fumigatus, niger, etc.)
- Genus Mucorales micor, absidia, rhizophus
- Sporothrix schenkii Blastomyces dermatitidis
- Paracoccidioides brasiliensis C
- Pathogenic parasites causing infections treatable by methods of the disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
- more than one pharmaceutical agent When more than one pharmaceutical agent is administered to a patient, they can be administered simultaneously, separately, sequentially, or in combination (e.g., for more than two agents).
- the compounds of the present disclosure can be administered in the form of pharmaceutical compositions.
- a composition comprising a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any of the embodiments thereof, and at least one pharmaceutically acceptable carrier or excipient.
- These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated.
- Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, e.g., by a continuous perfusion pump.
- Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- compositions which contain, as the active ingredient, the compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers or excipients.
- the composition is suitable for topical administration.
- the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g., a capsule, sachet, paper, or other container.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g., up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
- the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
- the compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
- Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose.
- the formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof.
- SMCC silicified microcrystalline cellulose
- the silicified SMCC silicified microcrystalline cellulose
- microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
- the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
- the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxy propyl methylcellulose and polyethylene oxide.
- the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxy propyl methylcellulose.
- the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide.
- the composition further comprises magnesium stearate or silicon dioxide.
- the microcrystalline cellulose is Avicel PHI 02TM.
- the lactose monohydrate is Fast-flo 316TM.
- the hy droxypropy 1 methylcellulose is hydroxy propyl methylcellulose 2208 K4M (e.g., Methocel K4 M
- the polyethylene oxide is polyethylene oxide WSR 1 105 (e.g., Poly ox WSR 1 105TM).
- a wet granulation process is used to produce the composition.
- a dry granulation process is used to produce the composition.
- compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable
- the components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade).
- the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration.
- suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good
- the active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms and the like.
- the therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
- the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
- Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
- the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
- a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
- the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention.
- the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
- Topical formulations can contain one or more conventional carriers.
- ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, poly oxy ethylene alkyl ether, propylene glycol, white Vaseline, and the like.
- Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol.
- Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxy ethyl cellulose, and the like.
- topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention.
- the topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
- compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like.
- compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the compound preparations typically will be between 3 and 1 1, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts.
- the therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
- the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
- Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
- the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the compounds of the present disclosure can further be useful in investigations of biological processes in normal and abnormal tissues.
- another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quanti taring PD-1 or PD-L1 protein in tissue samples, including human, and for identifying PD-L1 ligands by inhibition binding of a labeled compound.
- the present invention includes PD-1/PD-L1 binding assays that contain such labeled compounds.
- the present invention further includes isotopically -substituted compounds of the disclosure.
- An "isotopically -substituted" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having the same atomic number but different atomic mass or mass number e.g., a different atomic mass or mass number from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
- a "radio-labeled” is a compound that has incorporated at least one one isotope that is radioactive (e.g., radionuclide). Suitable radionuclides that may be
- incorporated in compounds of the present invention include but are not limited to 3 H (also written as T for tritium), n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 13 'I.
- the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro PD-L1 protein labeling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, 125 1, 13 '1, 35 S or will generally be most useful.
- n C, 18 F, 125 1, 123 1, 124 I, 13 '1, 75 Br, 76 Br or 77 Br will generally be most useful.
- a "radio-labeled" or “labeled compound” is a compound that has incorporated at least one radionuclide.
- the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1, 35 S and 82 Br. Synthetic methods for incorporating radio-isotopes into organic compounds are known in the art.
- a radio-labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds.
- a newly synthesized or identified compound i.e., test compound
- a test compound which is labeled can be evaluated for its ability to bind a PD- Ll protein by monitoring its concentration variation when contacting with the PD-L1 protein, through tracking of the labeling.
- a test compound radio-labeled
- the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
- kits useful useful, e.g., in the treatment or prevention of diseases or disorders associated with the activity of PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80), such as cancer or infections, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof.
- kits can further include one or more of various conventional pharmaceutical kit components, such as, e.g., containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
- Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components can also be included in the kit.
- Step 1 5-( ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ methyl)-l,3-oxazole
- Step 2 5-( ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ methyl)-l,3-oxazole-2-carboxylic acid
- Step 4 5-(hydroxymethyl)-N-(2-methylbiphenyl-3-yl)-l, 3-oxazole-2-carboxamide
- Step 5 5-formyl-N-(2-methylbiphenyl-3-yl)- 1 , 3-oxazole-2-carboxamide
- Dimethyl sulfoxide 40 ⁇ L , 0.56 mmol
- oxalyl chloride 2M in DCM, 0.14 mL, 0.28 mmol
- methylene chloride 0.6 mL
- 5-(hydroxymethyl)-N-(2-methylbiphenyl-3-yl)-l,3-oxazole-2-carboxamide 43 mg, 0.14 mmol
- methylene chloride 0.2 mL
- Step 6 5- ⁇ [(2-hydroxyethyl)amino]methyl ⁇ -N-(2-methylbiphenyl-3-yl)-l,3-oxazole-2- carboxamide
- Step 1 5-bromo-l -methyl- lH-imidazole-2-carboxylic acid
- ethyl 5-bromo-l-methyl-lH-imidazole-2-carboxylate (Anichem, cat#K20110: 250 mg, 1.1 mmol) in tetrahydrofuran (20 mL) were added lithium hydroxide monohydrate (230 mg, 5.6 mmol) and water (0.4 mL).
- the resulting mixture was stirred at room temperature for 2 h then concentrated. The residue was used in the next step without further purification.
- Step 1 This compound was prepared using similar procedures as described for Example 1 with 5-bromo-l-methyl-lH-imidazole-2-carboxylic acid (Step 1) replacing 5-bromo-l,3- thiazole-2-carboxylic acid in Step 2.
- LC-MS calculated for
- Step 3 4-chloro-5-( 1, 3-dioxolan-2-yl)-N-(2-methylbiphenyl-3-yl)-l, 3-thiazole-2-carboxamide
- Step 4 4 ⁇ hloro-5-formyl-N-(2-methylbiphenyl-3-yl)-J,3-thiazole-2-carboxamide
- Step 5 4-chloro-5- ⁇ [(2-hydroxyethyl)amino]methyl ⁇ -N-(2-methylbiphenyl-3-yl)-1,3-thiazole- 2-carboxamide
- Step 1 ethyl l-methyl-5-vinyl-lH-pyrazole-3-carboxylate
- Step 3 N-(3-bromo-2-cyanophenyl)-5-formyl-l -methyl- lH-pyrazole-3-carboxamide
- Step 4 N-(3-bromo-2-cyanophenyl)-5- ⁇ [(2-hydroxyethyl)amino]methyl ⁇ -l-methyl-lH- pyrazole-3-carboxamide
- Step 5 N-[ 2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl ]-5- ⁇ [ (2- hydroxyethyl)amino]methyl ⁇ -l -methyl- lH-pyrazole-3-carboxamide
- This compound was prepared using similar procedures as described for Example 10, Step 5 with 2-fluorophenylboronic acid (Aldrich, cat#445223) replacing 6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine.
- This compound was prepared using similar procedures as described for Example 10, Step 5 with l-Methylindazole-4-boronic acid (AstaTech, cat#64580) replacing 6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine.
- Step 1 N-(3-bromo-2-cyanophenyl)-5- ⁇ [(2-hydroxyethyl)amino]methyl ⁇ -l-methyl-lH- imidazole-2-carboxamide
- Step 2 N-[ 2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl ]-5- ⁇ [ (2- hydroxyethyl)amino]methyl ⁇ -l -methyl- lH-imidazole-2-carboxamide
- This compound was prepared using similar procedures as described for Example 15, Step 2 with l-Methylindazole-4-boronic acid (AstaTech, cat#64580) replacing 6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine.
- LC-MS calculated for C23H24N7O2 (M+H) + : m/z 430.2; found 430.1.
- Step 1 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-hydroxybenzaldehyde
- Step 3 (S)-l-(4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-((5-cyanopyridin-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid
- Methyl 5-bromothiazole-2-carboxylate (0.72 g, 3.24 mmol), 4,4,5,5-tetramethyl-2- vinyl-l,3,2-dioxaborolane (0.55 ml, 3.24 mmol), tetrakis(triphenylphosphine)palladium(0) (0.375 g, 0.324 mmol) and potassium carbonate (0.896 g, 6.48 mmol) were weighed into a microwave vial. 1,4-Dioxane (3 ml) and water (0.6 ml) were added and the mixture was purged with N 2 for 5 min. The mixture was heated at 100 °C for 2 h and then cooled to room temperature and concentrated. The residue was purified on silica gel column (0-100%
- Step 7 5-formyl-N-(2-methyl-3-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl)thiazole- 2-carboxamide
- Step 8 (S)-J-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-formylthiazo
- Step 9 (S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-(((2- hydroxyethyl)amino)methyl)thiazole-2-carboxamido)-2[
- Step 3 5-formyl-N-(3'-(5-formyl-l -methyl- lH-pyrazole-3-carboxamido)-2, 2 '-dimethyl- ⁇ [ 1, 1 '- biphenyl ]-3-yl) thiazole-2-carboxam ide
- Step 4 5-(((R)-3-hydroxypyrrolidin-l-yl)methyl)-N-(3'-(5-(((R)-3-hydroxypyrrolidin-l- yl)methyl)-l-methyl-lH-pyrazole-3-carboxamido)-2,2'-dimethyl-[l,r-biphenyl]-3- yl)thiazole-2-carboxamide
- the assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ⁇ . Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25° C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA.
- Recombinant human PD-L1 protein (19-238) with a His- tag at the C-terminus was purchased from AcroBiosy stems (PD1-H5229).
- Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from
- PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 nL was added to the plate well. Plates were centrifuged and proteins were
- Example 1 Data obtained for the Example compounds using the PD-1/PD-L1 homogenous time- resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 1.
- Table 1 Data obtained for the Example compounds using the PD-1/PD-L1 homogenous time- resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
Description
HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
FIELD OF THE INVENTION
The present application is concerned with pharmaceutically active compounds. The disclosure provides compounds as well as their compositions and methods of use. The compounds modulate PD-1/PD-L1 protein/protein interaction and are useful in the treatment of various diseases including infectious diseases and cancer.
BACKGROUND OF THE INVENTION
The immune system plays an important role in controlling and eradicating diseases such as cancer. However, cancer cells often develop strategies to evade or to suppress the immune system in order to favor their growth. One such mechanism is altering the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al, J. Clinical Oncology 2015, 1-9). Blocking the signaling of an inhibitory immune checkpoint, such as PD-1, has proven to be a promising and effective treatment modality.
Programmed cell death- 1 (PD-1), also known as CD279, is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al, Annu. Rev. Immunol 2005, 23:515-548; Okazaki and Honjo, Trends Immunol 2006, (4): 195-201). It functions as an intrinsic negative feedback system to prevent the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. In addition, PD- 1 is also known to play a critical role in the suppression of antigen-specific T cell response in diseases like cancer and viral infection (Sharpe et al, Nat Immunol 2007 8, 239-245; Postow et al, J. Clinical Oncol 2015, 1-9).
The structure of PD-1 consists of an extracellular immunoglobulin variable-like domain followed by a transmembrane region and an intracellular domain (Parry et al, Mol Cell Biol 2005, 9543-9553). The intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor- mediated signals. PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al, Mol Cell Biol 2005, 9543-9553; Latchman et al, Nat Immunol 2001, 2, 261-268), and they differ in their expression patterns. PD-L1 protein is upregulated on macrophages and dendritic cells in response to lipopolysaccharide and GM-CSF treatment, and on T cells and B cells upon T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN-γ treatment (Iwai et al,
PNAS2002, 99(19): 12293-7; Blank et al, Cancer Res 2004, 64(3): 1140-5). In fact, tumor PD- Ll expression status has been shown to be prognostic in multiple tumor types (Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015; Sabatier et al, Oncotarget 2015, 6(7): 5449-5464). PD-L2 expression, in contrast, is more restricted and is expressed mainly by dendritic cells (Nakae et al, J Immunol 2006, 177:566-73). Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers a signal that inhibits IL-2 and IFN-γ production, as well as cell proliferation induced upon T cell receptor activation (Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000, 192(7): 1027-34). The mechanism involves recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol 2007, 8, 239-245).
Activation of the PD-1 signaling axis also attenuates PKC-Θ activation loop phosphorylation, which is necessary for the activation of NF-κΒ and API pathways, and for cytokine production such as IL-2, IFN-γ and TNF (Sharpe et al, Nat Immunol 2007, 8, 239-245; Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000,
192(7): 1027-34).
Several lines of evidence from preclinical animal studies indicate that PD-1 and its ligands negatively regulate immune responses. PD-1 -deficient mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al, Immunity 1999, 1 1 : 141-151; Nishimura et al, Science 2001, 291 :319-322). Using an LCMV model of chronic infection, it has been shown that PD-1/PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus-specific CD8 T cells (Barber et al, Nature 2006, 439, 682-7). Together, these data support the development of a therapeutic approach to block the PD-1 -mediated inhibitory signaling cascade in order to augment or "rescue" T cell response. Accordingly, there is a need for new compounds that block PD-1/PD-L1 protein/protein interaction.
SUMMARY
The present disclosure provides, inter alia, a compound of Formula (I):
(I)
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein constituent variables are defined herein.
The present disclosure further provides a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof, and at least one pharmaceutically acceptable carrier or excipient.
The present disclosure further provides methods of modulating or inhibiting PD- 1/PD-Ll protein/protein interaction, which comprises administering to an individual a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
The present disclosure further provides methods of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
DETAILED DESCRIPTION
I. Compounds
Provided herein is a com ound of Formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10cycloalkyl, C3- 10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR10, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, -P(O)R10R10, -P(O)(OR10)(OR10), - B(OH)2, -B(OR10)2 and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alky 1, C2-4 alkenyl, C1-4 alkynyl, C1-4alkoxy, C3-6 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6- 10 aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N02, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, -P(0)RaRa, -P(0)(ORa)(ORa), -B(OH)2, - B(ORa)2, and S(0)2NRaRa, wherein the CM alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from B, P, N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR1R1 1, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR1R1 1, S(0)R11, S(0)NR11R11, S(0)2R11, -P(0)R11R11, - PCOXOR'OCOR11), -B(OH)2, -B(OR11)2, or SCO)2NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3
independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'^CONR1R1 1, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR11S(0)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, -P(0)R11R11, - PiOXOR'^iOR11), -B(OH)2, -B(OR11)2, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2- methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4
alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, -P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, -P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, - P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of
Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, -P(0)RgRg, -P(0)(ORg)(ORg), - B(OH)2, -B(ORg)2 and S(0)2NRgRg; wherein the CM alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°,
OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°, NR°S(0)2NR0R0, - P(0)R°R°, -P(0)(OR°)(OR°), -B(OH)2, -B(OR°)2 and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, -P(0)ReRe, -P(0)(ORe)(ORe), -B(OH)2, -B(ORe)2 and S(0)2NReRe, wherein the C1-6 alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCiCONRH', NHRr, NRTlr, NRrC(0)Rr, NR^CONRTl', NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRH', S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr, -Ρ(Ο)RrRr, -P(0)(ORr)(ORr), -B(OH)2, -B(OR02 and S(0)2NRrRr, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Ri substituents; or any two Ra substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10aryl, 5-6 membered heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, (4-7 membered heterocycloalkyl)-C1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR', SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NRiRi, NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi, NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)Ri, S(0)NRiRi, 8(0)2Ri, NR'SiO)2R1,
NRiS(0)2NRiRi, -Ρ(Ο)RiRi, -Ρ(0)(ΟΚ')(ΟΚ'), -B(OH)2, -B(OR)2 and SiO)2NRfc1, wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered
heterocycloalkyl, C6-10aryl, 5-6 membered heteroaryl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl- C14 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 Rj substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C1-4 alkenyl, C1-4 alkynyl, halo, C1-4haloalkyl, C1-4 haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(O)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, -P(0)R¾k, -P(0)(ORk)(ORk), -B(OH)2, -B(ORk)2 and S(0)2NRkRk, wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C1-4 haloalkyl, and C1- 4 haloalkoxy of R" are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents;
or any two Rk substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally
substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents;
or any two R° substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R10 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R11 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR.5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C1-4 alkenyl, C1-4 alkynyl, halo, CN, OR10, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, -P(O)R10R10, -P(O)(OR10)(OR10), - B(OH)2, -B(OR10)2 and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C1-4 alkynyl, C1-4alkoxy, C3-6 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6- 10 aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N02, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, -P(0)RaRa, -P(0)(ORa)(ORa), -B(OH)2, - B(ORa)2, and S(0)2NRaRa, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from B, P, N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'^CONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR1^1, S(0)R11, S(0)NR11R11, S(0)2R11, -P(0)R11R11, - PCOXOR'OCOR11), -B(OH)2, -B(OR11)2, or S^NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3
independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'^CONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, -P(0)R11R11, - PiOXOR'^iOR11), -B(OH)2, -B(OR11)2, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2-
methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2,
NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, -P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, -P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, - P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, -P(0)RgRg, -P(0)(ORg)(ORg), - B(OH)2, -B(ORG)2 and S(0>2NRgRg; wherein the C M alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°,
OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°, NR0S(0)2NR0R°, - P(0)R°R°, -P(0)(OR°)(OR°), -B(OH)2, -B(OR°)2 and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, -P(0)ReRe, -P(0)(ORe)(ORe), -B(OH)2,
-B(ORe)2 and S(0)2NReRe, wherein the C M alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCiCONRH', NHRr, NRTlr, NRrC(0)Rr, NR1C ONRTl', NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRH', S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr, -Ρ(Ο^Έ.Γ, -P(0)(ORr)(ORr), -B(OH)2, -B(OR02 and S(0)2NRrRr, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents; or any two Ra substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group
optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10aryl,
5- 6 membered heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, (4-7 membered heterocycloalkyl)-C1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR', SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NRiRi, NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi, NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)R', S(0)NRiRi, SiO)2R', NR'SiO)2R', NRiS(0)2NRiRi, -Ρ(Ο)RiRi, -Ρ(0)(0Ri)(0Ri), -B(OH)2, -B(OR)2 and SiO)2NRfc1, wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered
heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C6-10 aiyl-C1-4 alkyl-, C3-10 cycloalkyl- C14 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 R> substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4haloalkyl, C1-4 haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, CiCONR1^, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NR'K^OJR'S NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, -P(0)R¾k, -P(0)(ORk)(ORk), -B(OH)2, -B(ORk)2 and S(0)2NRkRk, wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or
6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C1-4 haloalkyl, and C1- 4 haloalkoxy of R" are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or any two Rk substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or any two R° substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R10 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R11 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments, the present disclosure provides a compound of Formula (I),
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C2^ alkenyl, C2^ alkynyl, halo, CN, OR10, C1^ haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-6alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the C1-6 alkyl, C_^ alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11,
NR11S(0)2R11, NR1 1C(O)2NR1*11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered
heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Cw alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C 1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°,
NR°S(0)2NR°R°, and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the C1-4 alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCXCONRH', NHRr, NRTlr, NRrC(0)Rr, NRtiCONRTl', NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRT^, S(0)2Rr, NRrS(0)2Rr, ΜΙ¾(0)2ΜΠΙΓ and S(0)2NRrRr, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered
heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, (4-7 membered heterocy cloalkyl)-C 1-4 alky 1-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, ORi, SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NRiRi,
NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi,
NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)R', S(0)NRiRi, SiO)2R', NR'SiO)2R',
NR'SiO)2NR'R', and SiCO-NR'R', wherein the C M alkyl, C1-6 haloalkyl, C M haloalkoxy, C3- 10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C6-10 aryl- C14 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocy cloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 R> substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2^ alkenyl, C2^ alkynyl, halo, C1-4 haloalkyl, C1-4 haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(C-JR* NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and S(0)2NRkRk; wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2^ alkenyl, C1-4 haloalkyl, and C1-4 haloalkoxy of Ri are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Ri substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Ri, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Ri is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C1-4 alkenyl, C1-4 alkynyl, halo, CN, OR10, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N02, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the C1-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered
heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR1^1, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4
alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2RC and S(0)2NRCRC; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10
cycloalkyl-C 1-4 alky 1-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocy cloalkyl)-C 1-4 alky 1-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Cw alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alky 1- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C 1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°,
NR°S(0)2NR°R°, and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Ri substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aiyl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocy cloalkyl)-C 1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the C1-4 alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1-
, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rs is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 RP substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCiCONRH', NHRr, NRTlr, NRrC(0)Rr, NR1C ONRTl', NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRTl', S(0)2Rr, NRrS(0)2Rr, NRiSiO)2NRH' and S(0>2NRrRr, wherein the C1-4 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered heterocycloalkyl)-C 1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NR'R',
NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi,
NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)R', S(0)NRiRi, 8(0)2Ri, NR'SiO)2R1, NRiS (0)2ΝRiRi, and 8(0>2ΝRiRi, wherein the C1-4 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3- 10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C6-10 aryl- C14 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 R>
substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C1-4 alkenyl, C1-4 alkynyl, halo, C1-4 haloalkyl, C1^ haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(C-JR* NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and S(O)2NRkRk; wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C1-4 alkenyl, C1-4 haloalkyl, and C1-4 haloalkoxy of R" are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-C 1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C2^ alkenyl, C2^ alkynyl, halo, CN, OR10, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10
cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-C 1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the C1-6 alkyl, C2* alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR1 1C(OJNR11!*11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11,
NR11S(0)2R11, NR1 1C(O)2NR1*11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR1 1C(OJNR111R1, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR1 1C(O)2NR1*11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered
heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2RC and S(0)2NRCRC; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2RC and S(0)2NRCRC; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-
io aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Cw alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected
from C 1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°,
NR°S(0)2NR°R°, and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the C1-4 alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl,
C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCiCONRH', NHRr, NRTlr, NRrC(0)Rr, NR1C ONRTl', NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRH', S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the C1-4 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, (4-7 membered heterocycloalkyl)-C 1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, ORi, SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NR'R',
NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi,
NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)R', S(0)NRiRi, 8(0)2Ri, NR'SiO)2R1, >ΠΙ'8(0)2ΝRiRi, and 8(0)2ΝRiRi, wherein the C1-4 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3- 10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C6-10 aryl- C14 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 Ri substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2^ alkenyl, C2^ alkynyl, halo, C1-4 haloalkyl, C1-4 haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NR^iOiR15, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and S(0)2NRkRk; wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2^ alkenyl, C1-4 haloalkyl, and C1-4 haloalkoxy of Ri are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl,
phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments, any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq.
In some embodiments, R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR1 1C(OJNR11!*11, C(=NR11)R11,
C(=NR11)NR11R11, NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR11S(0)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10 aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; and
R9 is C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1-
, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; each Rbl is independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6- lo aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alky 1- , C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
In some embodiments, the compound provided herein is a compound having Formula
(II):
(II)
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiments, (i) X1 is N, X2 is CR2 and X3 is CR3; (ii) X1 is CR1, X2 is N and X3 is CR3; (iii) X1 is CR1, X2 is CR2 and X3 is N; (iv) X1 is N, X2 is CR2 and X3 is N; (v) X1 is N, X2 is N and X3 is CR3; or (vi) X1 is CR1, X2 is N and X3 is N.
In some embodiments, X1 is N, X2 is CR2 and X3 is CR3. In some embodiments, X1 is CR1, X2 is N and X3 is CR3. In some embodiments, X1 is CR1, X2 is CR2 and X3 is N. In some embodiments, X1 is N, X2 is CR2 and X3 is N. In some embodiments, X1 is N, X2 is N and X3 is CR3. In some embodiments, X1 is CR1, X2 is N and X3 is N.
In some embodiments, the compound provided herein is a compound having Formula
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
L is a bond, -C(0)NR13-, -NR13C(0)-, O, -(CR14R15)q-, -(CR14R15)q-0-, -
0(CR14R15)q-, -NR13-, -(CR14R15)q-NR13-, -NR13-(CR14R15)q-, -CH=CH-,— C≡C- - SO2NR13-, -NR13S02-, -NR13S02NR13-, -NR13C(0)0-, -OC(0)NR13 or -NR13C(0)NR13-; each R13 is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CN, halo,
OH, -COOH, NH2, -NHC1-4 alkyl and -N(C1-4 alkyl)2;
R14 and R15 are each independently selected from H, halo, CN, OH, -COOH, C1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R14 or R15 are each optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or R14 and R15 taken together with the carbon atom to which they are attached form
3-, 4-, 5- or 6-membered cycloalkyl or 3-, 4-, 5- or 6-membered heterocycloalkyl, each of which is optionally substituted with 1 or 2 independently selected Rq substituents;
ring B is C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2 or 3 independently selected Rd substituents; and
the subscript n is an integer of 1, 2, 3 or 4.
In some embodiments, the compound provided herein is a compound having Formula
(Ilia):
R2, R3, R7, X4, X5, and R8 are as described herein.
In some embodiments, the compound provided herein is a compound having Formula
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein ring B, L, R6, R1, R2, R3, R7, X4, X5, and R8 are as described herein
In some embodiments, the compound provided herein is a compound having Formula (IIIa-2):
(IIIa-2) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein ring B, L, R6, n, R1, R2, R3, R7, R5, and R8 are as described herein.
In some embodiments, Rd is C1-6 alkyl, phenyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, ORe, C(0)Re, halo or CN, wherein the C1-6 alkyl, phenyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4
alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1, 2 or 3 independently selected Rf substituents.
In some embodiments, Rd is (3-carboxypyrrolidin-l-yl)methyl, (R)-(3- carboxypyrrolidin-l-yl)methyl, (S)-(3-carboxypyrrolidin-l-yl)methyl, (3-hydroxypyrrolidin- l-yl)methyl, (R)-(3-hydroxypyrrolidin-l-yl)methyl, (S)-(3-hydroxypyrrolidin-l-yl)methyl, (2-hydroxyethylamino)methyl, (2-hydroxy-2-methylpropylamino)methyl, 2- (dimethylamino)ethanoyl, 2-(3-carboxyazetidin-l-yl)ethanoyl, (R)-2-(3-carboxyazetidin-l- yl)ethanoyl, (S)-2-(3-carboxyazetidin-l-yl)ethanoyl, 2-(2-carboxypiperidin-l-yl)ethanoyl, (R)-2-(2-carboxypiperidin-l-yl)ethanoyl, (S)-2-(2-carboxypiperidin-l-yl)ethanoyl, 2-(3- carboxypyrrolidin-l-yl)ethanoyl, (S)-2-(3-carboxypyrrolidin-l-yl)ethanoyl, (R)-2-(3- carboxypyrrolidin-l-yl)ethanoyl, (5-cyanopyridin-3-yl)methoxy, (2- hydroxyethylamino)methyl, 2-carboxy-l-piperidinylmethyl, (S)-2-carboxy-l- piperidinylmethyl, (R)-2-carboxy-l-piperidinylmethyl, halo or CN.
In some embodiments, (i) X4 is S and X5 is CR5; (ii) X4 is O and X5 is CR5; (iii) X4 is NR4 and X5 is CR5; or (iv) X4 is CR4 and X5 is NR5. In some embodiments, X4 is S and X5 is CR5. In some embodiments, X4 is O and X5 is CR5. In some embodiments, X4 is NR4 and X5 is CR5. In some embodiments, X4 is CR4 and X5 is NR5.
In some embodiments, Cy is phenyl, 5- or 6-membered heteroaryl, C3-6 cycloalkyl or
5- or 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or
6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
In some embodiments, Cy is phenyl, 2-thiophenyl, 3-thiophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3,6-dihydro-2H-pyran-4-yl, cyclohexyl, cyclohexenyl, 2,3-dihydro-l,4- benzodioxin-6-yl, l,3-benzodioxin-5-yl, 2-methylindazol-6-yl or l-methylindazol-4-yl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents.
In some embodiments, Cy is phenyl, 2,3-dihydro-l,4-benzodioxin-6-yl, 2- fluorophenyl, 2-fluoro-3-methoxyphenyl, or l-methyl-lH-indazol-4-yl. For example, Cy is unsubstituted phenyl. In some embodiments, Cy is phenyl optionally substituted with 1 to 5 independently selected R6 substituents. In certain embodiments, Cy is phenyl is substituted with 1 to 5 substituents selected from halo or ORa. In certain embodiments, Cy is phenyl is substituted with 1 to 2 substituents selected from halo or 0-C1-6 alkyl.
In some embodiments, R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR10, C1-4haloalkyl, C1-4haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10,
C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10, NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 groups-independently selected from halo, OH, CN and C1-4 alkoxy.
In some embodiments, R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NH-C 1-4 alkyl, and -N(C1-4alkyl)2.
In some embodiments, R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, and OH. For example, R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl. In certain embodiments, R1, R2 and R3 are H.
In some embodiments, R4 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl or C1-6 haloalkoxy. In some embodiments, R4 is H.
In some embodiments, R5 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl or C1-6 haloalkoxy. In some embodiments, R5 is H.
In some embodiments, R6 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa, C(0)NRaRa, or NRaC(0)Ra, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
In some embodiments, R6 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CN, or ORa, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6- membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7- membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
In some embodiments, R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NH2, NH(C1-6 alkyl), N(C1-6 alky 1)2, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl or phenyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and phenyl are each optionally substituted with 1, 2 or 3 independently selected Rq substituents.
In some embodiments, R8 is C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents or (4-10 membered heterocycloalkyl)-C1-4 alkyl- optionally substituted with 1, 2 or 3 independently selected Rb substituents. In some embodiments, R8 is C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents.
In some embodiments, R8 is C1-6 alkyl or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl and (4-10 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
In some embodiments, R8 is C1-6 alkyl substituted with Rb.
In some embodiments, R8 is -CH2NHRC or -CH2NRCRC.
In some embodiments, R8 is (2-hydroxyethylamino)methyl, 2-carboxy-l- piperidinylmethyl, (S)-2-carboxy-l-piperidinylmethyl, (R)-2-carboxy-l-piperidinylmethyl, or 3 -hy droxy py rrol i din- 1 -y 1 methy 1.
In some embodiments, R8 is (2-hydroxyethylamino)methyl, 2-carboxy-l- piperidinylmethyl, (S)-2-carboxy-l-piperidinylmethyl, or (R)-2-carboxy-l-piperidinylmethyl.
In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, N NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is phenyl, C3-6 cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused 5-, 6- or 7-membered heterocycloalkyl ring, or a fused 5- or 6-membered heteroaryl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, halo, CN, OH, COOH, C1-4 alkoxy, C1^ haloalkyl, C1^ haloalkoxy, cyclopropyl, cyclopropylmethyl, phenyl, phenyl-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-C1- 4 alkyl-, NH2, -NHC1-4 alkyl, -N(C1-4 alkyl)2, -C(0)R10, -0(CO)R10, -C(0)OR10, - 0(CO)NHR10, -NHC(0)OR10, -NHC(0)NHR10, -C(0)NHR10, -NHC(0)R10, -SO2R10, - NHSO2R10 and -SO2NHR10, wherein the C1-4 alkyl, C1-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, cyclopropyl, cyclopropylmethyl, phenyl, phenyl-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, 4-6 membered heterocycloalkyl and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2 or R3 are each optionally substituted with halo, OH, CN or C1-4 alkoxy;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C1-6 alkoxy,
C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1- 4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- or (4-6 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, COOH, NO2, ORa, C(0)ORa, NH2, -NHRa, -N(Ra)2, -C(0)Ra, -0(CO)Ra, - C(0)ORa, -0(CO)NRaRa, -NHC(0)ORa, -NHC(0)NRaRa, -C(0)NRaRa, -NHC(0)Ra, -S02Ra, -NHS02Ra and -S02NRaRa, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C1-4 alkyl-, C3- 6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered
heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1 or 2 Rb substituents;
R7 is halo, C1-6 alkyl, CN, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C1-4 alkyl-, (4-6 membered heterocycloalkyl)-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl, wherein C1-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C1-4 alkyl-, (4-6 membered heterocycloalkyl)-C1-4 alkyl- and (5-6 membered heteroaryl)-C1-4 alkyl of R7 are each optionally substituted with 1 or 2 susbtituents independently selected from halo, C1-6 alkyl, C1-4 haloalkyl, C1-6haloalkoxy,CN, OH, NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, COOH, -OC 1-6 alkyl, -SC1-6 alkyl, C(0)NH2, -C(0)NH(C1-6 alkyl), -C(0)NH(C1-6 alkyl)2, -C(0)OC1-6 alkyl, -OC(0)NHC1-6 alkyl, -OC(0)NH2, -OC(0)NH(C1-6alkyl)2, -NHC(0)C1-6 alkyl, - NHC(0)H, -N(Cw alky 1)C(0)C 1-6 alkyl, -NHC(0)OC1-6 alkyl, -N(Cw alky l)C(0)OC1-6 alkyl, -NHC(0)NH(C1-6 alkyl), -NHC(0)N(C1-6alkyl)2, -NHC(0)NH2, -N(C1-6alkyl)C(0)NH(Cw alkyl), -N(C1-6 alkyl)C(0)N(C1-6 alkyl)2, -N(C1-6alkyl)C(0)NH2, -NHS(0)2(C1-6 alkyl), - N(C1-6 alky l)S(0)2(C1-6 alkyl), -NHS(0)2NH2, -NHS(0)2NH(C1-6 alkyl), -NHS(0)2N(C1^ alky 1)2, -N(C1-6alkyl)S(0)2NH2, -N(Cw alky l)S(0)2NH(C1-6 alkyl), -N(C1-6alkyl)S(0)2N(C1- 6 alkyl)2, -S(0)2(C1-6 alkyl), -S(0)2NH2, -S(0)2NH(C1-6 alkyl) and -S(0)2N(C1-6alkyl)2;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, OR11, NH2, -NHR9, -NR9R11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR1 1C(OJNR111R1, NR11S(0)R11, NR^iOfcR11, NR11S(0)2NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Cw haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; and
R9 is C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- or (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6
haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered
heterocycloalkyl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)- C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1 or 2 Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-;
each Rb is independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NHRC, N(RC)2, ORc, C(0)NRcRc, C(0)ORc, COOH, NRcC(0)Rc, OC(0)NRcRc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)2Rc and S(0)2NRcRc, wherein the C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C 1- 4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each optionally substituted with 1 or 2 Rd substituents independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, CN, OH, COOH, ORe, C(0)ORe, NH2, -NHRe, -N(Re)2, -C(0)NReRe, -NReC(0)Re, OC(0)NReRe, NReC(0)ORe, NReC(0)NReRe, NReS(0)2Re, NReS(0)2NReRe, S(0)2Re and S(0>2NReRe, wherein Re is H or C1-6 alkyl;
each Rc is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl,
pheny 1-C 1-4 alky 1-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl- C14 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of Rc are each optionally substituted with 1 or 2 Rf substituents;
or two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected Rh substituents;
each Rf is independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, 4-6 membered
heterocycloalkyl, 5-6 membered heteroaryl, CN, OH, COOH, ORg, C(0)ORg, NH2, -NHRg, - N(Rg)2, -C(0)NRgRg, -NRgC(0)Rg, OC(0)NRgRg, NRgC(0)ORg, NRgC(0)NRgRg,
NRgS(0)2RG, NRgS(0)2NRgRg, S(0>2RG and S(0>2NRgRg, wherein each Rg is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; and
each Rh is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, NHRi, N(R')2, OR', C(0)NRiRi, NR'CiO)Ri and C(0)OR', wherein R1 is H or C1-6 alkyl. In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C6- 10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4 haloalkyl, C 1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, and NR10C(O)OR10, wherein each R10 is independently selected from H, C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl,
wherein the C1-4 alkyl, C1-4alkoxy, C3-10 cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, and
NRaC(0)ORa, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- 14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, and NR11C(0)OR11, wherein the C1-6 alkyl, C2^ alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl, NO2, OR1 SR11, NH2, -NHR9, -NR'R1 \ NHOR1 \ C(0)Rl \ C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, or NR11C(0)OR11, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, and OC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, and NRcC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, and NRcC(0)ORc; wherein the C1-6 haloalkyl, Cw haloalkoxy,
C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents; each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, halo, CN, NHORg, ORs, SRs, C(0)Rs, C(0)NRgRg, C(0)ORg, OC(0)Rs, OC(0)NRSRg, NHRg, NRSRg, NRSC(0)RS,
NRSC(0)NRSRS, and NRSC(0)ORS; wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°,
NR°C(0)NR°R°, and NR°C(0)OR°, wherein the C1-4 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe,
NReC(0)Re, NReC(0)NReRe, and NReC(0)ORe, wherein the C1-6 alkyl, C1-6 haloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, and 4-10 membered heterocycloalkyl of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each R° is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl,
C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6
membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12 and each R12 is
independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, NR4 or CR4;
X5 is NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, halo, CN, OH, C1-6alkoxy, C1-4 haloalkyl, C1^ haloalkoxy, NH2, -NH-C1-4 alkyl, - N(C1-4 alky 1)2, wherein the C1-4 alkyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2^ alkynyl, C1-6 haloalkyl, C1-6haloalkoxy, CN, NO2, ORa, SRa, NHORa, C(0)Ra,
C(0)NRaRa, C(0)ORa, NHRa, and NRaRa, wherein the C1-6 alkyl, C2-6 alkenyl, and C2^ alkynyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN,
NO2, OR11, SR11, NH2, -NHR11, -NR11R11, C(0)R11, C(0)NR11R11, C(0)OR11, NR11C(0)R11, and NR11C(0)OR11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6
haloalkoxy of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, and phenyl substituted with 1-3 independently selected Rbl substituents, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C 1-6 haloalkoxy of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, CN, OH, NH2, NHORc, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, C(0)ORc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, and NRcC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, and NRcC(0)ORc; wherein the C1-6 haloalkyl, C1-4 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents; each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, C2^ alkenyl, C2^ alkynyl, halo, CN, ORs, C(0)Rs, C(0)NRSRg, C(0)ORS, NHRg, NRSRg, and NRSC(0)RS; each Rd is independently selected from C1-6 alkyl,
C1-6haloalkyl, halo, CN, NH2, NHORe, ORe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, and NReC(0)ORe;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and
C2-6 alkynyl;
In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, NR4 or CR4;
X5 is NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, halo, CN, OH, NH2, -NH-C1-4 alkyl, and -N(C1-4 alky 1)2;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and ORa, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or CN, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, and C2-6 alkenyl, wherein the C2-6 alkenyl of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; each Rb substituent is independently selected from halo and C1-6 alkyl;
each Rb2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, NHRC, NRCRC, and NRcC(0)Rc; wherein the C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, ORS, C(0)RS, C(0)NRgRS NHRg, and NRSRS;
each Rd is independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, CN, NH2, ORe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, and NReC(0)Re;
each Re is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; each Rg is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; ^^^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C6-
10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1^ alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, and
NR10C(O)OR10, wherein each R10 is independently selected from H, C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, ORa, SRa, NHORa, C(0)Ra,
C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, and
NRaC(0)ORa, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- 14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, and NR11C(0)OR11, wherein the C1-6 alkyl, C2^ alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11,
OC(0)NR11R11, NR11C(0)R11, or NR11C(0)OR11, wherein the C2^ alkenyl, C2^ alkynyl, Cw
haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alky 1 substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1-
6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, and OC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, and NRcC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH,
NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, and NRcC(0)ORc; wherein the C1-4 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents; each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORS, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRSRg, NHRS, NRSRg, NRSC(0)RS, NRgC(0)NRgRg, and NRgC(0)ORg; wherein the C1-4 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, and NR°C(0)OR°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents; each Rd is independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, and NReC(0)ORe, wherein the C1-6 alkyl, C 1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl and (5-10 membered heteroaryl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl,
halo, CN, ORr, C(0)Rr,€(0)ΝΚΈ.Γ, C(0)ORr, OC(0)Rr, OCCCONRT^, NHRr, NRH', and NRrC(0)Rr;
each R° is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12 and each R12 is independently C1-6 alkyl; and
^is a single bond or a double bond to maintain ring A being aromatic.
In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, NR4 or CR4;
X5 is NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, halo, CN, OH, C1^ alkoxy, C1-4 haloalkyl, C1^ haloalkoxy, NH2, -NH-C1-4 alkyl, - N(C1-4 alky 1)2, wherein the C1-4 alkyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2^ alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NO2, ORa, SRa, NHORa, C(0)Ra,
C(0)NRaRa, C(0)ORa, NHRa, NRaRa, and NRaC(0)Ra, wherein the C1-6 alkyl, C2^ alkenyl, and C2-6 alkynyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused
phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, C(0)R11, C(0)NR11R11, C(0)OR11, NR11C(0)R11, and NR11C(0)OR11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 haloalkoxy of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3
independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and
C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and 5-10 membered heteroaryl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, 5-10 membered heteroaryl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, CN, OH, NH2, NHORc, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, C(0)ORc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, and NRcC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, and NRcC(0)ORc; wherein the C1-6 haloalkyl, C1-4 haloalkoxy,
C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents; each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10aryl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10 aryl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, halo, CN, ORg, C(0)Rg, C(0)NRgRg, C(0)ORg, NHRg, NRgRg, and NRgC(0)Rg; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, OR0, C(0)R°, C(0)NR°R°, C(0)OR°, NHR°, NR°R°, and NR°C(0)R°;
each Rd is independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, and NReC(0)ORe, wherein the C1-4 alkyl and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rg is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2^ alkynyl, halo, CN, ORr, C(0)Rr, C(0)NRTlr, and C(0)ORr;
each R° is independently selected from H and C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic. In some embodiments:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, NR4 or CR4;
X5 is NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, CIA alkynyl, halo, CN, OH, NH2, -NH-C1-6 alkyl, and -N(C1-4 alkyl)2;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, ORa, C(0)NRaRa, and NR1RCOiR3, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or CN, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C2-6 alkenyl and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and 5-
10 membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and 5-10 membered heteroaryl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, and ORc;
each Rb2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, NHRC, NRCRC, and NRcC(0)Rc; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10aryl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10 aryl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, ORg, C(0)Rg, C(0)NRgRg, NHRg, and NRgRg; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, halo, CN, OR0, and C(0)OR°;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, ORe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, and NReC(0)Re; wherein the C1-6 alkyl and (4-10 membered
heterocycloalkyl)-C 1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; each Rg is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and
(5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 RP substituents independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, and CN; each R° is independently selected from H and C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. Thus, it is contemplated as features described as
embodiments of the compounds of Formula (I) can be combined in any suitable combination.
At various places in the present specification, certain features of the compounds are disclosed in groups or in ranges. It is specifically intended that such a disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term "C1-6 alkyl" is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C4 alkyl, Cs alkyl and C6 alkyl.
The term "n-membered," where n is an integer, typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
At various places in the present specification, variables defining divalent linking groups may be described. It is specifically intended that each linking substituent include both the forward and backward forms of the linking substituent. For example, -NR(CRiR")n- includes both -NR(CRiR")n- and -(CRiR")nNR- and is intended to disclose each of the forms individually. Where the structure requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl" then it is understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively.
The term "substituted" means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group. The term "substituted", unless otherwise indicated, refers to any level of substitution, e.g., mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule. The phrase "optionally substituted" means unsubstituted or substituted. The term "substituted" means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms.
The term "Cn-m" indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C1-4, C1-6 and the like.
The term "alkyl" employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched. The term "Cn-m alkyl", refers to an alkyl group having n to m carbon atoms. An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl,
ethyl, ^-propyl, isopropyl, w-butyl, ter/-butyl, isobutyl, sec-butyl; higher homologs such as 2- methyl-1 -butyl, w-pentyl, 3-pentyl, w-hexyl, 1,2,2-trimethylpropyl and the like.
The term "alkenyl" employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more double carbon-carbon bonds. An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound. The term "Cn-m alkenyl" refers to an alkenyl group having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
Example alkenyl groups include, but are not limited to, ethenyl, w-propenyl, isopropenyl, n- butenyl, seobutenyl and the like.
The term "alkynyl" employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more triple carbon-carbon bonds. An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. The term "Cn-m alkynyl" refers to an alkynyl group having n to m carbons.
Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
The term "alkylene", employed alone or in combination with other terms, refers to a divalent alkyl linking group. An alkylene group formally corresponds to an alkane with two C-H bond replaced by points of attachment of the alkylene group to the remainder of the compound. The term "Cn-m alkylene" refers to an alkylene group having n to m carbon atoms. Examples of alkylene groups include, but are not limited to, ethan-l,2-diyl, propan-l,3-diyl, propan-l,2-diyl, butan-l,4-diyl, butan-l,3-diyl, butan-l,2-diyl, 2-methyl-propan-l,3-diyl and the like.
The term "alkoxy", employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group is as defined above. The term "Cn-m alkoxy" refers to an alkoxy group, the alkyl group of which has n to m carbons. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., w-propoxy and isopropoxy), /-butoxy and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
The term "amino" refers to a group of formula -NH2.
The term "carbonyl", employed alone or in combination with other terms, refers to a -C(=0)- group, which also may be written as C(O).
The term "cyano" or "nitrile" refers to a group of formula -C≡N, which also may be written as -CN.
The terms "halo" or "halogen", used alone or in combination with other terms, refers to fluoro, chloro, bromo and iodo. In some embodiments, "halo" refers to a halogen atom selected from F, CI, or Br. In some embodiments, halo groups are F.
The term "haloalkyl" as used herein refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom. The term "Cn-m haloalkyl" refers to a Cn-m alkyl group having n to m carbon atoms and from at least one up to {2(n to m)+l } halogen atoms, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCb, CHCh, C2CI5 and the like. In some embodiments, the haloalkyl group is a fluoroalkyl group.
The term "haloalkoxy", employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl, wherein the haloalkyl group is as defined above. The term "Cn-m haloalkoxy" refers to a haloalkoxy group, the haloalkyl group of which has n to m carbons. Example haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
The term "oxo" refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N-oxide group. In some embodiments, heterocyclic groups may be optionally substituted by 1 or 2 oxo (=0) substituents.
The term "sulfido" refers to a sulfur atom as a divalent substituent, forming a thiocarbonyl group (C=S) when attached to carbon.
The term "aromatic" refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i.e., having (4n + 2) delocalized π (pi) electrons where n is an integer).
The term "aryl," employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or poly cyclic (e.g., having 2 fused rings). The term "Cn-m aryl" refers to an aryl group having from n to m ring carbon atoms. Aryl groups include, e.g., phenyl, naphthyl, indanyl, indenyl and the like. In some embodiments, aryl groups have from 6 to about 10 ring carbon atoms. In some embodiments aryl groups have 6 carbon atoms. In some embodiments aryl groups have 10 ring carbon
atoms. In some embodiments, the aryl group is phenyl. In some embodiments, the aryl group is naphthyl.
The term '¾eteroatom" used herein is meant to include boron, phosphorus, sulfur, oxygen and nitrogen.
The term "heteroaryl" or "heteroaromatic," employed alone or in combination with other terms, refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from boron, phosphorus, sulfur, oxygen and nitrogen. In some embodiments, the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, any ring- forming N in a heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl has 5-14 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-10 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight- membered, nine-membered or ten-membered fused bicyclic heteroaryl ring. Example heteroaryl groups include, but are not limited to, pyridintl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl, naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3- and 2,6-naphthyridine), indolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[l,2-6]thiazolyl, purinyl, and the like.
A five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
A six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
The term "cycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), including cyclized alkyl and alkenyl groups. The term "Cn-m cycloalkyl" refers to a cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6 or 7 ring-forming carbons (C3-7). In some embodiments, the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring- forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, bicyclo[l . l . l]pentanyl, bicyclo[2.1.1]hexanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
The term "heterocycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, boron, sulfur, oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term "heterocycloalkyl" are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring- forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(0)2, N-oxide etc.) or a nitrogen atom can be quaternized. The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some
embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some
embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Examples of heterocycloalkyl groups include azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, morpholino, 3-oxa-9- azaspiro[5.5]undecanyl, l-oxa-8-azaspiro[4.5]decanyl, piperidinyl, piperazinyl,
oxopiperazdnyl, pyranyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropanyl, and thiomorpholino.
At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, e.g., optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as β- camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods
include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
In some embodiments, the compounds of the invention have the (/^-configuration. In other embodiments, the compounds have the (/^-configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g., 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, 1H- and 2H- isoindole and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art.
The term, "compound," as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted. The term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g.,
synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated. When in the solid state, the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates. The compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, e.g., a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The expressions, "ambient temperature" and "room temperature," as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, e.g., a temperature from about 20 °C to about 30 °C.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. The term "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g., from non-toxic inorganic or organic acids. The
pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge e/ a/., J. Pharm. Sci., 1977, 66(\), 1-19 and in Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002). In some embodiments, the compounds described herein include the N- oxide forms.
II. Synthesis
Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes, such as those in the Schemes below.
The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of compounds of the invention can involve the protection and
deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups is described, e.g., in Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); Smith et al, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6th Ed. (Wiley, 2007); Peturssion et al, "Protecting Groups in Carbohydrate Chemistry," J. Chem. Educ, 1997, 74(\ 1), 1297; and Wuts et al., Protective Groups in Organic Synthesis, 4th Ed., (Wiley, 2006).
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., lH or 13C), infrared spectroscopy, spectrophotometry (e.g., UV -visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
The Schemes below provide general guidance in connection with preparing the compounds of the invention. One skilled in the art would understand that the preparations shown in the Schemes can be modified or optimized using general knowledge of organic chemistry to prepare various compounds of the invention.
Compounds of Formula (I) can be prepared, e.g., using a process as illustrated in
Schemes 1-3.
Scheme 1
1-5
Compounds of formula 1-5 can be prepared using procedures as outlined in Scheme 1. Acids of formula 1-2 can react with aromatic amines of formula 1-1 under amide coupling conditions [e.g., in the presence of l-[bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate (HATU) and a suitable base such as N,N- diisopropylethylamine (DIPEA)] to give amide derivatives of formula 1-3. The halide (e.g., Hal1 = CI, Br, I) in compounds 1-3 can be coupled to compounds of formula 1-4, in which M is a boronic acid, boronic ester or an appropriately substituted metal [e.g., M is B(OR)2, Sn(Alkyl)4, or Zn-Hal], under Suzuki coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or Stille coupling conditions (e.g., in the presence of a palladium catalyst), or Negishi coupling conditions (e.g., in the presence of a palladium catalyst) to give derivatives of formula 1-5. Alternatively, compound 1-4 can be a cyclic amine (where M is H and attached to an amine nitrogen in ring Cy) and the coupling of aryl
halide 1-3 with the cyclic amine 1-4 can be performed under Buchwald amination conditions (e.g., in the presence of a palladium catalyst and a base such as sodium tert-butoxide).
Scheme 2
2-5
Alternatively, compounds of formula 2-5 can also be prepared using reaction sequence as outlined in Scheme 2. Coupling of aromatic halides of formula 2-1 with compounds of formula 2-2 can be achieved using similar conditions as described in Scheme 1 to give compounds of formula 2-3. Acids of formula 2-4 can react with aromatic amines of formula 2-3 under amide coupling conditions to give compounds of formula 2-5.
Scheme 3
3-4 3-6
Compounds of formula 3-6 can be prepared as outlined in Scheme 3, starting from compounds of formula 3-1 which can be prepared using synthetic routes as outlined in Scheme 2 or Scheme 1. Coupling of heteroaryl halide 3-1 with vinyl boronic acid/ester 3-2 under Suzuki coupling conditions can give vinyl derivatives of formula 3-3. Oxidative cleavage of the vinyl group in 3-3 (i.e., in the presence of NalCu and OsCu) can provide
aldehyde 3-4. Reductive animation of aldehyde 3-4 with amine 3-5 can give the final compounds of formula 3-6.
III. Uses of the Compounds
Compounds of the present disclosure can inhibit the activity of PD-1/PD-L1 protein/protein interaction and, thus, are useful in treating diseases and disorders associated with activity of PD-1 and the diseases and disorders associated with PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80). Advantageously, the compounds of the present disclosure demonstrate better efficacy and favorable safety and toxicity profiles in animal studies. In certain embodiments, the compounds of the present disclosure, or pharmaceutically acceptable salts or stereoisomers thereof, are useful for therapeutic administration to enhance, stimulate and/or increase immunity in cancer, sepsis, or chronic infection, including enhancement of response to vaccination. In some
embodiments, the present disclosure provides a method for inhibiting or blocking the PD- 1/PD-Ll protein/protein interaction. The method includes administering to an individual or a patient a compound of Formula (I) or any of the formulas as described herein or of a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt or a stereoisomer thereof. The compounds of the present disclosure can be used alone, in combination with other agents or therapies or as an adjuvant or neoadjuvant for the treatment of diseases or disorders, including cancer or infection diseases. For the uses described herein, any of the compounds of the disclosure, including any of the embodiments thereof, may be used.
The compounds of the present disclosure inhibit the PD-1/PD-L1 protein/protein interaction, resulting in a PD-1 pathway blockade. The blockade of PD-1 can enhance the immune response to cancerous cells and infectious diseases in mammals, including humans. In some embodiments, the present disclosure provides treatment of an individual or a patient in vivo using a compound of Formula (I) or a salt or stereoisomer thereof such that growth of cancerous tumors is inhibited. A compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof, can be used to inhibit the growth of cancerous tumors. Alternatively, a compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof, can be used in conjunction with other agents or standard cancer treatments, as described below. In one embodiment, the present disclosure provides a method for inhibiting growth of tumor
cells in vitro. The method includes contacting the tumor cells in vitro with a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or of a salt or stereoisomer thereof. In another embodiment, the present disclosure provides a method for inhibiting growth of tumor cells in an individual or a patient. The method includes administering to the individual or patient in need thereof a therapeutically effective amount of a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or a salt or a stereoisomer thereof.
In some embodiments, provided herein is a method for treating cancer. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Examples of cancers include those whose growth may be inhibited using compounds of the disclosure and cancers typically responsive to immunotherapy.
In some embodiments, the present disclosure provides a method of enhancing, stimulating and/or increasing the immune response in a patient. The method includes administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
Examples of cancers that are treatable using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or urethra, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T -cell lymphoma, environmentally
induced cancers including those induced by asbestos, and combinations of said cancers. The compounds of the present disclosure are also useful for the treatment of metastatic cancers, especially metastatic cancers that express PD-L1.
In some embodiments, cancers treatable with compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, triple-negative breast cancer, colon cancer, lung cancer (e.g. non-small cell lung cancer and small cell lung cancer), squamous cell head and neck cancer, urothelial cancer (e.g. bladder ) and cancers with high microsatellite instability (MSHiigh). Additionally, the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure.
In some embodiments, cancers that are treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma or multiple myeloma) and combinations of said cancers.
In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL) and multiple myeloma (MM).
Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma.
Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma.
Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.
Exemplary genitourinary tract cancers include cancers of the kidney
(adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
Exemplary liver cancers include hepatoma (hepatocellular carcinoma),
cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma
Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma,
chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors
Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Duclos disease.
Exemplary gynecological cancers include cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma,
adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes
(carcinoma).
Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids. In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple-negative breast cancer (TNBC), myelodysplasia syndromes, testicular cancer, bile duct cancer, esophageal cancer, and urothelial carcinoma.
PD-1 pathway blockade with compounds of the present disclosure can also be used for treating infections such as viral, bacteria, fungus and parasite infections. The present disclosure provides a method for treating infections such as viral infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, a salt thereof. Examples of viruses causing infections treatable by methods of the present disclosure include, but are not limit to, human immunodeficiency virus, human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, and measles virus. In some embodiments, viruses causing infections treatable by methods of the present disclosure include, but are not limit to, hepatitis (A, B, or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
The present disclosure provides a method for treating bacterial infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of
pathogenic bacteria causing infections treatable by methods of the disclosure include chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
The present disclosure provides a method for treating fungus infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic fungi causing infections treatable by methods of the disclosure include Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus
(fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and
Histoplasma capsulatum.
The present disclosure provides a method for treating parasite infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic parasites causing infections treatable by methods of the disclosure include Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
The terms "individual" or "patient," used interchangeably, refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
The phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
As used herein, the term "treating" or "treatment" refers to one or more of (1) inhibiting the disease; e.g., inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and
(2) ameliorating the disease; e.g., ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
In some embodiments, the compounds of the invention are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g., preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
Combination Therapies
Cancer cell growth and survival can be impacted by multiple signaling pathways. Thus, it is useful to combine different enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
The compounds of the present disclosure can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of diseases, such as cancer or infections. Examples of cancers include solid tumors and liquid tumors, such as blood cancers. Examples of infections include viral infections, bacterial infections, fungus infections or parasite infections. For example, the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-βΙΙ, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR,
PDGFPR, PI3K (alpha, beta, gamma, delta), CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt- 1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some
embodiments, the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infections. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for treatment of cancer and infections include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g.,
INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib or INCB391 10), an IDO inhibitor (e.g., epacadostat, NLG919, and BMS-986205), an LSD1 inhibitor (e.g., INCB59872 and INCB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50797 and INCB50465), a PI3K-gamma inhibitor such as a PI3K-gamma selective inhibitor, a Pirn inhibitor (e.g., INCB53914), a CSF1R inhibitor, a TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer), an adenosine receptor antagonist (e.g., A2a/A2b receptor antagonist), an HPK1 inhibitor, an angiogenesis inhibitor, an interleukin receptor inhibitor, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors such as INCB54329 and INCB57643), an arginase inhibitor (INCBOl 158), and an adenosine receptor antagonist or combinations thereof.
Compounds of the present disclosure can be used in combination with one or more immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1 BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, ΉΜ3, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD 137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, ΉΜ3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
In some embodiments, the inhibitor of an immune checkpoint molecule is anti-PDl antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PDl antibody is pembrolizumab. In some embodiments, the anti PD-1 antibody is SHR-1210.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446),
or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is
MPDL3280A or MEDI4736.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, INCAGN2385 or LAG525.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is
TRX518, INC AGN 1876, MK-1248, AMG228, BMS-986156, GWN323, MEDI1873 or MK- 4166.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS- 986178. In some embodiments, the OX40L fusion protein is MEDI6383.
Compounds of the present disclosure can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
The compounds of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor- targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207
immunotherapy, cancer vaccine, monoclonal antibody, adoptive T cell transfer, Toll receptor agonists, STING agonists, oncolytic virotherapy and immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor and the like. The compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutics. Example
chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine,
bevacizumab, bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine,
meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine,
nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat and zoledronate.
Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4 (e.g., ipilimumab), 4- 1BB (e.g. urelumab, utomilumab), antibodies to PD-1 and PD-L1, or antibodies to cytokines (IL-10, TGF-β, etc.). Examples of antibodies to PD-1 and/or PD-L1 that can be combined with compounds of the present disclosure for the treatment of cancer or infections such as viral, bacteria, fungus and parasite infections include, but are not limited to, nivolumab, pembrolizumab, MPDL3280A, MEDI-4736 and SHR-1210.
The compounds of the present disclosure can further be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants or therapeutic antibodies.
The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of
tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with a vaccination protocol for the treatment of cancer. In some embodiments, the tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself. In some embodiments, the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
The compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells. The compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self antigens. Examples of pathogens for which this therapeutic approach may be particularly useful, include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to, HIV, Hepatitis (A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa
Viruses causing infections treatable by methods of the present disclosure include, but are not limit to human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus,
respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
Pathogenic bacteria causing infections treatable by methods of the disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
Pathogenic fungi causing infections treatable by methods of the disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.
Pathogenic parasites causing infections treatable by methods of the disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
When more than one pharmaceutical agent is administered to a patient, they can be administered simultaneously, separately, sequentially, or in combination (e.g., for more than two agents).
IV. Formulation, Dosage Forms and Administration
When employed as pharmaceuticals, the compounds of the present disclosure can be administered in the form of pharmaceutical compositions. Thus the present disclosure provides a composition comprising a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any of the embodiments thereof, and at least one pharmaceutically acceptable carrier or excipient. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or
intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, e.g., by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g., a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g., up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl
cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified
microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
In some embodiments, the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxy propyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxy propyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some
embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PHI 02™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hy droxypropy 1 methylcellulose is hydroxy propyl methylcellulose 2208 K4M (e.g., Methocel K4 M
Premier™) and/or hydroxy propyl methylcellulose 2208 K100LV (e.g., Methocel K00LV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1 105 (e.g., Poly ox WSR 1 105™).
In some embodiments, a wet granulation process is used to produce the composition.
In some embodiments, a dry granulation process is used to produce the composition.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active
ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable
pharmaceutical excipient.
The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration. For example, suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good
Manufacturing Practice regulations of the U.S. Food and Drug Administration.
The active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms and the like.
The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a
pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its
route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, poly oxy ethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxy ethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 1 1, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a
pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example,
the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
V. Labeled Compounds and Assay Methods
The compounds of the present disclosure can further be useful in investigations of biological processes in normal and abnormal tissues. Thus, another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quanti taring PD-1 or PD-L1 protein in tissue samples, including human, and for identifying PD-L1 ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes PD-1/PD-L1 binding assays that contain such labeled compounds.
The present invention further includes isotopically -substituted compounds of the disclosure. An "isotopically -substituted" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having the same atomic number but different atomic mass or mass number e.g., a different atomic mass or mass number from the atomic mass or mass number typically found in nature (i.e., naturally occurring). It is to be understood that a "radio-labeled" is a compound that has incorporated at least one one isotope that is radioactive (e.g., radionuclide). Suitable radionuclides that may be
incorporated in compounds of the present invention include but are not limited to 3H (also written as T for tritium), nC, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36C1, 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I and 13 'I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro PD-L1 protein labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251, 13 '1, 35S or will generally be most useful. For radio-imaging applications nC, 18F, 1251, 1231, 124I, 13 '1, 75Br, 76Br or 77Br will generally be most useful.
It is understood that a "radio-labeled" or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251, 35S and 82Br. Synthetic methods for incorporating radio-isotopes into organic compounds are known in the art.
A radio-labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind a PD- Ll protein by monitoring its concentration variation when contacting with the PD-L1 protein, through tracking of the labeling. For example, a test compound (radio-labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a PD-L1 protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the PD-L1 protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
VI. Kits
The present disclosure also includes pharmaceutical kits useful, e.g., in the treatment or prevention of diseases or disorders associated with the activity of PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80), such as cancer or infections, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof. Such kits can further include one or more of various conventional pharmaceutical kit components, such as, e.g., containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non- critical parameters which can be changed or modified to yield essentially the same results.
The compounds of the Examples have been found to inhibit the activity of PD-1/PD-L1 protein/protein interaction according to at least one assay described herein.
EXAMPLES
Experimental procedures for compounds of the invention are provided below. Open
Access Preparative LCMS Purification of some of the compounds prepared was performed on Waters mass directed fractionation systems. The basic equipment setup, protocols and control software for the operation of these systems have been described in detail in literature. See, e.g., Blom, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 2002, 4, 295-301 ; Blom et al, "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. Combi. Chem., 2003, 5, 670-83; and Blom et al., "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. Combi. Chem., 2004, 6, 874-883. Example 1
(2S)-l-[(2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-l,3-thiazol-5-yl)methyl]piperidin^ 2-carboxylic acid
To a solution of 3-bromo-2-methylaniline (1.0 g, 5.4 mmol) in water (2.9 mL) and 1,4-dioxane (10 mL) were added phenylboronic acid (0.79 g, 6.4 mmol), [Ι,Γ- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (0.3 g, 0.3 mmol) and sodium carbonate (1.2 g, 1 1 mmol). The resulting mixture was purged with nitrogen then stirred at 100 °C for 3 h. The reaction mixture was cooled to room temperature then filtered and concentrated to dryness. The residue was purified by silica gel chromatography eluting with 20% ethyl acetate in hexanes to give the desired product. LC- MS calculated for C13H14N (M+H)+: m/z = 184.1 ; found 184.1.
Step 2: 5-bromo-N-(2-methylbiphenyl-3-yl)-l, 3-thiazole-2-carboxamide
To a solution of 5-bromo-l,3-thiazole-2-carboxylic acid (AstaTech, cat#450324: 90 mg, 0.43 mmol) and 2-methylbiphenyl-3-amine (87 mg, 0.48 mmol) in N,N- dimethylformamide (5 mL) was added N^N^N'-tetramemyl-O-^-azabenzotriazol-l- yl)uronium hexafluorophosphate (250 mg, 0.65 mmol), followed by N,N- diisopropylethylamine (230μ L , 1.3 mmol). The resulting mixture was stirred at room temperature for 3 h then diluted with EtOAc and washed with water and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C1?Hi4BrN2OS (M+H)+: m/z = 373.0; found 373.0.
A mixture of 5-bromo-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2-carboxamide (crude product from Step 2: 160 mg, 0.43 mmol), 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (1 10 μί, 0.64 mmol), [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (20 mg, 0.02 mmol) and sodium carbonate (95 mg, 0.90 mmol) in 1,4-dioxane (4.7 mL) and water (800μ L ) was purged with nitrogen and then stirred at 100 °C for 2 hours. The reaction mixture was cooled to room temperature then filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 15% AcOEt in hexanes to give the desired product (1 15 mg, 84 %). LC-MS calculated for C19Hi7N2OS (M+H)+: m/z = 321.1 ; found 321.1. Step 4: 5-formyl-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2-carboxamide
To a solution of N-(2-methylbiphenyl-3-yl)-5-vinyl-l,3-thiazole-2-carboxamide (115 mg, 0.359 mmol) in 1,4-dioxane (3.6 mL) was added 2,6-lutidine (170μ L , 1.4
mmol), followed osmium tetraoxide (4 wt.% in water, 340μ L , 0.054 mmol) at room temperature. The mixture was stirred for 10 min then sodium periodate (230 mg, 1.1 mmol) in water (1.5 mL) was added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with water and then extracted with DCM. The combined extracts were washed with water and brine and then dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 20% AcOEt in hexanes to give the desired product. LC- MS calculated for C18Hi5N202S (M+H)+: m/z = 323.1 ; found 323.1. Step 5: (2S)-l-[(2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-l,3-thiazol-5- yljmethyl ] piper idine-2-carboxylic acid
To a solution of 5-formyl-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2-carboxamide (20 mg, 0.062 mmol) in 1,2-Dichloroethane (1 mL) was added (2S)-piperidine-2-carboxylic acid (TCI, cat#P1404: 16 mg, 0.12 mmol). The mixture was stirred at room temperature for 20 min, then sodium triacetoxyborohydride (39 mg, 0.19 mmol) was added. The reaction mixture was stirred at room temperature overnight then concentrated. The residue was dissolved in MeOH and purified by prep-HPLC (pH = 10, acetonitrile/water+NH40H) to give the desired product. LC-MS calculated for C24H26N3O3S (M+H)+: m/z = 436.2; found 436.2. Example 2
5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2- carboxamide
To a solution of 5-formyl-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2-carboxamide (Example 1, Step 4: 12.0 mg, 0.0372 mmol) in 1,2-dichloroethane (0.8 mL) was
added ethanolamine (4.5μ L , 0.074 mmol). The resulting mixture was stirred at room temperature for 20 min, then sodium triacetoxyborohydride (24 mg, 0.1 1 mmol) was added. The mixture was stirred at room temperature overnight and then concentrated. The residue was dissolved in MeOH then purified by prep-HPLC (pH = 10, acetonitrile/water+NHiOH) to give the desired product. LC-MS calculated for C2oH22N302S (M+H)+: m/z = 368.1 ; found
368.1.
Example 3
5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-l,3-oxazole-2- carboxamide
To a solution of l,3-oxazol-5-ylmethanol (Ark Pharm, cat#AK-25343: 1.0 g, 10. mmol) in methylene chloride (10 mL) were added triethylamine (1.68 mL, 12.0 mmol) and 4- dimethylaminopyridine (65.2 mg, 0.534 mmol), followed by tert-butyldimethylsilyl chloride (1.59 g, 10.6 mmol) at room temperature. The mixture was stirred at room temperature overnight then diluted with water and extracted with DCM. The combined extracts were washed with water and brine, dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 18% AcOEt in hexanes to give the desired product. LC-MS calculated for C10H20NO2S1 (M+H)+: m/z = 214.1; found 214.1.
To a solution of 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-l,3-oxazole (0.75 g, 3.5 mmol) in tetrahydrofuran (30 mL) was added 2.5 M n-butyllithium in hexane (2.25 mL, 5.62 mmol) at -78 °C dropwise. The resulting mixture was stirred at -78 °C for 1 h then dry ice was added. The reaction mixture was slowly warmed to room temperature and stirred at room temperature overnight then quenched with water. The mixture was extracted with
DCM/iPrOH. The combined extracts were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 10 to 20 % MeOH in DCM to give the desired product. LC-MS calculated for C11H20NO4S- (M+H)+: m/z = 258.1 ; found 258.1.
Step 3: 5-( {[ tert-butyl(dimethyl)silyl ]oxy}methyl)-N-(2-methylbiphenyl-3-yl)-l, 3-oxazole-2- carboxamide
To a solution of 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-l,3-oxazole-2-carboxylic acid (42 mg, 0.16 mmol) and 2-methylbiphenyl-3-amine (Example 1, Step 1 : 35 mg, 0.19 mmol) in N,N-dimethylformamide (2 mL) was added N,N,N',N'-tetramethyl-0-(7- azabenzotriazol-l-yl)uronium hexafluorophosphate (93 mg, 0.24 mmol), followed by N,N- diisopropylethylamine (85 μ L, 0.49 mmol). The resulting mixture was stirred at room temperature for 3 h. The reaction was diluted with EtOAc and washed with water and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C24H31N2O3S1 (M+H)+: m/z = 423.2; found 423.1.
To a solution of 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-N-(2-methylbiphenyl-3- yl)-l,3-oxazole-2-carboxamide (180 mg, 0.42 mmol) in tetrahydrofuran (2 mL) was added tetra-n-butylammonium fluoride (1M in THF, 0.85 mL, 0.85 mmol). The mixture was stirred at room temperature for 3 h and then diluted with EtOAc, washed with water and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 50% AcOEt in Hexanes to give the desired product. LC-MS calculated for C18H17N2O3 (M+H)+: m/z = 309.1 ; found 309.2. 1H NMR (600 MHz, DMSO) δ 10.37 (s, 1H), 7.49 - 7.44 (m, 2H), 7.42 - 7.37 (m, 2H), 7.35 - 7.28 (m, 4H), 7.17 - 7.14 (m, 1H), 5.61 (s, 1H), 4.58 (s, 2H), 2.10 (s, 3H).
Step 5: 5-formyl-N-(2-methylbiphenyl-3-yl)- 1 , 3-oxazole-2-carboxamide
Dimethyl sulfoxide (40 μ L , 0.56 mmol) was added to a solution of oxalyl chloride (2M in DCM, 0.14 mL, 0.28 mmol) in methylene chloride (0.6 mL) at -78 °C then a solution of 5-(hydroxymethyl)-N-(2-methylbiphenyl-3-yl)-l,3-oxazole-2-carboxamide (43 mg, 0.14 mmol) in methylene chloride (0.2 mL) was slowly added. The mixture was stirred at - 78 °C for 30 min and then Ν,Ν-diisopropy lethy lamine (0.19 mL, 1.1 mmol) was added. The reaction mixture was warmed slowly to 0 °C, which was then quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The combined extracts were washed with water and brine, dried over Na2S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C18HisN2O3 (M+H)+: m/z = 307.1; found 307.1.
Step 6: 5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-l,3-oxazole-2- carboxamide
To a solution of 5-formyl-N-(2-methylbiphenyl-3-yl)-l,3-oxazole-2-carboxamide (1 1.4 mg, 0.0372 mmol) in methylene chloride (1 mL) was added ethanolamine (4.5 μί, 0.074 mmol). The mixture was stirred at room temperature for 20 min, then sodium triacetoxyborohydride (24 mg, 0.11 mmol) was added. The reaction mixture was stirred at room temperature overnight and then NaBH4 (10 mg) and MeOH (0.2 mL) were added. The mixture was stirred for another 2 h at room temperature, which was then concentrated. The residue was dissolved in MeOH then purified by prep-HPLC (pH = 10,
acetonitrile/water+NH40H) to give the desired product. LC-MS calculated for C2oH22N3O3 (M+H)+: m/z = 352.2; found 352.2.
Example 4
(2S)-l-[(l-methyl-2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-lH-imidazol-5- yl)methyl] piperidine-2-carboxylic acid
Step 1: 5-bromo-l -methyl- lH-imidazole-2-carboxylic acid
To a mixture of ethyl 5-bromo-l-methyl-lH-imidazole-2-carboxylate (Anichem, cat#K20110: 250 mg, 1.1 mmol) in tetrahydrofuran (20 mL) were added lithium hydroxide monohydrate (230 mg, 5.6 mmol) and water (0.4 mL). The resulting mixture was stirred at room temperature for 2 h then concentrated. The residue was used in the next step without further purification. LC-MS calculated for C5H6BrN202 (M+H)+: m/z = 205.0; found 205.0.
Step 2: (2S)-l-[(l-methyl-2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-lH-imidazol-5- yljmethyl ] piper idine-2-carboxylic acid
This compound was prepared using similar procedures as described for Example 1 with 5-bromo-l-methyl-lH-imidazole-2-carboxylic acid (Step 1) replacing 5-bromo-l,3- thiazole-2-carboxylic acid in Step 2. The reaction mixture was purified by prep-HPLC (pH = 10, acetonitrile/water+NH40H) to give the desired product. LC-MS calculated for
C25H29N4O3 (M+H)+: m/z = 433.2; found 433.2.
Example 5
5-{[(2-hydroxyethyl)amino]methyl}-l-methyl-N-(2-methylbiphenyl-3-yl)-lH-imidazole- 2-carboxamide
This compound was prepared using similar procedures as described for Example 4 with ethanolamine replacing (2S)-piperidine-2-carboxylic acid. The reaction mixture was purified by prep-HPLC (pH = 10, acetonitrile/water+NLkOH) to give the desired product. LC-MS calculated for C21H25N4O2 (M+H)+: m/z = 365.2; found 365.2.
Example 6
(2S)-l-[(l-methyl-3-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-lH-pyrazol-5- yl)methyl] piperidine-2-carboxylic acid
This compound was prepared using similar procedures as described for Example 1
with 5-bromo-l-methyl-lH-pyrazole-3-carboxylic acid (AstaTech, cat#80200) replacing 5- bromo-l,3-thiazole-2-carboxylic acid in Step 2. The reaction mixture was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C25H29N4O3 (M+H)+: m/z = 433.2; found 433.2.
Example 7
5-{[(2-hydroxyethyl)amino]methyl}-l-methyl-N-(2-methylbiphenyl-3-yl)-lH-pyrazole-3- carboxamide
This compound was prepared using similar procedures as described for Example 6 with ethanolamine replacing (2S)-piperidine-2-carboxylic acid. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H25N4O2 (M+H)+: m/z = 365.2; found 365.2.
Example 8
4-chloro-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2- carboxamide
2,4-Dichloro-l,3-thiazole-5-carbaldehyde (Combi-Blocks, cat#HI-1210 3.5 g, 19 mmol) and p-toluenesulfonic acid monohydrate (180 mg, 0.96 mmol) were dissolved in toluene (40 mL) and then 1,2-ethanediol (3.2 mL, 58 mmol) was added. The mixture was heated to reflux for overnight with azotropic removal of water via Dean Stark trap. The solution was cooled to room temperature and washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was
purified by flash chromatography eluting with 15% EtOAc/Hexanes to give the desired product (3.9 g, 90 %). LC-MS calculated for C6HeChNC S (M+H)+: m/z = 225.9; found 226.0. Step 2: 4-chloro-5-( 1, 3-dioxolan-2-yl)-l, 3-thiazole-2-carboxylic acid
O
To a solution of 2,4-dichloro-5-(l,3-dioxolan-2-yl)-l,3-thiazole (3.9 g, 17 mmol) in tetrahydrofuran (60 mL) was added 2.5 M n-butyllithium in hexanes (7.24 mL, 18.1 mmol) dropwise at -78 °C. The resulting mixture was stirred at -78 °C for 30 min then CO2 gas (generated from dry ice) was bubbled through the mixture for 10 min. The reaction mixture was slowly warmed to room temperature and stirred overnight, then concentrated to dryness. The residue was titurated with cold EtOAc then filtered and dried to give the desired product (4.0 g, 98 %), which was used in the next step without further purification. LC-MS calculated for C7H7CINO4S (M+H)+: m/z = 236.0; found 235.9.
Step 3: 4-chloro-5-( 1, 3-dioxolan-2-yl)-N-(2-methylbiphenyl-3-yl)-l, 3-thiazole-2-carboxamide
To a solution of 4-chloro-5-(l,3-dioxolan-2-yl)-l,3-thiazole-2-carboxylic acid (400.0 mg, 1.697 mmol) and 2-methylbiphenyl-3-amine (Example 1, Step 1: 360 mg, 2.0 mmol) in N,N-dimethylformamide (20 mL) was added N,N,N,,N,-tetramethyl-0-(7-azabenzotriazol-l- yl)uronium hexafluorophosphate (970 mg, 2.5 mmol), followed by N,N- diisopropylethylamine (890 μί, 5.1 mmol). The mixture was stirred at room temperature for 3 h and then diluted with EtOAc, washed with water and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 25% AcOEt in Hexanes to give the desired product (0.65 g, 96 %). LC-MS calculated for C20H18CIN2O3S (M+H)+: m/z = 401.1 ; found 401.1.
To a solution of 4-chloro-5-(l,3-dioxolan-2-yl)-N-(2-methylbiphenyl-3-yl)-l,3- thiazole-2-carboxamide (650 mg, 1.6 mmol) in tetrahydrofuran (3 mL) was added 2.0 M hydrogen chloride in water (8.1 mL, 16 mmol). The resulting mixture was stirred at 50 °C overnight then cooled to room temperature and concentrated. The residue was dissolved in EtOAc then washed with saturated NaHCO3 aqueous solution and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C18Hi4ClN202S (M+H)+: m/z = 357.0; found 357.0.
Step 5: 4-chloro-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-1,3-thiazole- 2-carboxamide
To a solution of 4-chloro-5-formyl-N-(2-methylbiphenyl-3-yl)-l,3-thiazole-2- carboxamide (200. mg, 0.560 mmol) in methylene chloride (20 mL) was added ethanolamine (68 nL, 1.1 mmol). The mixture was stirred at room temperature for 20 min, then sodium triacetoxyborohydride (360 mg, 1.7 mmol) was added. The reaction mixture was stirred at room temperature overnight. LC-MS indicated that some of the imine-intermediate was not reduced, so a small amount NaBH4 (30 mg) and MeOH (1 mL) were added. The mixture was stirred for another 2 h at room temperature then concentrate. The residue was dissolved in DCM, then washed with NaHCO3 solution and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 5 % MeOH in DCM to give the desired product (105 mg, 47 %). LC-MS calculated for C2oH2iClN302S (M+H)+: m/z = 402.1; found 402.1. Example 9
5-{[(2-hydroxyethyl)amino]methyl}-4-methyl-N-(2-methylbiphenyl-3-yl)-l^-thiazole-2- carboxamide
To a solution of 4-chloro-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl- 3-yl)-l,3-thiazole-2-carboxamide (Example 8: 20.0 mg, 0.0498 mmol) in tetrahydrofuran (1 mL) was added 2.0 M dimethylzinc in toluene (50 μί, 0.10 mmol). The mixture was purged with nitrogen then stirred in a sealed vial at 1 10 °C for 2 h. The mixture was cooled to room temperature, concentrated then dissolved in MeOH and purified by prep-HPLC
(Acetonitrile/water+NH40H) to give the desired product. LC-MS calculated for C21H24N3O2S (M+H)+: m/z = 382.2; found 382.1.
Example 10
N- [2-cyano-3-(2,3-dihyd ro- l,4-benzodioxin-6-yl)phenyl]-5- { [(2- hydroxyethyl)amino] methyl }- 1-methyl- lH-py razole-3-carboxamide
To the mixture of ethyl 5-bromo-l-methyl-lH-pyrazole-3-carboxylate (AstaTech, cat#80198: 500 mg, 2 mmol) in 1,4-dioxane (20 mL) was added 4,4,5,5-tetramethyl-2-vinyl- 1,3,2-dioxaborolane (730 μί, 4.3 mmol) followed by [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (1 : 1) (100 mg, 0.1 mmol), sodium carbonate (0.45 g, 4.3 mmol) and water (4 mL). The resulting mixture was purged with nitrogen and stirred at 95 °C for 3 h. The reaction mixture was cooled to room temperature, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 20% AcOEt in DCM to give the desired product. LC-MS calculated for C9H13N2O2 (M+H)+: m/z = 181.1 ; found 181.1. Step 2: N-(3-bromo-2-cyanophenyl)-l-methyl-5-vinyl-lH-pyrazole-3-carboxamide
To a mixture of 2-amino-6-bromobenzonitrile (AstaTech, cat#CL8148: 407 mg, 2.06 mmol) and ethyl l-methyl-5-vinyl-lH-pyrazole-3-carboxylate (310.0 mg, 1.720
mmol) in tetrahydrofuran (20 mL) was added 1.0 M Sodium hexamethyldisilazane in THF (2.06 mL, 2.06 mmol) dropwise at room temperature. The mixture was stirred at room temperature for 1 h then quenched with water and extracted with DCM. The combined extracts were washed with brine then dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with DCM to give the desired product. LC-MS calculated for C14Hi2BrN40 (M+H)+: m/z = 331.0; found 331.0.
Step 3: N-(3-bromo-2-cyanophenyl)-5-formyl-l -methyl- lH-pyrazole-3-carboxamide
To a solution of N-(3-bromo-2-cyanophenyl)-l-methyl-5-vinyl-lH-pyrazole-3- carboxamide (0.41 g, 1.2 mmol) in 1,4-dioxane (8 mL) and water (2 mL) was added osmium tetraoxide (4wt.% in water, 0.79 mL, 0.12 mmol). The resulting mixture was stirred for 5 min then sodium periodate (794 mg, 3.71 mmol) was added. The mixture was stirred for another 2 h at room temperature and then diluted with DCM, washed with water and brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 10% AcOEt in DCM to give the desired product. LC-MS calculated for C13HioBrN402 (M+H)+: m/z = 333.0; found 333.0.
Step 4: N-(3-bromo-2-cyanophenyl)-5-{[(2-hydroxyethyl)amino]methyl}-l-methyl-lH- pyrazole-3-carboxamide
To a solution of N-(3-bromo-2-cyanophenyl)-5-formyl-l-methyl-lH-pyrazole-3- carboxamide (0.20 g, 0.60 mmol) in methylene chloride (5 mL) was added ethanolamine (140 HL, 2.4 mmol). The mixture was stirred at room temperature for 20 min, then sodium triacetoxyborohydride (300 mg, 1.4 mmol) was added. The reaction mixture was stirred at
room temperature overnight. LC-MS indicated that some of the imine-intermediate still existed, so NaBH4 (45 mg, 1.2 mmol) and MeOH (2 mL) were added. The mixture was stirred at room temperature for another 2 h and then concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 15% MeOH in DCM to give the desired product. LC-MS calculated for C1sHnBrNsCh (M+H)+: m/z = 378.1 ; found 378.0.
Step 5: N-[ 2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl ]-5-{[ (2- hydroxyethyl)amino]methyl}-l -methyl- lH-pyrazole-3-carboxamide
A mixture of N-(3-bromo-2-cyanophenyl)-5-{[(2-hydroxyethyl)amino]methyl}-l- methyl-lH-pyrazole-3-carboxamide (10 mg, 0.03 mmol), 6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine (14 mg, 0.053 mmol), [Ι,Γ- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (0.9 mg, 0.001 mmol) and sodium carbonate (3.8 mg, 0.036 mmol) in 1,4-dioxane (1 mL) and water (0.2 mL) was purged with N2 then stirred at 95 °C overnight. The reaction mixture was cooled to room temperature, diluted with MeOH, filtered and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C23H24N504 (M+H)+: m/z = 434.2; found 434.2.
Example 11
N-(2-cyano-2'-fluorobiphenyl-3-yl)-5- { [(2-hyd roxyethyl)amino] methyl }- 1 -methyl- 1 H- pyrazole-3-carboxamide
This compound was prepared using similar procedures as described for Example 10, Step 5 with 2-fluorophenylboronic acid (Aldrich, cat#445223) replacing 6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C2iH2iFN502 (M+H)+: m/z = 394.2; found 394.1.
Example 12
N-il-cyano-l'-fluoro-3'-methoxybiphenyl-3-ylJ-5-fliZ-hydroxyethylJaminolmethyl}-1- methyl- lH-pyrazole-3-carboxamide
This compound was prepared using similar procedures as described for Example 10, Step 5 with 2-Fluoro-3-methoxyphenylboronic acid (Aldrich, cat#594253) replacing 6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H23FN5O3 (M+H)+: m/z = 424.2; found 424.2.
Example 13
N-[2-cyano-3-(l -methyl- lH-indazol-4-yl)phenyl]-5-{ [(2-hydroxyethyl)amino] methyl }- 1- methyl- lH-pyrazole-3-carboxamide
This compound was prepared using similar procedures as described for Example 10, Step 5 with l-Methylindazole-4-boronic acid (AstaTech, cat#64580) replacing 6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C23H24N7O2 (M+H)+: m/z = 430.2; found 430.2.
Example 14
N- [2-cyano-3-(2,3-dihyd ro- l,4-benzodioxin-6-yl)phenyl]-5- { [(2- hydroxyethyl)amino] methyl }- 1-methyl- lH-imidazole-2-carboxamide
Step 1: N-(3-bromo-2-cyanophenyl)-5-{[(2-hydroxyethyl)amino]methyl}-l-methyl-lH- imidazole-2-carboxamide
This compound was prepared using similar procedures as described for Example 10, Step 1-4 with ethyl 5-bromo-l -methyl- lH-imidazole-2-carboxy late (Anichem, cat#K20110) replacing ethyl 5-bromo-l-methyl-lH-pyrazole-3-carboxylate in Step 1. The crude product was purified by flash chromatography on a silica gel column eluting with 15% MeOH in DCM to give the desired product. LC-MS calculated for C1sHnBrNsCh (M+H)+: m/z = 378.1; found 378.0.
Step 2: N-[ 2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl ]-5-{[ (2- hydroxyethyl)amino]methyl}-l -methyl- lH-imidazole-2-carboxamide
A mixture of N-(3-bromo-2-cyanophenyl)-5-{[(2-hydroxyethyl)amino]methyl}-l- methyl-lH-imidazole-2-carboxamide (10 mg, 0.03 mmol), 6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine (14 mg, 0.053 mmol), [Ι, 1-- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (0.9 mg, 0.001 mmol) and sodium carbonate (3.8 mg, 0.036 mmol) in 1,4-dioxane (1 mL) and water (0.2 mL) was purged with nitrogen then stirred at 95 °C overnight. The reaction mixture was cooled to room temperature, diluted with methanol, filtered then purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C23H24N5O4 (M+H)+: m/z = 434.2; found 434.2.
Example 15
N-il-cyano-l'-fluoroO'-methoxybiphenyl-3-ylJ-5-fliZ-hydroxyethylJaminolmethyl}-!- methyl- lH-imidazole-2-carboxamide
This compound was prepared using similar procedures as described for Example 14,
Step 2 with 2-Fluoro-3-methoxyphenylboronic acid (Aldrich, cat#594253) replacing 6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired
product as the TFA salt. LC-MS calculated for C22H23FN5O3 (M+H)+: m/z = 424.2; found 424.1.
Example 16
N-[2-cyano-3-(l -methyl- lH-indazol-4-yl)phenyl]-5-{ [(2-hydroxyethyl)amino] methyl }- 1- methyl- lH-imidazole-2-carboxamide
This compound was prepared using similar procedures as described for Example 15, Step 2 with l-Methylindazole-4-boronic acid (AstaTech, cat#64580) replacing 6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l,4-benzodioxine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C23H24N7O2 (M+H)+: m/z = 430.2; found 430.1.
Example 17
(S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-(((2- hydroxyethyl)amino)methyl)thiazole-2-carboxamido)-2^,-dimethyl-[l,l,-biphi yl)methoxy)benzyl)piperidine-2-carboxylic acid
To a mixture of (3-bromo-2-methylphenyl)methanol (2.33 g, 1 1.59 mmol), 5-chloro- 2,4-dihydroxybenzaldehyde (2.0 g, 1 1.59 mmol) and triphenylphosphine (3.65 g, 13.91 mmol) in THF (10 ml) at 0 °C was added DIAD (2.93 ml, 15.07 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated and diluted with EtOAc.
The solid was collected by filtration to give 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2- hydroxybenzaldehyde (2.0 g, 5.62 mmol, 48.5 % yield). LCMS calculated for C1sHnBrClOs (M+H)+: m/z = 355.0; found 355.2.
Step 2: 5-((5-((3-bromo-2-methylbenzyl)oxy)-4-chloro-2- formylphenoxy)methyl)nicotinonitrile
A mixture of 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-hydroxybenzaldehyde (2.0 g, 5.62 mmol), 5-(chloromethyl)nicotinonitrile (0.927 g, 6.07 mmol) and cesium carbonate (2.75 g, 8.44 mmol) in DMF (12 ml) was stirred at 70 °C for 3 hours. The mixture was cooled to room temperature and then poured into water. The solid was collected by filtration and air dried to give 5-((5-((3-bromo-2-methylbenzyl)oxy)-4-chloro-2- formylphenoxy)methyl)nicotinonitrile (2.2 g, 4.66 mmol, 83 % yield). LCMS calculated for C22Hi7BrClN203 (M+H)+: m/z = 471.0; found 471.2.
Step 3: (S)-l-(4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-((5-cyanopyridin-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid
Sodium triacetoxyborohydride (158 mg, 0.746 mmol) was added to a mixture of 5- ((5-((3-bromo-2-memylbenzyl)oxy)-4-cliloro-2-formylphenoxy)memyl)nicotinonitrile (176 mg, 0.373 mmol), (S)-piperidine-2-carboxylic acid (72.3 mg, 0.560 mmol) and triethylamine (0.156 ml, 1.1 19 mmol) in DCM (1.0 ml). After stirring at room temperature overnight, the mixture was purified on prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt (150 mg). LCMS calculated for C28H28BrClN304 (M+H)+: m/z =
584.1; found 584.1.
Methyl 5-bromothiazole-2-carboxylate (0.72 g, 3.24 mmol), 4,4,5,5-tetramethyl-2- vinyl-l,3,2-dioxaborolane (0.55 ml, 3.24 mmol), tetrakis(triphenylphosphine)palladium(0) (0.375 g, 0.324 mmol) and potassium carbonate (0.896 g, 6.48 mmol) were weighed into a microwave vial. 1,4-Dioxane (3 ml) and water (0.6 ml) were added and the mixture was purged with N2 for 5 min. The mixture was heated at 100 °C for 2 h and then cooled to room temperature and concentrated. The residue was purified on silica gel column (0-100%
EtOAc/Hexanes) to give methyl 5-vinylthiazole-2-carboxylate (0.3 g, 1.773 mmol, 54.7 % yield). LCMS calculated for CvHgNChS (M+H)+: m/z = 170.0; found 170.0.
1.0 M THF solution of potassium tert-butoxide (5.32 mL, 5.32 mmol) was added to a solution of methyl 5-vinylthiazole-2-carboxylate (0.3 g, 1.773 mmol) and 3-bromo-2- methylaniline (0.24 mL, 1.950 mmol) in THF (5 mL) at 0 °C. After being stirred at room temperature for 2 h, the reaction mixture was quenched with water, extracted with ethyl acetate, concentrated and purified on silica gel column (0-100% EtOAc/Hexanes) to give N- (3-bromo-2-methylphenyl)-5-vinylthiazole-2-carboxamide (0.4 g, 1.238 mmol, 69.8 % yield). LCMS calculated for CnHi2BrN2OS (M+H)+: m/z = 323.0; found 323.0.
To a mixture of N-(3-bromo-2-methylphenyl)-5-vinylthiazole-2-carboxamide (0.22 g, 0.681 mmol) in THF (4 ml)/Water (1 ml) cooled in an ice bath was added 4% water solution of osmium tetroxide (0.83 ml, 0.136 mmol). The reaction was stirred for 5 min and then
sodium periodate (0.437 g, 2.042 mmol) was added. After stirring at room temperature overnight, the reaction was quenched with saturated aqueous solution of sodium thiosulfate. The mixture was then extracted with DCM, concentrated in vacuo and purified on silica gel column (0-100% EtOAc in hexanes) to give N-(3-bromo-2-methylphenyl)-5-formylthiazole- 2-carboxamide (0.19 g, 0.584 mmol, 86 % yield). LCMS calculated for C12HioBrN202S (M+H)+: m/z = 325.0; found 325.0.
Step 7: 5-formyl-N-(2-methyl-3-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl)thiazole- 2-carboxamide
A mixture of N-(3-bromo-2-methylphenyl)-5-formylthiazole-2-carboxamide (0.17 g, 0.523 mmol), bis(pinacolato)diboron (0.199 g, 0.784 mmol), potassium acetate (0.103 g, 1.046 mmol) and [l,r-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.043 g, 0.052 mmol) was purged with nitrogen and then 1,4-dioxane (4 ml) was added. The resulting mixture was stirred at 100 °C for 2 h and then cooled to room temperature and concentrated. The residue was purified on silica gel column (0-100% EtOAc/Hexanes) to give 5-formyl-N- (2-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)thiazole-2-carboxamide (0.17 g, 0.457 mmol, 87 % yield). LCMS calculated for C1gH22BN204S (M+H)+: m/z = 373.1; found 373.1.
Step 8: (S)-J-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-formylthiazo
carboxamido)-2, 2'-dimethyl-[ J, J '-biphenyl ]-3-yl)methoxy)benzyl)piperidine-2-carboxylic acid
A mixture of (S)-l-(4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-((5-cyanopyridin-
3-yl)methoxy)benzyl)piperidine-2-carboxylic acid (24 mg, 0.04 mmol), 5-formyl-N-(2-
methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)thiazole-2-carboxamide (15 mg, 0.040 mmol), potassium carbonate (1 1 mg, 0.08 mmol) and
tetrakis(triphenylphosphine)palladium(0) (4.7 mg, 4.0 μmol) in 1,4-dioxane (2 ml) and water (1 ml) was purged with nitrogen, and then heated at 100 °C for 2 h. After cooled to room temperature, the mixture was concentrated and the residue was purified on silica gel column (0-15% MeOH/DCM) to give (S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5- forrrtyltliiazole-2-carboxamido)-2,2,-dimethyl-[l,r-biphenyl]-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid (20 mg, 0.027 mmol, 66.2 % yield). LCMS calculated for C40H37CIN5O6S (M+H)+: m/z = 750.2; found 750.2.
Step 9: (S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-(((2- hydroxyethyl)amino)methyl)thiazole-2-carboxamido)-2[
yl)methoxy)benzyl)piperidine-2-carboxylic acid
A mixture of (S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5- forrrtyltliiazole-2-carboxamido)-2,2,-dimethyl-[l,r-biphenyl]-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid (6 mg, 8.00 μmol) and 2-aminoethan-l-ol (0.5 mg, 8.00 μmol) in DCM (1.0 ml) was stirred for 30 min at room temperature and then sodium triacetoxyborohydride (2.5 mg, 0.012 mmol) was added. After stirring at room temperature for 2 h, the mixture was purified on prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product as the TFA salt. LCMS calculated for C42H44CIN6O6S (M+H)+: m/z = 795.3; found 795.3.
Example 18
(SJ-l-i5-chloro-l-ii5-cyanopyridin-3-ylJmethoxy^-iiS'-i5-iiiKJO-hydroxypyrrolidin-l- yl)methyl)thiazole-2-carboxamido)-2,2'-dimethyl-[l,r-biphenyl]-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid
This compound was prepared using similar procedures as described for Example 17, Step 9 with (R)-pyrrolidin-3-ol replacing 2-aminoethan-l-ol. The reaction mixture was
purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product TFA salt. LC-MS calculated for C44H46C1N606S (M+H)+: m/z = 821.3; found 821.3.
Example 19
5-(((R)0-hydroxypyrrolidin-l-yl)methyl)-N-(3'-(5-(((R)-3-hydroxypyrrolidiii-l- yl)methyl)-l-methyl-lH-pyrazole-3-carboxamido)-2,2'-dimethyl-[l,r-biphenyl]-3- yl)thiazole-2-carboxamide
Step 1: N-(3-bromo-2-methylphenyl)-l-methyl-5-vinyl-lH-pyrazole-3-carboxamide
1M THF solution of potassium tert-butoxide (4.16 mL, 4.16 mmol) was added to a solution of ethyl l-methyl-5-vinyl-lH-pyrazole-3-carboxylate (Example 10, Step 1 : 0.25 g, 1.387 mmol) and 3-bromo-2-methylaniline (0.188 mL, 1.526 mmol) in THF (5 mL) at 0 °C. After being stirred at room temperature for 2 h, the reaction mixture was quenched with water, extracted with ethyl acetate, concentrated and purified on silica gel column (0-100% EtOAc/Hexanes) to give N-(3-bromo-2-methylphenyl)-l-methyl-5-vinyl-lH-pyrazole-3- carboxamide (0.4 g, 1.249 mmol, 90 % yield). LCMS calculated for CuHisBrNsO (M+H)+: m/z = 320.0; found 320.0. Step 2: N-(3-bromo-2-methylphenyl)-5-formyl-l -methyl- lH-pyrazole-3-carboxamide
To a mixture of N-(3-bromo-2-methylphenyl)-l-methyl-5-vinyl-lH-pyrazole-3- carboxamide (0.4 g, 1.25 mmol) in THF (10 ml) and water (2.5 ml) cooled in an ice bath was added 4% aq. osmium tetroxide (1.53 ml, 0.25 mmol). The reaction mixture was stirred for 5
min and then sodium periodate (0.802 g, 3.75 mmol) was added. After stirring at room temperature for 1 h, the reaction was quenched with sat. aq. solution of sodium thiosulfate. The mixture was then extracted with DCM, concentrated in vacuo and purified on silica gel column (0-100% EtOAc/Hexanes) to give N-(3-bromo-2-methylphenyl)-5-formyl-l-methyl- lH-pyrazole-3-carboxamide (0.29 g, 0.900 mmol, 72.1 % yield). LCMS calculated for CnHnBrNsCh (M+H)+: m/z = 322.0; found 322.0.
Step 3: 5-formyl-N-(3'-(5-formyl-l -methyl- lH-pyrazole-3-carboxamido)-2, 2 '-dimethyl-■[ 1, 1 '- biphenyl ]-3-yl) thiazole-2-carboxam ide
A mixture of N-(3-bromo-2-methylphenyl)-5-formy 1-1 -methyl- lH-pyrazole-3- carboxamide (17.31 mg, 0.054 mmol), 5-formyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)thiazole-2-carboxamide (Example 17, Step 7: 20 mg, 0.054 mmol), potassium carbonate (15 mg, 0.11 mmol) and tetrakis(triphenylphosphine)palladium(0) (6.2 mg, 5.4 μmol) in 1,4-dioxane (3 ml) and water (0.6 ml) was purged with nitrogen, and heated at 100 °C for 2 h. The mixture was purified on silica gel column (0-100% EtOAc/Hexanes) to give 5-formyl-N-(3'-(5-formyl-l-methyl-lH-pyrazole-3-carboxamido)-2,2'-dimethyl-[l,r- biphenyl]-3-yl)thiazole-2-carboxamide (20 mg, 0.041 mmol, 76 % yield). LCMS calculated for C25H22N5O4S (M+H)+: m/z = 488.1 ; found 488.1.
Step 4: 5-(((R)-3-hydroxypyrrolidin-l-yl)methyl)-N-(3'-(5-(((R)-3-hydroxypyrrolidin-l- yl)methyl)-l-methyl-lH-pyrazole-3-carboxamido)-2,2'-dimethyl-[l,r-biphenyl]-3- yl)thiazole-2-carboxamide
A mixture of 5-formyl-N-(3,-(5-formyl-l-methyl-lH-pyrazole-3-carboxamido)-2,2'- dimethyl-[l,r-biphenyl]-3-yl)thiazole-2-carboxamide (20 mg, 0.041 mmol) and (R)- pyrrolidin-3-ol (7.9 mg, 0.09 mmol) in DCM (1.0 ml) was stirred for 30 min at room temperature then sodium triacetoxyborohydride (26.1 mg, 0.123 mmol) was added. After stirring at room temperature for 2 h, the mixture was purified on prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LCMS calculated for C33H40N7O4S (M+H)+: m/z = 630.3; found 630.3.
Example A. PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) binding assay
The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μί. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25° C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His- tag at the C-terminus was purchased from AcroBiosy stems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from
AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 nL was added to the plate well. Plates were centrifuged and proteins were
preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 μΐ,- of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight®- Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25° C for 60 min. before reading on a PHERAstar FS plate reader
(665nm/620nm ratio). Final concentrations in the assay were - 3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.ICso determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
Compounds of the present disclosure, as exemplified in the Examples, showed ICso values in the following ranges: + = ICso < 100 nM; ++ = 100 nM < ICso < 500 nM; +++ = 500 nM < ICso < 10000 nM
Data obtained for the Example compounds using the PD-1/PD-L1 homogenous time- resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 1.
Table 1
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including without limitation all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.
Claims
What is claimed is:
1. A compound of Formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C2^ alkenyl, C2^ alkynyl, halo, CN, OR10, C1^ haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, -P(O)R10R10, -P(O)(OR10)(OR10), - B(OH)2, -B(OR10)2 and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, C1-4alkoxy, C3-6 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4alkoxy, C3-10 cycloalkyl, C3-10cycloalkyl-C1-4 alkyl-, C6-10aryl, C6- 10 aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, -P(0)RaRa, -P(0)(ORa)(ORa), -B(OH)2, - B(ORa)2, and S(0)2NRaRa, wherein the C M alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from B, P, N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR1 1C(OJNR11!*11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR'^O)2R11, NR'^O)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, -P(0)R11R11, - PiOXOR^iOR11), -B(OH)2, -B(ORN)2, or S(0)2NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3
independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, Cs-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR^CCONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, -P(0)R11R11, - PCOXOR'^COR11), -B(OH)2, -B(OR11)2, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2- methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10
membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, -P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, -P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, - P(0)RcRc, -P(0)(ORc)(ORc), -B(OH)2, -B(ORc)2 and S(0)2NRcRc; wherein the C M haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cy cloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, -P(0)RgRg, -P(0)(ORg)(ORg), - B(OH)2, -B(ORg)2 and S(0)2NRgRg; wherein the C M alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl,
C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°,
OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°, NR°S(0)2NR°R°, - P(0)R°R°, -P(0)(OR°)(OR°), -B(OH)2, -B(OR°)2 and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, -P(0)ReRe, -P(0)(ORe)(ORe), -B(OH)2, -B(ORe)2 and S(0)2NReRe, wherein the C1-6 alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are
each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCiCONRH', NHRr, NRTlr, NRrC(0)Rr, NRtCCONRT^, NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRH', S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr, -Ρ(Ο^Έ.Γ, -P(0)(ORr)(ORr), -B(OH)2, -B(OR02 and S(0)2NRrRr, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents; or any two Ra substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10aryl,
5- 6 membered heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, (4-7 membered heterocycloalkyl)-C1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR', SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NRiRi, NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi, NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)R', S(0)NRiRi, 8(0)2Ri, NR'SiO)2R1, NRiS(0)2NRiRi, -PiOiRiR, -PiOKORiKORi), -B(OH)2, -B(OR)2 and S1 1C(NR'R1, wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered
heterocycloalkyl, C6-10aryl, 5-6 membered heteroaryl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl- C14 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 R> substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2^ alkenyl, C2^ alkynyl, halo, C1-4haloalkyl, C1-4 haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, CiOiNRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NR^iOiR15, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, -P(0)R¾k, -P(0)(ORk)(ORk), -B(OH)2, -B(ORk)2 and S(0)2NRkRk, wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or
6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C1-4 haloalkyl, and C1-
4 haloalkoxy of R" are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Ri substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents;
or any two Rk substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents;
or any two R° substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R10 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R11 substituents together with the nitrogen, phosphorus or boron atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Ri is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
2. The compound of claim 1, having Formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10cycloalkyl, C3- io cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, C1-4 alkenyl, C1-4 alkynyl, halo, CN, OR10, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, N02, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa,
NRaC(=NRa)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the C1-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered
heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR1^1, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, ethyl, propyl, isopropyl, butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3 independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4- 10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR'1C ONR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR11S(0)2R11, NR'^O)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the butyl, 2-butyl, 2-methylpropyl, C5-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4
alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents; each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2RC and S(0)2NRCRC; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- 10 aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C 1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10
cycloalkyl-C 1-4 alky 1-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered
heterocy cloalkyl)-C 1-4 alky 1-, halo, CN, NHORg, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NR«R« S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Cw alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alky 1- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C 1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°,
NR°S(0)2NR°R°, and S(0)2NR°R°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Ri substituents;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aiyl-C1-4alkyl- , C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocy cloalkyl)-C 1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the C1-4 alkyl, C1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocy cloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alky 1-
, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rs is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 RP substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, CiCONRH', C(0)ORr, OC(0)Rr, OCiCONRH', NHRr, NRTlr, NRrC(0)Rr, NR1C ONRTl', NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, SiCONRTl', S(0)2Rr, NRrS(0)2Rr, NRiSiO)2NRH' and S(0>2NRrRr, wherein the C1-4 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered heterocycloalkyl)-C 1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR', NHORi, C(0)R', C(0)NRiRi, C(0)OR', OC(0)R', OC(0)NRiRi, NHRi, NR'R',
NRiC(0)Ri, NRiC(0)NRiRi, NRiC(0)ORi, C(=NRi)NRiRi, NRiC(=NRi)NRiRi,
NRiC(=NOH)NRiRi, NRiC(=NCN)NRiRi, S(0)R', S(0)NRiRi, 8(0)2Ri, NR'SiO)2R1, >ΠΙ'8(0)2ΝRiRi, and 8(0>2ΝRiRi, wherein the C1-4 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3- 10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C6-10 aryl- C14 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 R>
substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C1-4 alkenyl, C1-4 alkynyl, halo, C1-4 haloalkyl, C1^ haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(C-JR* NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and SCCO.NRkRk, wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C1-4 alkenyl, C1-4 haloalkyl, and C1-4 haloalkoxy of R" are each optionally substituted with 1, 2 or 3 independently selected Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rg substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
3. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rq.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR^^NR11R11, C(=NR11)R11,
C(=NR11)NR11R11, NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NR11S(0)R11, NR^iOfcR11, NR11S(0)2NR11R11, S(0)R11, S(0)NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10 aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 ary 1-C 1-4 alky 1-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocy cloalky 1)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; and
R9 is C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 ary 1-C 1-4 alkyl-, C3-10 cy cloalky 1-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- or (4-10 membered heterocy cloalky 1)-C 1-4 alkyl-, wherein the C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 ary 1-C1-4 alkyl-, C3-10 cy cloalky 1-C 1-4 alky 1- , (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; each Rbl is independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6- 10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 ary 1-C 1-4 alkyl-, C3-10cy cloalky 1-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocy cloalky 1)-Cu alkyl-, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 ary 1-C 1-4 alky 1- , C3-10 cy cloalky 1-C 1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocy cloalky 1)-C 1-4 alkyl- of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
(II)
or a pharmaceutically acceptable salt or a stereoisomer thereof.
6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein (i) X1 is N, X2 is CR2 and X3 is CR3; (ii) X1 is CR1, X2 is N and X3 is CR3; (iii) X1 is CR1, X2 is CR2 and X3 is N; (iv) X1 is N, X2 is CR2 and X3 is N; (v) X1 is N, X2 is N and X3 is CR3; or (vi) X1 is CR1, X2 is N and X3 is N.
7. The compound of any one of claims 1-5, having Formula (III):
L is a bond, -C(0)NR13-, -NR13C(0)-, O, -(CR14R15)q-, -(CR14R15)Q-0-, - 0(CR14R15)q-, -NR13-, -(CR14R15)q-NR13-, -NR13-(CR14R15)q-, -CH=CH-,— C≡C~ - SO2NR13-, -NR13S02-, -NR13S02NR13-, -NR13C(0)0-, -OC(0)NR13 or -NR13C(0)NR13-; each R13 is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CN, halo, OH, -COOH, NH2, -NHC1-4 alkyl and -N(C1-4 alkyl)2;
R14 and R15 are each independently selected from H, halo, CN, OH, -COOH, C1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R14 or R15 are each optionally substituted with 1, 2, or 3 independently selected Rq substituents;
or R14 and R15 taken together with the carbon atom to which they are attached form 3-, 4-, 5- or 6-membered cycloalkyl or 3-, 4-, 5- or 6-membered heterocycloalkyl, each of which is optionally substituted with 1 or 2 independently selected Rq substituents;
ring B is C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2 or 3 independently selected Rd substituents; and
the subscript n is an integer of 1, 2, 3 or 4.
8. The compound of any one of claims 1-5 and 7, having Formula (Ilia):
(Ilia) or a pharmaceutically acceptable salt or a stereoisomer thereof. 9. The compound of any one of claims 1-5 and 7-8, having Formula (IIIa-1):
or a pharmaceutically acceptable salt or a stereoisomer thereof.
The compound of any one of claims 1-5 and 7, having Formula (IIIa-2):
(IIIa-2) harmaceutically acceptable salt or a stereoisomer thereof.
11. The compound of any one of claims 7-10, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Rd is C1-6 alkyl, phenyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, ORe, C(0)Re, halo or CN, wherein the C1-6 alkyl, phenyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1, 2 or 3 independently selected Rf substituents.
12. The compound of any one of claims 7-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Rd is (3-carboxypyrrolidin-l-yl)methyl, (R)-(3- carboxypyrrolidin-l-yl)methyl, (S)-(3-carboxypyrrolidin-l-yl)methyl, (3-hydroxypyrrolidin- l-yl)methyl, (R)-(3-hydroxypyrrolidin-l-yl)methyl, (S)-(3-hydroxypyrrolidin-l-yl)methyl, (2-hydroxyethylamino)methyl, (2-hydroxy-2-methylpropylamino)methyl, 2- (dimethylamino)ethanoyl, 2-(3-carboxyazetidin-l-yl)ethanoyl, (R)-2-(3-carboxyazetidin-l- yl)ethanoyl, (S)-2-(3-carboxyazetidin-l-yl)ethanoyl, 2-(2-carboxypiperidin-l-yl)ethanoyl, (R)-2-(2-carboxypiperidin-l-yl)ethanoyl, (S)-2-(2-carboxypiperidin-l-yl)ethanoyl, 2-(3- carboxypyrrolidin-l-yl)ethanoyl, (S)-2-(3-carboxypyrrolidin-l-yl)ethanoyl, (R)-2-(3- carboxypyrrolidin-l-yl)ethanoyl, (5-cyanopyridin-3-yl)methoxy, (2- hydroxyethylamino)methyl, 2-carboxy-l-piperidinylmethyl, (S)-2-carboxy-l- piperidinylmethyl, (R)-2-carboxy-l-piperidinylmethyl, halo or CN.
13. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or a
14. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein (i) X4 is S and X5 is CR5; (ii) X4 is O and X5 is CR5; (iii) X4 is NR4 and X5 is CR5; or (iv) X4 is CR4 and X5 is NR5.
15. The compound of any one of claims 1-6 and 13-14 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Cy is phenyl, 5- or 6-membered heteroaryl, C3-6 cycloalkyl or 5- or 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
16. The compound of any one of claims 1-6 and 13-14, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Cy is phenyl, 2-thiophenyl, 3-thiophenyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 3,6-dihydro-2H-pyran-4-yl, cyclohexyl, cyclohexenyl, 2,3-dihydro-l,4-
benzodioxin-6-yl, l,3-benzodioxin-5-yl, 2-methylindazol-6-yl or l-methylindazol-4-yl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents.
17. The compound of any one of claims 1-6 and 13-14, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Cy is phenyl optionally substituted with 1 to 5 independently selected R6 substituents.
18. The compound of any one of claims 1-6 and 13-14, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Cy is phenyl, 2,3-dihydro-l,4-benzodioxin-6-yl, 2- fluorophenyl, 2-fluoro-3-methoxyphenyl, or l-methyl-lH-indazol-4-yl.
19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4haloalkyl, C1^ haloalkoxy, NH2, -NH-C1-4 alkyl, -N(C1-4 alkyl)2, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10,
NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10, NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C1-4alkoxy, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, C6-10aryl, C6-10aryl-C1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)- C14 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 groups-independently selected from halo, OH, CN and C1-4 alkoxy.
20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl or C1-6 haloalkoxy.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R5 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl or C1-6 haloalkoxy.
22. The compound of any one of claims 1-17 and 19-21, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R6 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa, C(0)NRaRa, or NRaC(0)Ra, wherein the C1-4 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered
heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
23. The compound of any one of claims 1-17 and 19-21, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R6 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CN, or ORa, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents; or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6- membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7- membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NH2, NH(C1-6 alkyl), N(C1-6 alky 1)2, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl or phenyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6
alkynyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and phenyl are each optionally substituted with 1, 2 or 3 independently selected Rq substituents.
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R8 is C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents or (4-10 membered heterocycloalkyl)-C1-4 alkyl- optionally substituted with 1, 2 or 3 independently selected Rb substituents.
26. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R8 is C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents.
27. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R8 is -CH2NHRC or -CH2NRCRC.
28. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R8 is (2-hydroxyethylamino)methyl, 2-carboxy-l- piperidinylmethyl, (S)-2-carboxy-l-piperidinylmethyl, (R)-2-carboxy-l-piperidinylmethyl, or 3 -hy droxy py rrol i din- 1 -y 1 methy 1.
29. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R8 is (2-hy droxy ethylamino)methyl, 2-carboxy-l- piperidinylmethyl, (S)-2-carboxy-l-piperidinylmethyl, or (R)-2-carboxy-l-piperidinylmethyl.
30. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, N NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is phenyl, C3-6 cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused 5-, 6- or 7-membered heterocycloalkyl ring, or a fused 5- or 6-membered heteroaryl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, CIA alkynyl, halo, CN, OH, COOH, C1-4 alkoxy, C1^ haloalkyl, C1^ haloalkoxy, cyclopropyl, cyclopropylmethyl, phenyl, phenyl-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-C1- 4 alkyl-, NH2, -NHC1-4 alkyl, -N(C1-4 alkyl)2, -C(0)R10, -0(CO)R10, -C(0)OR10, - 0(CO)NHR10, -NHC(0)OR10, -NHC(0)NHR10, -C(0)NHR10, -NHC(0)R10, -SO2R10, - NHSO2R10 and -SO2NHR10, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, cyclopropyl, cyclopropylmethyl, phenyl, phenyl-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, 4-6 membered heterocycloalkyl and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R1, R2 or R3 are each optionally substituted with halo, OH, CN or C1-4 alkoxy;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1- 4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- or (4-6 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, COOH, NO2, ORa, C(0)ORa, NH2, -NHRa, -N(Ra)2, -C(0)Ra, -0(CO)Ra, - C(0)ORa, -0(CO)NRaRa, -NHC(0)ORa, -NHC(0)NRaRa, -C(0)NRaRa, -NHC(0)Ra, -S02Ra, -NHS02Ra and -S02NRaRa, wherein the C1-6 alkyl, C2-6 alkenyl, Ci- alkynyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C1-4 alkyl-, C3- 6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R4, R5 and R6 are each optionally substituted with 1 or 2 Rb substituents;
R7 is halo, C1-6 alkyl, CN, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C1-4 alkyl-, (4-6 membered heterocycloalkyl)-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl, wherein C1-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C 1-4 alkyl-, (4-6 membered heterocycloalkyl)-C1-4 alkyl- and (5-6 membered heteroaryl)-C1-4 alkyl of R7 are
each optionally substituted with 1 or 2 susbtituents independently selected from halo, C1-6 alkyl, C M haloalkyl, C1-6haloalkoxy,CN, OH, NH2, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, COOH, -OC 1-6 alky 1, -SC1-6 alkyl, C(0)NH2, -C(0)NH(C1-6 alkyl), -C(0)NH(C1-6 alkyl)2, -C(0)OC1-6 alkyl, -OC(0)NHC1-6 alkyl, -OC(0)NH2, -OC(0)NH(C1-6alkyl)2, -NHC(0)C1-6 alkyl, - NHC(0)H, -N(C1-6 alky 1)C(0)C1-6 alkyl, -NHC(0)OC1-6 alkyl, -N(C1-6 alky l)C(0)OC1-6 alkyl, -NHC(0)NH(C1-6 alkyl), -NHC(0)N(C1-6alkyl)2, -NHC(0)NH2, -N(C1-6alkyl)C(0)NH(Cw alkyl), -N(C1-6 alkyl)C(0)N(C1-6 alkyl)2, -N(C1-6alkyl)C(0)NH2, -NHS(0)2(C1-6 alkyl), - N(C1-6 alky l)S(0)2(C1-6 alkyl), -NHS(0)2NH2, -NHS(0)2NH(C1-6 alkyl), -NHS(0)2N(C1^ alky 1)2, -N(C1-6alkyl)S(0)2NH2, -N(§1-6 alky l)S(0)2NH(C1-6 alkyl), -N(C1-6alkyl)S(0)2N(C1- 6 alkyl)2, -S(0)2(C1-6 alkyl), -S(0)2NH2, -S(0)2NH(C1-6 alkyl) and -S(0)2N(C1-6alkyl)2;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, OR11, NH2, -NHR9, -NR9R11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)NR11R11, NR11C(0)R11, NR11C(0)OR11, NR1 1C(OJNR11R11, NR11S(0)R11, NR11S(OfcR11, NR11S(0)2NR11R11, S(0)2R11, or S(0)2NR11R11, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Cw haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4 alkyl-, C3-10cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; and
R9 is C 1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- or (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6
membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered
heterocycloalkyl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)- C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of R11 are each optionally substituted with 1 or 2 Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-;
each Rb is independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NHRC, N(RC)2, ORc, C(0)NRcRc, C(0)ORc, COOH, NRcC(0)Rc, OC(0)NRcRc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)2Rc and S(0)2NRcRc, wherein the C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C1-4 alkyl-, C3-6 cycloalkyl-C1- 4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of Rb are each optionally substituted with 1 or 2 Rd substituents independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-C1-4 alkyl-, 5-6 membered heteroaryl, (5-6 membered heteroaryl)-C1-4 alkyl-, CN, OH, COOH, ORe, C(0)ORe, NH2, -NHRe, -N(Re)2, -C(0)NReRe, -NReC(0)Re, OC(0)NReRe, NReC(0)ORe, NReC(0)NReRe, NReS(0)2Re, NReS(0)2NReRe, S(0)2Re and S(0>2NReRe, wherein Re is H or C1-6 alkyl;
each Rc is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-4 alkyl-, C3-6 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-6 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl- C14 alkyl-, C3-6 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl- and (4-6 membered heterocycloalkyl)-C1-4 alkyl- of Rc are each optionally substituted with 1 or 2 Rf substituents;
or two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected Rh substituents;
each Rf is independently selected from halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, C3-6 cycloalkyl, 4-6 membered
heterocycloalkyl, 5-6 membered heteroaryl, CN, OH, COOH, ORS, C(0)ORS, NH2, -NHRg, - N(RS)2, -C(0)NRgRg, -NRSC(0)RS, OC(0)NRSRg, NRSC(0)ORS, NRgC(0)NRgRg,
NRgS(0)2Rg, NRSS(0)2NRSRg; S(0)2RS and S(0)2NRSRg, wherein each Rs is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl; and
each Rh is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, NHRi, N(R')2, OR', CCOiNR'R', NR'CCO)Ri and C(0)OR', wherein R1 is H or C1-6 alkyl.
31. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, N, NR4 or CR4;
X5 is O, S, N, NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C6- 10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, and NR10C(O)OR10, wherein each R10 is independently selected from H, C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R1, R2, R3 and R10 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, ORa, SRa, NHORa, C(0)Ra,
C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, and
NRaC(0)ORa, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- 14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11, OC(0)NR11R11, NR11C(0)R11, and NR11C(0)OR11, wherein the C1-6 alkyl, C2^ alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, and 4-10 membered heterocycloalkyl of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, C7-10aryl, cyclopropyl substituted with 1-3 independently selected Rb substituents, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NO2, OR11, SR11, NH2, -NHR9, -NR9R11, NHOR11, C(0)R11, C(0)NR11R11, C(0)OR11, OC(0)R11,
OC(0)NR11R11, NR11C(0)R11, or NR11C(0)OR11, wherein the C2^ alkenyl, C2^ alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C7-10aryl, C4-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is methyl, ethyl, propyl, isopropyl, C5-6 alkyl, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, wherein the C5-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10
membered heteroaryl, and 4-10 membered heterocycloalkyl of R9 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, and OC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, and NRcC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents.
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, and NRcC(0)ORc; wherein the Cw haloalkyl, Cw haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents; each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl,
C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHORS, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRSRg, NHRg, NRSRg, NRgC(0)Rg, NRGC(0)NRgRg, and NRgC(0)ORg; wherein the C M alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, and NR°C(0)OR°, wherein the C1-6 alkyl, C1-6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents; each Rd is independently selected from C1-6 alkyl, C 1-6 haloalkyl, halo, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, and NReC(0)ORe, wherein the C1-6 alkyl, C 1-6 haloalkyl, C6-10aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl and (5-10 membered heteroaryl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, ORr, C(0)Rr, CiOiNRH', C(0)ORr, OC(0)Rr, OCiOiNRH', NHRr, NRH', and NRrC(0)Rr;
each R° is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C 1-6 alky lthio, phenyl, 5-6 membered heteroaryl, 4-6
membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12 and each R12 is
independently C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
32. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, NR4 or CR4;
X5 is NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, halo, CN, OH, C1^ alkoxy, C1-4 haloalkyl, C1^ haloalkoxy, NH2, -NH-C1-4 alkyl, - N(C1-4 alky 1)2, wherein the C1-4 alkyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 independently selected Rd substituents;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2^ alkynyl, C1-6 haloalkyl, C1-6haloalkoxy, CN, NO2, ORa, SRa, NHORa, C(0)Ra,
C(0)NRaRa, C(0)ORa, NHRa, NRaRa, and NRaC(0)Ra, wherein the C1-6 alkyl, C2^ alkenyl, and C2-6 alkynyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, NO2, OR11, SR11, NH2, -NHR11, -NR11R11, C(0)R11, C(0)NR11R11, C(0)OR11, NR11C(0)R11, and NR11C(0)OR11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6
haloalkoxy of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C 1-6 haloalkoxy, phenyl substituted with 1-3
independently selected Rbl substituents, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3
independently selected Rb substituents;
each R11 is independently selected from H, C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R11 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and 5-10 membered heteroaryl, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, 5-10 membered heteroaryl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, C1- 6 haloalkoxy, CN, OH, NH2, NHORc, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rbl is independently selected from CI, Br, I, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, C(0)ORc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, and NRcC(0)NRcRc; wherein the C1-6 alkyl, C1-6 haloalkyl, and C1-6 haloalkoxy of Rbl are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rb2 is independently selected from halo, C1-6 haloalkyl, C 1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, and NRcC(0)ORc; wherein the C1-6 haloalkyl, C M haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents; each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10aryl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10 aryl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, (4-10 membered
heterocy cloalkyl)-C 1-4 alky 1-, halo, CN, ORg, C(0)Rg, C(0)NRgRg, C(0)ORg, NHRg, NRgRg, and NRgC(0)Rg; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (4-10 membered heterocy cloalkyl)-C 1-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, phenyl, OR0, C(0)R°, C(0)NR°R°, C(0)OR°, NHR°, NR°R°, and NR°C(0)R°;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, (4-10 membered heterocy cloalkyl)-C1-4 alkyl-, CN, NH2, NHORe, ORe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, and NReC(0)ORe, wherein the CM alkyl and (4-10 membered heterocy cloalkyl)-C1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rg is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C 1-4 alkyl-; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C 1-4 alkyl- of Rg are each optionally substituted with 1-3 RP substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2^ alkynyl, halo, CN, ORr, C(0)Rr, C(0)NRTlr, and C(0)ORr;
each R° is independently selected from H and C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
33. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
X1 is CR1;
X2 is CR2;
X3 is CR3;
X4 is O, S, NR4 or CR4;
X5 is NR5 or CR5;
Cy is C6-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R6 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2^ alkynyl, halo, CN, OH, NH2, -NH-C1-4 alkyl, and -N(C1-4 alky 1)2;
R4, R5 and R6 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, ORa, C(0)NRaRa, and NR^^R3, wherein the C1-4 alkyl, C2-6 alkenyl, and C2-6
alkynyl of R4, R5 and R6 are each optionally substituted with 1, 2, 3, 4 or 5 independently selected Rb substituents;
or two adjacent R6 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R7 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or CN, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R7 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R8 is halo, C1-6 alkyl substituted with 1-3 independently selected Rb2 substituents, C2-6 alkenyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C2-6 alkenyl and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R8 are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
each Ra is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and 5- 10 membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and 5-10 membered heteroaryl of Ra are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
each Rb substituent is independently selected from halo, C1-6 alkyl, and ORc;
each Rb2 is independently selected from halo, C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, NHRC, NRCRC, and NRcC(0)Rc; wherein the C1-6 haloalkyl, C1-6 haloalkoxy, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Rb2 are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10aryl, wherein the C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C6-10 aryl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from C1-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, halo, ORs, C(0)Rs, C(0)NRSRg, NHRg, and NRSRS; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of
Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from C1-6 alkyl, halo, CN, OR0, and C(0)OR°;
each Rd is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, ORe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, and NReC(0)Re; wherein the C1-4 alkyl and (4-10 membered
heterocycloalkyl)-C 1-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; each Rs is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl-; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and (5-10 membered heteroaryl)-C1-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, and CN; each R° is independently selected from H and C1-6 alkyl; and
^^^is a single bond or a double bond to maintain ring A being aromatic.
34. The compound of claim 1, selected from:
(2S)-l-[(2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-l,3-thiazol-5- yl)methyl]piperidine-2-carboxylic acid,
5- { [(2-hydroxyethyl)amino]methyl} -N-(2-methylbiphenyl-3-yl)-l ,3-thiazole-2- carboxamide,
5- { [(2-hydroxyethyl)amino]methyl} -N-(2-methylbiphenyl-3-yl)-l ,3-oxazole-2- carboxamide,
(2S)-l-[(l-memyl-2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-lH-imidazol-5- yl)methyl]piperidine-2-carboxylic acid,
5- { [(2-hy droxy ethy l)amino]methy 1 } - 1 -methy l-N-(2-methy lbipheny 1-3-y 1)- 1 H- imidazole-2-carboxamide,
(2S)-l-[(l-methyl-3-{[(2-methylbiphenyl-3-yl)amino]carbonyl}-lH-pyrazol-5- yl)methyl]piperidine-2-carboxylic acid,
5- { [(2-hy droxy ethy l)amino]methyl }- 1 -methy l-N-(2-methy lbipheny 1-3-y 1)- 1 H- py razole-3 -carboxami de,
4- chloro-5- {[(2-hy droxy ethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-l, 3- thiazole-2-carboxamide,
5- { [(2-hy droxy ethy l)amino]methy 1 } -4-methy l-N-(2-methy lbipheny 1-3-y 1)- 1 ,3- thiazole-2-carboxamide,
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-5-{[(2- hydroxyethyl)amino]methyl}-l-methyl-lH-pyrazole-3-carboxamide,
N-(2-cy ano-2'-fluorobipheny 1-3-y l)-5- { [(2-hy droxy ethy l)amino]methy 1 } - 1 -methy 1- lH-pyrazole-3-carboxamide
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]methyl}- 1 -methy 1- lH-pyrazole-3-carboxamide,
N-[2-cyano-3-(l-methyl-lH-indazol-4-yl)phenyl]-5-{[(2- hy droxy ethyl)amino]methyl}-l-methyl-lH-pyrazole-3-carboxamide,
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-5-{[(2- hy droxy ethy l)amino] methy 1 } - 1 -methy 1- lH-imidazole-2-carboxamide,
N-(2-cyano-2'-fluoro-3,-methoxybiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]methyl}- 1 -methyl- 1 H-imidazole-2-carboxamide, and
N-[2-cyano-3-(l-methyl-lH-indazol-4-yl)phenyl]-5-{[(2- hy droxy ethy l)amino] methy 1 } - 1 -methy 1- lH-imidazole-2-carboxamide
or a pharmaceutically acceptable salt or a stereoisomer thereof.
35. The compound of claim 1, selected from:
(S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-(((2- hy droxy emyl)amino)methyl)tliiazole-2-carboxarnido)-2,2,-dimethyl-[l,r-biphenyl]-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid;
(S)-l-(5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((3'-(5-(((R)-3- hydroxypyrrolidin-l-yl)memyl)miazole-2-carboxamido)-2,2'-dimethyl-[l,r-biphenyl]-3- yl)methoxy)benzyl)piperidine-2-carboxylic acid; and
5-(((R)-3-hydroxypyrrolidin-l-yl)methyl)-N-(3'-(5-(((R)-3-hydroxypyrrolidin-l- yl)methyl)-l-methyl-lH-pyrazole-3-carboxamido)-2,2'-dimethyl-[l,r-biphenyl]-3- yl)thiazole-2-carboxamide;
or a pharmaceutically acceptable salt or a stereoisomer thereof.
36. A pharmaceutical composition comprising a compound of any one of claims 1-35, or a pharmaceutically acceptable salt or a stereoisomer thereof, and at least one
pharmaceutically acceptable carrier or excipient.
37. A method of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient a compound of any one of claims 1-35, or a pharmaceutically acceptable salt or a stereoisomer thereof.
38. A method of treating a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of any one of claims 1-35, or a
pharmaceutically acceptable salt or a stereoisomer thereof.
39. A method of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-35, or a pharmaceutically acceptable salt or a stereoisomer thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17761781.8A EP3504198B1 (en) | 2016-08-29 | 2017-08-28 | Heterocyclic compounds as immunomodulators |
ES17761781T ES2941716T3 (en) | 2016-08-29 | 2017-08-28 | Heterocyclic compounds as immunomodulators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662380599P | 2016-08-29 | 2016-08-29 | |
US62/380,599 | 2016-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018044783A1 true WO2018044783A1 (en) | 2018-03-08 |
Family
ID=59772844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/048880 WO2018044783A1 (en) | 2016-08-29 | 2017-08-28 | Heterocyclic compounds as immunomodulators |
Country Status (5)
Country | Link |
---|---|
US (3) | US20180057486A1 (en) |
EP (1) | EP3504198B1 (en) |
ES (1) | ES2941716T3 (en) |
MA (1) | MA46045A (en) |
WO (1) | WO2018044783A1 (en) |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018195321A1 (en) | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019032547A1 (en) | 2017-08-08 | 2019-02-14 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
WO2019149183A1 (en) * | 2018-02-05 | 2019-08-08 | 上海和誉生物医药科技有限公司 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof |
CN110128415A (en) * | 2019-05-31 | 2019-08-16 | 沈阳药科大学 | Indoline-like compound as immunomodulator and preparation method thereof |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
WO2019193542A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
WO2019192506A1 (en) * | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
WO2019193533A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2'-cyclic dinucleotides |
WO2019200247A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
WO2020014643A1 (en) | 2018-07-13 | 2020-01-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US10618916B2 (en) | 2018-05-11 | 2020-04-14 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
WO2020088357A1 (en) | 2018-11-02 | 2020-05-07 | 上海再极医药科技有限公司 | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
US10669271B2 (en) | 2018-03-30 | 2020-06-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2020151589A1 (en) * | 2019-01-25 | 2020-07-30 | 北京赛特明强医药科技有限公司 | Acylamino bridged heterocyclic compound, and composition and application thereof |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020192570A1 (en) | 2019-03-22 | 2020-10-01 | 上海再极医药科技有限公司 | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
US10793565B2 (en) | 2016-12-22 | 2020-10-06 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10800768B2 (en) | 2016-12-22 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10806785B2 (en) | 2016-12-22 | 2020-10-20 | Incyte Corporation | Immunomodulator compounds and methods of use |
WO2020214663A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214652A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021008491A1 (en) * | 2019-07-18 | 2021-01-21 | 上海和誉生物医药科技有限公司 | Biphenyl derivatives for blocking pd-1/pd-l1 interaction, preparation method therefor and use thereof |
US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021136354A1 (en) | 2020-01-03 | 2021-07-08 | 上海翰森生物医药科技有限公司 | Biphenyl derivative inhibitor, preparation method therefor and use thereof |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
CN113461668A (en) * | 2021-04-30 | 2021-10-01 | 西安新通药物研究股份有限公司 | Novel biphenyl derivative, preparation method and medical application thereof |
US11135210B2 (en) | 2018-02-22 | 2021-10-05 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
WO2021226206A2 (en) | 2020-05-05 | 2021-11-11 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11266643B2 (en) | 2019-05-15 | 2022-03-08 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
WO2022052926A1 (en) | 2020-09-09 | 2022-03-17 | 广州再极医药科技有限公司 | Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof |
RU2768830C9 (en) * | 2018-02-05 | 2022-06-17 | Aббиско Тхерaпеутицс Цо., Лтд. | Biaryl derivative, method for production thereof and pharmaceutical application thereof |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
US11407749B2 (en) | 2015-10-19 | 2022-08-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11426364B2 (en) | 2016-06-27 | 2022-08-30 | Chemocentryx, Inc. | Immunomodulator compounds |
US11465981B2 (en) | 2016-12-22 | 2022-10-11 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11485708B2 (en) | 2019-06-20 | 2022-11-01 | Chemocentryx, Inc. | Compounds for treatment of PD-L1 diseases |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
US11535615B2 (en) | 2015-12-22 | 2022-12-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11572366B2 (en) | 2015-11-19 | 2023-02-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
US11608337B2 (en) | 2016-05-06 | 2023-03-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11613536B2 (en) | 2016-08-29 | 2023-03-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
US11673883B2 (en) | 2016-05-26 | 2023-06-13 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
US11718605B2 (en) | 2016-07-14 | 2023-08-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
US11866451B2 (en) | 2019-11-11 | 2024-01-09 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11872217B2 (en) | 2019-07-10 | 2024-01-16 | Chemocentryx, Inc. | Indanes as PD-L1 inhibitors |
US11873309B2 (en) | 2016-06-20 | 2024-01-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107383009B (en) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | Substituted tricyclic compounds as FGFR inhibitors |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
CN107438607B (en) | 2015-02-20 | 2021-02-05 | 因赛特公司 | Bicyclic heterocycles as FGFR inhibitors |
US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
CA3093851A1 (en) | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
WO2019232319A1 (en) | 2018-05-31 | 2019-12-05 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
KR20210049090A (en) | 2018-07-05 | 2021-05-04 | 인사이트 코포레이션 | Pyrazine derivatives fused as A2A/A2B inhibitors |
TWI826492B (en) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same |
MA53726A (en) | 2018-09-25 | 2022-05-11 | Incyte Corp | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
TW202415643A (en) | 2018-12-12 | 2024-04-16 | 加拿大商愛彼特生物製藥公司 | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
SG11202106582YA (en) | 2018-12-20 | 2021-07-29 | Incyte Corp | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
EA202192260A1 (en) | 2019-02-15 | 2021-12-17 | Инсайт Корпорейшн | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND THEIR APPLICATIONS |
TW202100520A (en) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
JP2022552324A (en) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (en) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Derivatives of FGFR inhibitors |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20230017165A (en) | 2020-03-06 | 2023-02-03 | 인사이트 코포레이션 | Combination therapy with AXL/MER and PD-1/PD-L1 inhibitors |
PE20230825A1 (en) | 2020-04-16 | 2023-05-19 | Incyte Corp | FUSIONED TRICYCLIC KRAS INHIBITORS |
US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
BR112022025191A2 (en) | 2020-06-12 | 2023-03-07 | Incyte Corp | IMIDAZOPYRIDAZINE COMPOUNDS WITH ALK2 INHIBITORY ACTIVITY |
US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
JP2024522189A (en) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Tricyclic Heterocycles as FGFR Inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
TW202317565A (en) | 2021-07-07 | 2023-05-01 | 美商英塞特公司 | Tricyclic compounds as inhibitors of kras |
US20230114765A1 (en) | 2021-07-14 | 2023-04-13 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
US20230174555A1 (en) | 2021-08-31 | 2023-06-08 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
WO2023050104A1 (en) * | 2021-09-28 | 2023-04-06 | 中国医学科学院药物研究所 | Indoline derivative, preparation method therefor, pharmaceutical composition, and use |
WO2023056421A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
IL312114A (en) | 2021-10-14 | 2024-06-01 | Incyte Corp | Quinoline compounds as inhibitors of kras |
MX2024006113A (en) | 2021-11-22 | 2024-07-29 | Incyte Corp | Combination therapy comprising an fgfr inhibitor and a kras inhibitor. |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
EP4198033A1 (en) * | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
AR128043A1 (en) | 2021-12-22 | 2024-03-20 | Incyte Corp | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR THEIR PREPARATION |
WO2023239768A1 (en) | 2022-06-08 | 2023-12-14 | Incyte Corporation | Tricyclic triazolo compounds as dgk inhibitors |
CN115385865B (en) * | 2022-06-29 | 2023-06-16 | 深圳大学 | Small molecule inhibitor with CXCR2 inhibition activity and preparation method and application thereof |
US20240101557A1 (en) | 2022-07-11 | 2024-03-28 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
US20240217989A1 (en) | 2022-11-18 | 2024-07-04 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
US20240270739A1 (en) | 2023-01-12 | 2024-08-15 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
WO2006053121A2 (en) * | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
WO2012080376A1 (en) * | 2010-12-17 | 2012-06-21 | Syngenta Participations Ag | Insecticidal compounds |
EP2824099A1 (en) * | 2012-03-09 | 2015-01-14 | Carna Biosciences Inc. | Novel triazine derivative |
WO2016057500A1 (en) * | 2014-10-06 | 2016-04-14 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
Family Cites Families (332)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272781A (en) | 1963-08-07 | 1966-09-13 | American Potash & Chem Corp | Boroureas of phosphinoborine polymers |
FR1425700A (en) | 1965-02-22 | 1966-01-24 | Basf Ag | Compounds forming metal complexes and method of preparing and using them |
US4208328A (en) | 1978-04-27 | 1980-06-17 | General Electric Company | Alkyl 3,5-dihydroxy-4-(2-benzothiazolyl)benzoates |
US4789711A (en) | 1986-12-02 | 1988-12-06 | Ciba-Geigy Corporation | Multifunctional epoxide resins |
DE3828535A1 (en) | 1988-08-23 | 1990-03-08 | Basf Ag | BENZIMIDAZOLE-2-CARBON-ACIDANILIDE, THEIR USE AS ANTI-LIGHTING AGENT FOR ORGANIC MATERIAL AND ORGANIC MATERIAL STABILIZED THEREOF |
US5077164A (en) | 1989-06-21 | 1991-12-31 | Minolta Camera Kabushiki Kaisha | Photosensitive member containing an azo dye |
DE69421982T2 (en) | 1993-09-20 | 2000-03-30 | Fuji Photo Film Co., Ltd. | Positive working photoresist composition |
JP3461397B2 (en) | 1995-01-11 | 2003-10-27 | 富士写真フイルム株式会社 | Positive photoresist composition |
JP2001505585A (en) | 1996-12-16 | 2001-04-24 | 藤沢薬品工業株式会社 | Novel amide compounds and their use as nitric oxide synthase inhibitors |
JPH10316853A (en) | 1997-05-15 | 1998-12-02 | Sumitomo Bakelite Co Ltd | Resin composition for interlaminar insulating membrane for multilayer interconnection of semiconductor, and production of the insulating membrane |
WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO1999044992A1 (en) | 1998-03-05 | 1999-09-10 | Nissan Chemical Industries, Ltd. | Anilide compounds and herbicide |
JP2000128986A (en) | 1998-10-28 | 2000-05-09 | Sumitomo Bakelite Co Ltd | Polybenzoxazole precursor and polybenzoxazole |
JP2000128987A (en) | 1998-10-28 | 2000-05-09 | Sumitomo Bakelite Co Ltd | Polybenzoxazole precursor and polybenzoxazole |
JP2000128984A (en) | 1998-10-28 | 2000-05-09 | Sumitomo Bakelite Co Ltd | Polybenzoxazole precursor and resin |
US6297351B1 (en) | 1998-12-17 | 2001-10-02 | Sumitomo Bakelite Company Limited | Polybenzoxazole resin and precursor thereof |
US6867200B1 (en) | 1998-12-18 | 2005-03-15 | Axys Pharmaceuticals, Inc. | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
JP2000212281A (en) | 1999-01-27 | 2000-08-02 | Sumitomo Bakelite Co Ltd | Polybenzoxazole precursor and polybenzoxazole resin |
AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
JP2001114893A (en) | 1999-10-15 | 2001-04-24 | Sumitomo Bakelite Co Ltd | Polybenzoxazole resin and its precursor |
US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
JP2001163975A (en) | 1999-12-03 | 2001-06-19 | Sumitomo Bakelite Co Ltd | Polybenzoxazole resin and its precursor |
CN1623984A (en) | 1999-12-27 | 2005-06-08 | 日本烟草产业株式会社 | Fused-ring compounds and use thereof as drugs |
WO2001057038A1 (en) | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterocyclic compounds and their use as parp inhibitors |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2001074815A2 (en) | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Phenyl-substituted imidazopyridines |
AU2001254555A1 (en) | 2000-04-24 | 2001-11-07 | Merck Frosst Canada & Co | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
WO2002014321A1 (en) | 2000-08-11 | 2002-02-21 | The Regents Of The University Of California | Use of stat-6 inhibitors as therapeutic agents |
WO2002048146A2 (en) | 2000-12-13 | 2002-06-20 | Basf Aktiengesellschaft | Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds |
DE60112609T2 (en) | 2000-12-15 | 2006-01-19 | Glaxo Group Ltd., Greenford | pyrazolopyridines |
SE0100567D0 (en) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
JP2004532194A (en) | 2001-03-14 | 2004-10-21 | エリ リリー アンド カンパニー | Retinoid X receptor modulator |
US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
WO2002083672A1 (en) | 2001-04-10 | 2002-10-24 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
JP2002316966A (en) | 2001-04-19 | 2002-10-31 | Ueno Seiyaku Oyo Kenkyusho:Kk | Binaphthol derivative and method for producing the same |
DE60204452T2 (en) | 2001-04-27 | 2005-12-15 | Smithkline Beecham Corp. | [1,5] pyridine derivatives |
AR035543A1 (en) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS |
JP2005507878A (en) | 2001-09-07 | 2005-03-24 | スミスクライン ビーチャム コーポレーション | Pyrazolo-pyridines for the treatment of herpes infections |
TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
BR0213208A (en) | 2001-10-09 | 2004-08-31 | Upjohn Co | Substituted arylsulfonyl tetrahydro- and hexahydro-carbazoles compounds, their compositions and uses |
AU2002334969A1 (en) | 2001-10-09 | 2003-04-22 | Sylvie Barchechath | Use of stat-6 inhibitors as therapeutic agents |
JP4024579B2 (en) | 2002-01-22 | 2007-12-19 | 住友ベークライト株式会社 | Plastic optical waveguide material and optical waveguide |
PL373399A1 (en) | 2002-04-11 | 2005-08-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
BR0309475A (en) | 2002-04-23 | 2005-03-01 | Shionogi & Co | Pyrazolo [1,5-a] pyrimidine derivatives and nad (p) h oxidase inhibitors containing them |
WO2004007472A1 (en) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
JP2004059761A (en) | 2002-07-30 | 2004-02-26 | Sumitomo Bakelite Co Ltd | Polybenzoxazole resin, its precursor, and optical waveguide material and optical waveguide using these |
EP1547996A4 (en) | 2002-08-30 | 2006-08-02 | Bf Res Inst Inc | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
JP2004091369A (en) | 2002-08-30 | 2004-03-25 | Sumitomo Pharmaceut Co Ltd | New biphenyl compound |
WO2004033454A1 (en) | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
WO2004035588A1 (en) | 2002-10-15 | 2004-04-29 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
KR100624406B1 (en) | 2002-12-30 | 2006-09-18 | 삼성에스디아이 주식회사 | Biphenyl derivatives and organo-electroluminescent device employing the same |
US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
JP4595288B2 (en) | 2003-03-25 | 2010-12-08 | 住友ベークライト株式会社 | Polybenzoxazole resin, precursor thereof, optical waveguide material using the same, and optical waveguide |
PT1620429E (en) | 2003-04-11 | 2009-04-28 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
JP2005002330A (en) | 2003-05-19 | 2005-01-06 | Sumitomo Electric Ind Ltd | Optical resin material, optical element, optical module, precursor of fluorinated polymer, and fluorinated polymer |
CA2524048C (en) | 2003-05-19 | 2013-06-25 | Irm Llc | Immunosuppressant compounds and compositions |
US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005007111A2 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
JP5001650B2 (en) | 2003-07-11 | 2012-08-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzimidazole carboxamide |
US20100267778A1 (en) | 2003-08-04 | 2010-10-21 | Shinya Kusuda | Diphenyl ether compound, process for producing the same, and use |
WO2005014543A1 (en) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | Condensed ring compound and use thereof as hcv polymerase inhibitor |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
EP1673343A4 (en) | 2003-10-08 | 2008-09-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JPWO2005040135A1 (en) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | Anti-stress drugs and their medicinal uses |
WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
WO2005063710A1 (en) | 2003-12-23 | 2005-07-14 | Basf Aktiengesellschaft | 3-trifluoromethyl picolinic acid anilides, and use thereof as fungicides |
AU2005215379A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
WO2005077948A1 (en) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | Fungicidal heterocyclic compounds |
GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
JP2005248082A (en) | 2004-03-05 | 2005-09-15 | Sumitomo Electric Ind Ltd | Manufacturing process of polybenzoxazole resin precursor and manufacturing process of polybenzoxazole resin |
US20050250820A1 (en) | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
US7432278B2 (en) | 2004-03-08 | 2008-10-07 | The University Of North Carolina At Chapel Hill | Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents |
EP1761496A2 (en) | 2004-03-31 | 2007-03-14 | Janssen Pharmaceutica N.V. | Non-imidazole heterocyclic compounds as histamine h3-receptor ligands |
JP2005290301A (en) | 2004-04-02 | 2005-10-20 | Sumitomo Electric Ind Ltd | Method for manufacturing polybenzoxazol resin precursor and polybenzoxazol resin |
WO2005099656A2 (en) | 2004-04-06 | 2005-10-27 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
JP4879165B2 (en) | 2004-04-20 | 2012-02-22 | トランス テック ファーマ,インコーポレイテッド | Substituted thiazole and pyrimidine derivatives as modulators of melanocortin receptors |
DE102004021716A1 (en) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds |
WO2005108387A2 (en) | 2004-05-03 | 2005-11-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
US7250441B2 (en) | 2004-09-23 | 2007-07-31 | Wyeth | Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
DE102004054665A1 (en) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituted bicyclic and tricyclic pyrazole derivatives Methods for the preparation and use as herbicides and plant growth regulators |
AU2006218403A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
MX2007011041A (en) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Certain substituted amides, method of making, and method of use thereof. |
JP2006290883A (en) | 2005-03-17 | 2006-10-26 | Nippon Nohyaku Co Ltd | Substituted heterocycle carboxylic anilide derivative, its intermediate and chemical for agriculture and horticulture and method for using the same |
AU2006247118A1 (en) | 2005-05-20 | 2006-11-23 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
US20080220968A1 (en) | 2005-07-05 | 2008-09-11 | Ge Healthcare Bio-Sciences Ab | [1, 2, 4] Triazolo [1, 5-A] Pyrimidine Derivatives as Chromatographic Adsorbent for the Selective Adsorption of Igg |
WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CN103936690B (en) | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | Aminodihydrothiazinederivative derivative |
JP5249772B2 (en) | 2005-11-22 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | Tricyclic compounds useful as inhibitors of kinases |
WO2007067711A2 (en) | 2005-12-08 | 2007-06-14 | Amphora Discovery Corporation | Certain chemical entities, compositions, and methods for modulating trpv1 |
US20090281120A1 (en) | 2005-12-12 | 2009-11-12 | Ono Pharmaceutical Co., Ltd | Bicyclic heterocyclic compound |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
JPWO2007102531A1 (en) | 2006-03-08 | 2009-07-23 | 武田薬品工業株式会社 | Concomitant medication |
MX2008012617A (en) | 2006-03-31 | 2008-10-10 | Novartis Ag | Organic compounds. |
US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
DE102006035018B4 (en) | 2006-07-28 | 2009-07-23 | Novaled Ag | Oxazole triplet emitter for OLED applications |
WO2008021745A2 (en) | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
TWI389895B (en) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
US7563797B2 (en) | 2006-08-28 | 2009-07-21 | Forest Laboratories Holding Limited | Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands |
PE20080839A1 (en) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME |
SG174810A1 (en) | 2006-09-11 | 2011-10-28 | Matrix Lab Ltd | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
PE20081370A1 (en) | 2006-09-11 | 2008-11-28 | Cgi Pharmaceuticals Inc | CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
JP2010502751A (en) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ,インコーポレイティド | Kinase inhibitors and methods of using and identifying kinase inhibitors |
FR2906250B1 (en) | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | DERIVATIVES OF 2-ARYL-6PHENYL-IMIDAZO (1,2-A) PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
CA2667644A1 (en) | 2006-10-27 | 2008-05-15 | Wyeth | Tricyclic compounds as matrix metalloproteinase inhibitors |
EP2089364B1 (en) | 2006-11-08 | 2013-06-12 | Bristol-Myers Squibb Company | Pyridinone compounds |
GB0623209D0 (en) | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
JP2010513253A (en) | 2006-12-14 | 2010-04-30 | ベーリンガー インゲルハイム インテルナショナール ゲーエムベーハー | Benzoxazoles useful for the treatment of inflammation |
CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
JP2008218327A (en) | 2007-03-07 | 2008-09-18 | Hitachi Ltd | Electrolyte, electrolyte film, film-electrode assembly using the same, fuel cell power supply, and fuel cell power supply system |
JP2010120852A (en) | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | New diamide derivative |
JP2010522227A (en) | 2007-03-22 | 2010-07-01 | アストラゼネカ・アクチエボラーグ | Quinoline derivatives for the treatment of inflammatory diseases |
KR20100017255A (en) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | Aminodihydrothiazine derivatives substituted with cyclic groups |
EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | Pharmaceutical composition for treatment of alzheimer's disease |
WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
CL2008002793A1 (en) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others |
AU2008302746B2 (en) | 2007-09-20 | 2014-07-03 | Amgen Inc. | 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders |
DE102007048716A1 (en) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo [1,2-a] pyrimidine derivatives |
TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
CN101910158A (en) | 2007-10-25 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
WO2009062059A2 (en) | 2007-11-08 | 2009-05-14 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
EP2231143B1 (en) | 2007-12-13 | 2013-07-03 | Merck Sharp & Dohme Corp. | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES |
RU2364597C1 (en) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM |
GEP20125588B (en) | 2007-12-19 | 2012-07-25 | Syngenta Participations Ag | Insecticidal compounds |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | Method for altering the lifespan of eukaryotic organisms |
EP2231659A4 (en) | 2007-12-21 | 2011-10-26 | Univ Sydney | Translocator protein ligands |
PL2233474T3 (en) | 2008-01-18 | 2015-12-31 | Eisai R&D Man Co Ltd | Condensed aminodihydrothiazine derivative |
WO2009096202A1 (en) | 2008-01-31 | 2009-08-06 | Konica Minolta Holdings, Inc. | Halogenated polycyclic aromatic compound and method for producing the same |
AU2009218515A1 (en) | 2008-02-26 | 2009-09-03 | Novartis Ag | Heterocyclic compounds as inhibitors of CXCR2 |
EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
FR2928924B1 (en) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2928922B1 (en) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | DERIVATIVES OF POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2928921B1 (en) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
JP5432982B2 (en) | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | Apoptosis signal-regulating kinase 1 inhibitor |
KR101034351B1 (en) | 2008-05-14 | 2011-05-16 | 한국화학연구원 | Novel benzoxazole-pyridine derivatives or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of abnormal cell growth diseases containing the same as an active ingredient |
CA2724842A1 (en) | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
JP2011521960A (en) | 2008-05-29 | 2011-07-28 | サートリス ファーマシューティカルズ, インコーポレイテッド | Imidazopyridine and related analogs as sirtuin modulators |
ES2566339T3 (en) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | 4-Carboxamide indazole derivatives useful as PI3-kinase inhibitors |
JP2011529073A (en) | 2008-07-24 | 2011-12-01 | ブリストル−マイヤーズ スクイブ カンパニー | Fused heterocyclic compounds useful as kinase regulators |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
JP2011231017A (en) | 2008-09-09 | 2011-11-17 | Nissan Chem Ind Ltd | Process for producing optically active epoxy compound and optically active sulfoxide compound, ligand and complex for use in the process, and process for producing the complex |
WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
JP5557849B2 (en) | 2008-12-19 | 2014-07-23 | ブリストル−マイヤーズ スクイブ カンパニー | Carbazole and carboline kinase inhibitors |
TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
CA2747670A1 (en) | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
JP5624275B2 (en) | 2008-12-22 | 2014-11-12 | ユー・ディー・シー アイルランド リミテッド | Organic electroluminescence device |
JP2012513409A (en) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | Antiviral compounds |
WO2010074284A1 (en) | 2008-12-26 | 2010-07-01 | 味の素株式会社 | Pyrazolopyrimidine compound |
JP2010202530A (en) | 2009-02-27 | 2010-09-16 | Tokyo Institute Of Technology | Heterocycle-containing aromatic compound, and optical material |
WO2010104307A2 (en) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm |
CN102574786A (en) | 2009-04-02 | 2012-07-11 | 默克雪兰诺有限公司 | Dihydroorotate dehydrogenase inhibitors |
DK2419429T3 (en) | 2009-04-16 | 2014-06-23 | Ct Nac De Investigaciones Oncológicas Cnio | IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN CHINAS |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
JP2012532102A (en) | 2009-06-30 | 2012-12-13 | シガ・テクノロジーズ・インコーポレーテッド | Treatment and prevention of dengue virus infection |
TWI598347B (en) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | Apoptosis signal-regulating kinase inhibitors |
JP2011057661A (en) | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | Pesticidal carboxamides |
UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
CA2777734A1 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
WO2011078221A1 (en) | 2009-12-24 | 2011-06-30 | 味の素株式会社 | Imidazopyridazine compounds |
WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
AR080433A1 (en) | 2010-03-02 | 2012-04-11 | Merck Sharp & Dohme | USEFUL BENZOFURANCARBOXAMIDS DERIVATIVES TO TREAT OR PREVENT HCV INFECTIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US9024032B2 (en) | 2010-03-04 | 2015-05-05 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
RU2576662C2 (en) | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Antiinfective compounds |
US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
WO2011159857A1 (en) | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
CN102295642B (en) | 2010-06-25 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-Aryimidazole is [1,2-a] pyridine-3-acetamide, Preparation Method And The Use also |
EP2402345A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
CN101891895B (en) | 2010-07-28 | 2011-11-30 | 南京航空航天大学 | Benzothiazole derivatives metal coordination polymer based on bridged bis-salicylaldehyde structure as well as manufacture method and application thereof |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
CN101993415B (en) | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof |
WO2012047856A2 (en) | 2010-10-04 | 2012-04-12 | Institute For Hepatitis And Virus Research | Novel inhibitors of secretion of hepatitis b virus antigens |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
WO2012068406A2 (en) | 2010-11-18 | 2012-05-24 | Ligand Pharmaceuticals Incorporated | Use of hematopoietic growth factor mimetics |
TWI617559B (en) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives |
KR20140027090A (en) | 2011-01-04 | 2014-03-06 | 노파르티스 아게 | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
US9018395B2 (en) | 2011-01-27 | 2015-04-28 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
EP2685981B1 (en) | 2011-03-17 | 2016-08-24 | Bristol-Myers Squibb Company | Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
WO2012139425A1 (en) | 2011-04-13 | 2012-10-18 | Schering Corporation | 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use |
CN102796103A (en) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-(aryl formyl) imidazo [1,2-a] pyrimidine and 6-(aryl formyl) [1,2,4] triazol [4,3-a] pyrimidine serving as Hedgehog inhibitors and application thereof |
EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
GB201109763D0 (en) | 2011-06-10 | 2011-07-27 | Ucl Business Plc | Compounds |
WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
CA2841111A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013040528A1 (en) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Antimicrobial compounds |
WO2013043521A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
JP6040677B2 (en) | 2011-09-29 | 2016-12-07 | 東洋インキScホールディングス株式会社 | Resin composition for solar cell encapsulant |
WO2013054291A1 (en) | 2011-10-13 | 2013-04-18 | Novartis Ag | Novel oxazine derivatives and their use in the treatment of disease |
CN103998451A (en) | 2011-10-20 | 2014-08-20 | 葛兰素史密斯克莱有限责任公司 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
EP2768832A1 (en) | 2011-10-21 | 2014-08-27 | Torrent Pharmaceuticals Limited | Novel substituted imidazopyrimidines as gpbar1 receptor modulators |
WO2013120040A1 (en) | 2012-02-10 | 2013-08-15 | Children's Medical Center Corporation | Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
PE20141558A1 (en) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | DERIVATIVES OF BENZOTHIAZOLE-6-IL ACETIC ACID AND THEIR USE TO TREAT HIV INFECTION |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
US20150105433A1 (en) | 2012-04-27 | 2015-04-16 | The Uab Research Foundation | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM |
EP2862853B1 (en) | 2012-06-18 | 2020-01-22 | Sumitomo Chemical Co., Ltd | Fused heterocyclic compound |
WO2014007228A1 (en) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
JP6259823B2 (en) | 2012-07-13 | 2018-01-10 | ユーシービー バイオファルマ エスピーアールエル | Imidazopyridine derivatives as modulators of TNF activity |
JP2015178457A (en) | 2012-07-25 | 2015-10-08 | 杏林製薬株式会社 | Pyrazolopyridine derivative and pharmacologically permissible salt of the same |
EP2892899B1 (en) | 2012-09-06 | 2018-03-21 | Bristol-Myers Squibb Company | Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
EP2900657B1 (en) | 2012-09-26 | 2020-03-11 | F.Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
WO2014061693A1 (en) | 2012-10-17 | 2014-04-24 | 塩野義製薬株式会社 | Novel non-aromatic carbocyclic or non-aromatic heterocyclic derivative |
EP2922548A4 (en) | 2012-11-21 | 2016-06-01 | Stategics Inc | Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival |
JP6037804B2 (en) | 2012-12-03 | 2016-12-07 | 富士フイルム株式会社 | Gas separation membrane |
EA035929B1 (en) | 2013-01-15 | 2020-09-02 | Инсайт Холдингс Корпорейшн | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDES USEFUL AS Pim KINASE INHIBITORS |
CA2896185A1 (en) | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
CN103933036B (en) | 2013-01-23 | 2017-10-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 2 Aryimidazoles simultaneously the acetamide derivative of [1,2 α] pyridine 3 prepare preventing and treating PTSD medicine in purposes |
US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
KR102169426B1 (en) | 2013-02-27 | 2020-10-23 | 모찌다 세이야쿠 가부시끼가이샤 | Novel pyrazole derivative |
KR20150124985A (en) | 2013-03-08 | 2015-11-06 | 암젠 인크 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
AU2014231768A1 (en) | 2013-03-13 | 2015-09-24 | Australian Nuclear Science And Technology Organisation | Transgenic non-human organisms with non-functional TSPO genes |
CN104045552B (en) | 2013-03-13 | 2019-06-11 | 江苏先声药业有限公司 | Medicinal compound as neuroprotective agent |
EP2968265A4 (en) | 2013-03-14 | 2016-12-28 | Celtaxsys Inc | Inhibitors of leukotriene a4 hydrolase |
MA38461B1 (en) | 2013-03-14 | 2021-10-29 | Curadev Pharma Private Ltd | Kynurenine pathway inhibitors |
DK2968304T3 (en) | 2013-03-14 | 2019-01-28 | Univ Columbia | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE. |
CN105189503B (en) | 2013-03-14 | 2017-03-22 | 百时美施贵宝公司 | Inhibitors of human immunodeficiency virus replication |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
ME03307B (en) | 2013-06-26 | 2019-10-20 | Abbvie Inc | Primary carboxamides as btk inhibitors |
WO2015000715A1 (en) | 2013-07-02 | 2015-01-08 | Syngenta Participations Ag | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents |
SG11201600108PA (en) | 2013-07-17 | 2016-02-26 | Otsuka Pharma Co Ltd | Cyanotriazole compounds |
RU2016105108A (en) | 2013-07-25 | 2017-08-30 | Дана-Фарбер Кэнсер Инститьют, Инк. | TRANSCRIPTION FACTOR INHIBITORS AND THEIR APPLICATION |
EP2835375A1 (en) | 2013-08-09 | 2015-02-11 | Fundació Institut Català d'Investigació Química | Bis-salphen compounds and carbonaceous material composites comprising them |
KR101715090B1 (en) | 2013-08-28 | 2017-03-13 | 한국화학연구원 | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient |
ES2642074T3 (en) | 2013-09-04 | 2017-11-15 | Bristol-Myers Squibb Company | Useful compounds as immunomodulators |
ES2788848T3 (en) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazole derivatives as immunomodulators |
PT3041828T (en) | 2013-09-06 | 2018-10-09 | Aurigene Discovery Tech Ltd | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
JP6336870B2 (en) | 2013-09-30 | 2018-06-06 | 日本ポリプロ株式会社 | Biphenol compound, olefin polymerization catalyst using the same, and process for producing olefin polymer |
GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321733D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015095337A2 (en) | 2013-12-18 | 2015-06-25 | The Rockefeller University | PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT |
ES2683693T3 (en) | 2014-01-03 | 2018-09-27 | Bayer Animal Health Gmbh | New pyrazolyl heteroarylamides as pesticide agents |
US20160356794A1 (en) | 2014-02-10 | 2016-12-08 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
US9732103B2 (en) | 2014-02-25 | 2017-08-15 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders |
JP6490464B2 (en) | 2014-03-26 | 2019-03-27 | 三井化学株式会社 | Transition metal compound, catalyst for olefin polymerization, and process for producing olefin polymer |
EP3125883B1 (en) | 2014-04-04 | 2020-08-12 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2015197028A1 (en) | 2014-06-28 | 2015-12-30 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine |
CN104211726B (en) | 2014-08-11 | 2017-06-16 | 中南民族大学 | The tooth double-core titanium complex of non-luxuriant class three, Preparation method and use |
EP3193608A4 (en) | 2014-09-17 | 2018-05-02 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2016041511A1 (en) | 2014-09-19 | 2016-03-24 | Yen-Ta Lu | Benzo-heterocyclic compounds and their applications |
AU2015360416A1 (en) | 2014-12-10 | 2017-06-08 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
JP6853619B2 (en) | 2015-01-16 | 2021-03-31 | 大塚製薬株式会社 | Pharmaceutical use of cyanotriazole compounds |
DE112016000383A5 (en) | 2015-01-20 | 2017-10-05 | Cynora Gmbh | Organic molecules, in particular for use in optoelectronic components |
US10071998B2 (en) | 2015-01-20 | 2018-09-11 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use |
WO2016156282A1 (en) | 2015-04-02 | 2016-10-06 | Bayer Cropscience Aktiengesellschaft | Novel triazole compounds for controlling phytopathogenic harmful fungi |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
MA52119A (en) | 2015-10-19 | 2018-08-29 | Ncyte Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
WO2017070320A1 (en) | 2015-10-21 | 2017-04-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Phenyl indole allosteric inhibitors of p97 atpase |
KR101717601B1 (en) | 2015-11-10 | 2017-03-20 | 한국화학연구원 | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient |
SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
TW201726623A (en) | 2015-12-17 | 2017-08-01 | 英塞特公司 | Heterocyclic compounds as immunomodulators |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
EP4292650A3 (en) | 2015-12-22 | 2024-02-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2016378482A1 (en) | 2015-12-22 | 2018-07-12 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
JP6943857B2 (en) | 2015-12-22 | 2021-10-06 | シンジェンタ パーティシペーションズ アーゲー | Pest control active pyrazole derivative |
SG10202111399YA (en) | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
KR101653560B1 (en) | 2016-02-02 | 2016-09-12 | 한국화학연구원 | Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient |
AR109452A1 (en) | 2016-04-22 | 2018-12-12 | Incyte Corp | PHARMACEUTICAL FORMULATION OF AN LSD1 INHIBITOR AND TREATMENT METHOD |
AR108396A1 (en) | 2016-05-06 | 2018-08-15 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MX2018016331A (en) | 2016-06-20 | 2019-05-20 | Novartis Ag | Crystalline forms of triazolopyrimidine compound. |
CN109641034B (en) | 2016-06-20 | 2023-08-15 | 伊兰科美国公司 | Pegylated porcine interferon and methods of use thereof |
KR102685249B1 (en) | 2016-06-20 | 2024-07-17 | 인사이트 코포레이션 | Heterocyclic Compounds as Immunomodulators |
JP7054529B2 (en) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | CXCR4 inhibitor and its use |
MA45669A (en) | 2016-07-14 | 2019-05-22 | Incyte Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
CA3030773A1 (en) | 2016-08-03 | 2018-02-08 | Arising International, Inc. | Symmetric or semi-symmetric compounds useful as immunomodulators |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
SG11201901390TA (en) | 2016-08-30 | 2019-03-28 | Tetraphase Pharmaceuticals Inc | Tetracycline compounds and methods of treatment |
JP7022131B2 (en) | 2016-12-21 | 2022-02-17 | アセルタ ファーマ ビー.ブイ. | Bruton's tyrosine kinase imidazole pyrazine inhibitor |
TWI795381B (en) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | Pyrazole derivatives as malt1 inhibitors |
US20180177784A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2017382405B2 (en) | 2016-12-22 | 2021-12-16 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
PL3558990T3 (en) | 2016-12-22 | 2022-12-19 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
CA3070794A1 (en) | 2017-07-28 | 2019-01-31 | Chemocentryx, Inc. | Immunomodulator compounds |
EP3664793B1 (en) | 2017-08-08 | 2022-06-29 | ChemoCentryx, Inc. | Macrocyclic immunomodulators |
EP3669872A4 (en) | 2017-08-18 | 2021-05-05 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Compound having pd-l1 inhibitory activity, preparation method therefor and use thereof |
WO2019191707A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2021520342A (en) | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | Immunomodulators, compositions and methods thereof |
JP7242702B2 (en) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | PD-1/PD-L1 inhibitor |
DK3790877T3 (en) | 2018-05-11 | 2023-04-24 | Incyte Corp | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNE MODULATORS |
KR102635333B1 (en) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | PD-1/PD-L1 inhibitors |
JP2022513592A (en) | 2018-11-02 | 2022-02-09 | シャンハイ マキシノベル ファーマシューティカルズ カンパニー リミテッド | Biphenyl compounds, their intermediates, manufacturing methods, pharmaceutical compositions and uses |
CN113365995A (en) | 2019-01-31 | 2021-09-07 | 贝达药业股份有限公司 | Immunomodulator, composition and method thereof |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
KR20220075382A (en) | 2019-09-30 | 2022-06-08 | 인사이트 코포레이션 | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
BR112022009031A2 (en) | 2019-11-11 | 2022-10-11 | Incyte Corp | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
TW202233615A (en) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Crystalline form of a pd-1/pd-l1 inhibitor |
TW202241420A (en) | 2020-12-18 | 2022-11-01 | 美商英塞特公司 | Oral formulation for a pd-l1 inhibitor |
-
2017
- 2017-08-28 US US15/687,697 patent/US20180057486A1/en not_active Abandoned
- 2017-08-28 WO PCT/US2017/048880 patent/WO2018044783A1/en unknown
- 2017-08-28 ES ES17761781T patent/ES2941716T3/en active Active
- 2017-08-28 EP EP17761781.8A patent/EP3504198B1/en active Active
- 2017-08-28 MA MA046045A patent/MA46045A/en unknown
-
2020
- 2020-02-04 US US16/781,920 patent/US20200172533A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,547 patent/US11613536B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
WO2006053121A2 (en) * | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
WO2012080376A1 (en) * | 2010-12-17 | 2012-06-21 | Syngenta Participations Ag | Insecticidal compounds |
EP2824099A1 (en) * | 2012-03-09 | 2015-01-14 | Carna Biosciences Inc. | Novel triazine derivative |
WO2016057500A1 (en) * | 2014-10-06 | 2016-04-14 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
Non-Patent Citations (29)
Title |
---|
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418 |
BARBER ET AL., NATURE, vol. 439, 2006, pages 682 - 7 |
BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19 |
BLANK ET AL., CANCER RES, vol. 64, no. 3, 2004, pages 1140 - 5 |
BLOM ET AL.: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670 - 83 |
BLOM ET AL.: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883 |
BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295 - 301 |
CARTER ET AL., EUR J IMMUNOL, vol. 32, no. 3, 2002, pages 634 - 43 |
FREEMAN ET AL., J EXP MED, vol. 192, no. 7, 2000, pages 1027 - 34 |
GREENWALD ET AL., ANNU. REV. IMMUNOL, vol. 23, 2005, pages 515 - 548 |
HUANG ET AL., ONCOL REP, 2015 |
IWAI ET AL., PNAS2002, vol. 99, no. 19, pages 12293 - 7 |
KOCIENSKI: "Protecting Groups", 2007, THIEME |
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 268 |
NAKAE ET AL., J IMMUNOL, vol. 177, 2006, pages 566 - 73 |
NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 151 |
NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 322 |
OKAZAKI; HONJO, TRENDS IMMUNOL, vol. 4, 2006, pages 195 - 201 |
PARRY ET AL., MOL CELL BIOL, 2005, pages 9543 - 9553 |
PETURSSION ET AL.: "Protecting Groups in Carbohydrate Chemistry", J. CHEM. EDUC., vol. 74, no. 11, 1997, pages 1297 |
POSTOW ET AL., J. CLINICAL ONCOL, 2015, pages 1 - 9 |
POSTOW ET AL., J. CLINICAL ONCOLOGY, 2015, pages 1 - 9 |
ROBERTSON: "Protecting Group Chemistry", 2000, OXFORD UNIVERSITY PRESS |
SABATIER ET AL., ONCOTARGET, vol. 6, no. 7, 2015, pages 5449 - 5464 |
SHARPE ET AL., NAT IMMUNOL, vol. 8, 2007, pages 239 - 245 |
SMITH ET AL.: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2007, WILEY |
STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY |
WANG ET AL., EUR J SURG ONCOL, 2015 |
WUTS ET AL.: "Protective Groups in Organic Synthesis", 2006, WILEY |
Cited By (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11407749B2 (en) | 2015-10-19 | 2022-08-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11572366B2 (en) | 2015-11-19 | 2023-02-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11866435B2 (en) | 2015-12-22 | 2024-01-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11535615B2 (en) | 2015-12-22 | 2022-12-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11608337B2 (en) | 2016-05-06 | 2023-03-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11673883B2 (en) | 2016-05-26 | 2023-06-13 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11873309B2 (en) | 2016-06-20 | 2024-01-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11426364B2 (en) | 2016-06-27 | 2022-08-30 | Chemocentryx, Inc. | Immunomodulator compounds |
US11793771B2 (en) | 2016-06-27 | 2023-10-24 | Chemocentryx, Inc. | Immunomodulator compounds |
US11718605B2 (en) | 2016-07-14 | 2023-08-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11613536B2 (en) | 2016-08-29 | 2023-03-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
US11274285B2 (en) | 2016-10-14 | 2022-03-15 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome |
US10800768B2 (en) | 2016-12-22 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11339149B2 (en) | 2016-12-22 | 2022-05-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11465981B2 (en) | 2016-12-22 | 2022-10-11 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11566026B2 (en) | 2016-12-22 | 2023-01-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11787793B2 (en) | 2016-12-22 | 2023-10-17 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10806785B2 (en) | 2016-12-22 | 2020-10-20 | Incyte Corporation | Immunomodulator compounds and methods of use |
US10793565B2 (en) | 2016-12-22 | 2020-10-06 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4026835A2 (en) | 2017-04-20 | 2022-07-13 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2018195321A1 (en) | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US11708326B2 (en) | 2017-07-28 | 2023-07-25 | Chemocentryx, Inc. | Immunomodulator compounds |
US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
US11059834B2 (en) | 2017-08-08 | 2021-07-13 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
WO2019032547A1 (en) | 2017-08-08 | 2019-02-14 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
US10392405B2 (en) | 2017-08-08 | 2019-08-27 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
US11691985B2 (en) | 2017-08-08 | 2023-07-04 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2019214089B2 (en) * | 2018-02-05 | 2021-02-11 | Abbisko Therapeutics Co., Ltd. | Biaryl derivative, preparation method therefor and pharmaceutical use thereof |
CN111448189A (en) * | 2018-02-05 | 2020-07-24 | 上海和誉生物医药科技有限公司 | Biaryl derivative, preparation method and pharmaceutical application thereof |
CN111448189B (en) * | 2018-02-05 | 2024-09-10 | 上海和誉生物医药科技有限公司 | Biaryl derivative, preparation method and pharmaceutical application thereof |
EP3750887A4 (en) * | 2018-02-05 | 2021-10-20 | Abbisko Therapeutics Co., Ltd. | Biaryl derivative, preparation method thereof and pharmaceutical application thereof |
RU2768830C2 (en) * | 2018-02-05 | 2022-03-24 | Аббиско Тхерапеутицс Цо., Лтд. | Biaryl derivative, method for production thereof and pharmaceutical application thereof |
WO2019149183A1 (en) * | 2018-02-05 | 2019-08-08 | 上海和誉生物医药科技有限公司 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof |
US11459339B2 (en) | 2018-02-05 | 2022-10-04 | Abbisko Therapeutics Co., Ltd. | Biaryl derivative, preparation method thereof and pharmaceutical application thereof |
KR102534185B1 (en) | 2018-02-05 | 2023-05-18 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | Biaryl derivatives, synthesis method thereof and pharmaceutical use thereof |
KR20200100717A (en) * | 2018-02-05 | 2020-08-26 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | Biaryl derivatives, their synthesis and their pharmaceutical use |
RU2768830C9 (en) * | 2018-02-05 | 2022-06-17 | Aббиско Тхерaпеутицс Цо., Лтд. | Biaryl derivative, method for production thereof and pharmaceutical application thereof |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US11135210B2 (en) | 2018-02-22 | 2021-10-05 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
US11759458B2 (en) | 2018-02-22 | 2023-09-19 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
US10669271B2 (en) | 2018-03-30 | 2020-06-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11124511B2 (en) | 2018-03-30 | 2021-09-21 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2021520342A (en) * | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | Immunomodulators, compositions and methods thereof |
CN111936475B (en) * | 2018-04-03 | 2024-05-10 | 贝达药业股份有限公司 | Immunomodulator, composition and preparation method thereof |
WO2019192506A1 (en) * | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
CN111936475A (en) * | 2018-04-03 | 2020-11-13 | 贝达药业股份有限公司 | Immunomodulator, composition and preparation method thereof |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
US11149052B2 (en) | 2018-04-06 | 2021-10-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides |
WO2019193542A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides |
US11292812B2 (en) | 2018-04-06 | 2022-04-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotides |
WO2019193533A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2'-cyclic dinucleotides |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
WO2019200247A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
US11788077B2 (en) | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
US10906920B2 (en) | 2018-05-11 | 2021-02-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10618916B2 (en) | 2018-05-11 | 2020-04-14 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11414433B2 (en) | 2018-05-11 | 2022-08-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
EP4234030A2 (en) | 2018-07-13 | 2023-08-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020014643A1 (en) | 2018-07-13 | 2020-01-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
EP4371987A1 (en) | 2018-10-31 | 2024-05-22 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
WO2020088357A1 (en) | 2018-11-02 | 2020-05-07 | 上海再极医药科技有限公司 | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof |
AU2020210455B2 (en) * | 2019-01-25 | 2023-02-02 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
CN113166116A (en) * | 2019-01-25 | 2021-07-23 | 北京赛特明强医药科技有限公司 | Amido bridged heterocyclic compound, and composition and application thereof |
WO2020151589A1 (en) * | 2019-01-25 | 2020-07-30 | 北京赛特明强医药科技有限公司 | Acylamino bridged heterocyclic compound, and composition and application thereof |
JP2022523655A (en) * | 2019-01-25 | 2022-04-26 | 北京賽特明強医薬科技有限公司 | Amide Group Crosslinked Heterocyclic Compounds, Their Compositions and Applications |
JP7268921B2 (en) | 2019-01-25 | 2023-05-08 | 北京賽特明強医薬科技有限公司 | Amido group-bridged heterocyclic compounds, compositions and applications thereof |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020192570A1 (en) | 2019-03-22 | 2020-10-01 | 上海再极医药科技有限公司 | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
WO2020214652A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214663A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
US11266643B2 (en) | 2019-05-15 | 2022-03-08 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CN110128415A (en) * | 2019-05-31 | 2019-08-16 | 沈阳药科大学 | Indoline-like compound as immunomodulator and preparation method thereof |
CN110128415B (en) * | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | Indoline compound used as immunomodulator and preparation method thereof |
US11485708B2 (en) | 2019-06-20 | 2022-11-01 | Chemocentryx, Inc. | Compounds for treatment of PD-L1 diseases |
US11872217B2 (en) | 2019-07-10 | 2024-01-16 | Chemocentryx, Inc. | Indanes as PD-L1 inhibitors |
WO2021008491A1 (en) * | 2019-07-18 | 2021-01-21 | 上海和誉生物医药科技有限公司 | Biphenyl derivatives for blocking pd-1/pd-l1 interaction, preparation method therefor and use thereof |
CN113825751A (en) * | 2019-07-18 | 2021-12-21 | 上海和誉生物医药科技有限公司 | Biphenyl derivative for blocking PD-1/PD-L1 interaction and preparation method and application thereof |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
US11866451B2 (en) | 2019-11-11 | 2024-01-09 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021136354A1 (en) | 2020-01-03 | 2021-07-08 | 上海翰森生物医药科技有限公司 | Biphenyl derivative inhibitor, preparation method therefor and use thereof |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021226206A2 (en) | 2020-05-05 | 2021-11-11 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
WO2022052926A1 (en) | 2020-09-09 | 2022-03-17 | 广州再极医药科技有限公司 | Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof |
US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US12084443B2 (en) | 2020-11-06 | 2024-09-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
CN113461668A (en) * | 2021-04-30 | 2021-10-01 | 西安新通药物研究股份有限公司 | Novel biphenyl derivative, preparation method and medical application thereof |
CN113461668B (en) * | 2021-04-30 | 2022-12-09 | 西安新通药物研究股份有限公司 | Novel biphenyl derivative, preparation method and medical application thereof |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US11613536B2 (en) | 2023-03-28 |
ES2941716T3 (en) | 2023-05-25 |
EP3504198B1 (en) | 2023-01-25 |
US20200172533A1 (en) | 2020-06-04 |
EP3504198A1 (en) | 2019-07-03 |
US20180057486A1 (en) | 2018-03-01 |
MA46045A (en) | 2021-04-28 |
US20220089588A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11718605B2 (en) | Heterocyclic compounds as immunomodulators | |
US11613536B2 (en) | Heterocyclic compounds as immunomodulators | |
US11673883B2 (en) | Heterocyclic compounds as immunomodulators | |
US11866435B2 (en) | Heterocyclic compounds as immunomodulators | |
US11566026B2 (en) | Heterocyclic compounds as immunomodulators | |
EP3774791B1 (en) | Heterocyclic compounds as immunomodulators | |
EP3558973B1 (en) | Pyridine derivatives as immunomodulators | |
EP3390361B1 (en) | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators | |
EP3472167B1 (en) | Heterocyclic compounds as immunomodulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17761781 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017761781 Country of ref document: EP Effective date: 20190329 |